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RESUMEN	Durante	 los	 últimos	 años,	 el	 desarrollo	 de	 técnicas	 de	 secuenciación	masiva	 ha	 permitido	 la	caracterización	 de	 la	 heterogeneidad	 intratumoral	 (HIT)	 en	 múltiples	 tipos	 de	 tumores,	incluyendo	los	cánceres	ginecológicos.	En	este	sentido,	aunque	los	tumores	de	ovario	(COs)	se	han	estudiado	en	profundidad,	poco	se	sabe	sobre	los	cánceres	de	endometrio	(CEs).	El	CE	es	la	neoplasia	maligna	ginecológica	más	común	en	los	países	desarrollados,	sin	embargo	es	el	CO	el	que	 causa	 la	mayor	parte	de	 las	muertes	asociadas	a	 tumores	ginecológicos.	Esto	es	debido	a	que	mientras	 que	 el	 CE	 se	 diagnostica	 principalmente	 en	 estadios	 tempranos,	 los	 COs	 suelen	detectarse	en	estadios	avanzados.	Sin	embargo,	cuando	el	CE	presenta	metástasis	al	diagnóstico	tiene	un	peor	pronóstico,	con	una	tasa	de	supervivencia	global	incluso	menor	que	la	de	los	COs.		Partiendo	 de	 estas	 premisas,	 los	 principales	 objetivos	 de	 la	 presente	 tesis	 implican	 la	caracterización	de	la	HIT	en	tumores	ginecológicos,	además	de	examinar	la	posible	utilidad	del	análisis	 genético	 en	 biopsias	 alternativas	 como	 nueva	 herramienta	 diagnóstica	 que	 permita	capturar	la	HIT	en	estos	tipos	de	tumores,	especialmente	CE.	Como	abordaje	experimental	se	ha	analizado	la	HIT	mediante	secuenciación	masiva	de	exomas	o	 dirigida	 en	 múltiples	 regiones	 del	 tumor	 primario	 y	 de	 la	 metástasis.	 Estos	 estudios	 se	llevaron	a	 cabo	en	un	CO	poco	descrito	hasta	 la	 fecha,	 caracterizado	por	mutaciones	nulas	en	
TP53,	 en	 el	 que	 también	 se	 identificaron	 las	 vías	 de	 señalización	 alteradas	 según	 su	 perfil	mutacional,	así	como	en	varios	CE	metastáticos,	 incluyendo	los	subtipos	endometrioide	(CEE),	seroso	 (CES)	 y	 ambiguo	 (CEA).	 Los	 resultados	 obtenidos	 en	 el	 análisis	 de	 CE	 revelaron	diferentes	 grados	 de	 HIT	 a	 nivel	 genético,	 como	 así	 lo	 reflejan	 los	 múltiples	 patrones	 de	evolución	filogenética	encontrados.	Mientras	que	los	CESs	mostraron	principalmente	un	patrón	de	monofilia	 en	 su	evolución	 clonal,	 con	 las	 regiones	metastáticas	procedentes	de	un	 subclon	ancestral,	 los	CEEs	presentaron	patrones	heterogéneos	en	su	progresión	filogenética.	Además,	la	secuenciación	de	exomas	de	un	caso	de	CEA	nos	permitió	caracterizar	molecularmente	este	subtipo	de	tumor	así	como	los	modelos	animales	(patient	derived	xenografts,	PDX)	derivados	de	él.	Los	resultados	obtenidos	fueron	utilizados	en	un	estudio	in	silico	preliminar	que	permitió	el	testado	de	una	terapia	personalizada	en	dichos	modelos.	Finalmente,	mediante	secuenciación	masiva	dirigida	en	aspirados	uterinos	(AUs),	biopsias	pre-operatorias	mínimamente	invasivas,	observamos	que	su	análisis	representaba	con	precisión	el	perfil	mutacional	del	tumor,	incluso	en	muestras	histológicamente	no	diagnosticables.	Además,	observamos	que	los	AUs	eran	capaces	de	capturar	la	HIT	encontrada	en	las	regiones	del	tumor.	En	conjunto,	a	lo	largo	de	esta	tesis	doctoral	hemos	avanzado	en	la	caracterización	de	la	HIT	en	múltiples	subtipos	de	cáncer	ginecológico	además	de	plantear	nuevas	alternativas	diagnósticas	basadas	 en	 el	 uso	 de	 la	 secuenciación	 dirigida	 como	 una	 solución	 parcial	 para	 superar	 el	problema	clínico	derivado	de	la	HIT,	al	menos	en	CEs.	
		 	 	
RESUMEN/ABSTRACT	 		 	
ABSTRACT	During	 the	 last	 years,	 the	 development	 of	 next	 generation	 sequencing	 technologies	 has	 shed	light	on	intratumor	heterogeneity	(ITH)	and	clonal	evolution	in	multiple	tumor	types.	Regarding	gynecological	 cancers,	 this	 has	 been	 widely	 described	 on	 ovarian	 tumors,	 although	 little	 is	known	 about	 endometrial	 carcinomas	 (ECs).	 While	 EC	 is	 the	 most	 common	 gynecological	malignancy	in	the	developed	world,	 tumors	arising	from	the	ovary	account	for	the	majority	of	deaths	associated	to	gynecological	cancers.	The	main	reason	of	these	differences	is	that	whereas	EC	 are	 mainly	 diagnosed	 at	 early	 stages,	 ovarian	 carcinomas	 are	 usually	 high	 grade	 tumors	detected	in	advanced	stages	of	the	disease.	However,	ECs	showing	metastasis	at	diagnosis	have	a	worse	prognosis,	with	relative	overall	survival	even	lower	than	the	observed	in	the	ovary.		In	 this	 sense,	 the	 main	 objectives	 of	 the	 present	 thesis	 imply	 the	 characterization	 of	 ITH	 in	gynecological	 cancers	 and	 the	 advance	 in	 the	 utility	 of	 the	 genetic	 analysis	 in	 alternative	biopsies	as	new	diagnostic	tools	to	capture	ITH	in	these	types	of	tumors,	especially	EC.	In	general,	 ITH	was	evaluated	by	primary	 tumor	and	metastasis	multiregion	studies	based	on	targeted	 massive	 parallel	 or	 whole-exome	 sequencing	 (WES)	 analyses.	 These	 studies	 were	performed	in	a	less	common	ovarian	carcinoma	characterized	by	null	mutations	in	TP53,	where	we	also	identified	the	potential	signaling	pathways	altered	according	to	the	mutational	profile,	as	well	as	in	several	metastatic	ECs	including	endometrioid	(EEC),	serous	(SEC)	and	ambiguous	(AEC)	histologies.	Regarding	EC,	our	results	revealed	different	degrees	of	genetic	ITH	that	were	in	 turn	 reflected	 in	 the	 multiple	 phylogenetic	 evolution	 patterns	 found	 among	 the	 various	histological	and	molecular	subtypes.	While	SECs	had	mainly	a	monophyletic	clonal	progression,	with	 metastatic	 regions	 arising	 from	 an	 ancestral	 subclone,	 EECs	 showed	 heterogeneous	patterns	of	phylogenetic	evolution.	Additionally,	WES	allowed	the	molecular	characterization	of	an	AEC	and	the	patient	derived	xenografts	(PDXs)	obtained	from	this	case.	These	results	were	used	for	an	in	silico	study	that	allowed	the	personalized	treatment	of	these	PDXs.		Finally,	 the	 use	 of	 targeted	 sequencing	 in	 uterine	 aspirates	 (UAs),	 low	 invasive	 pre-operative	biopsies,	revealed	that	UA	accurately	represents	tumor	mutational	profile	even	in	histologically	non-diagnosable	samples.	Moreover,	the	genetic	study	of	UA	recapitulates	the	ITH	found	in	the	multiple	tumor	regions.		In	 conclusion,	 we	 have	 advanced	 in	 the	 characterization	 of	 ITH	 in	 multiple	 gynecological	cancers	subtypes	and	have	introduced	UAs	to	partially	overcome	the	clinical	problems	derived	from	ITH,	at	least	in	ECs.		
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1 INTRODUCTION	
1.1 Next-generation	 sequencing	 in	 cancer:	 unraveling	
intratumor	genetic	heterogeneity	
1.1.1 Cancer	genome	sequencing:	a	bit	of	history	The	necessity	of	unraveling	the	human	genome	sequence	to	understand	the	implication	of	genetic	changes	 in	cancer	was	proposed	by	Dulbecco	as	early	as	19861.	However,	 it	was	not	until	2001	that	the	International	Human	Genome	Sequencing	and	Celera	Consortiums	published	 the	 first	 drafts	 of	 the	 human	 genome	 reference2,	3.	 Nowadays	 gene	mutations	and	genome	instability	are	considered	one	of	the	hallmarks	of	cancer4.	During	the	period	in	which	 human	 genome	was	 sequenced,	 different	 strategies	 based	 on	 cloning	 and	 first	generation	 sequencing	 identified	 a	 large	 number	 of	 cancer	 related	 genes,	 including	 the	most	recurrent	oncogenes	and	tumor	suppressors5.	The	introduction	of	massively	parallel	sequencing	 around	 20056,	 7	 revealed	 the	 feasibility	 of	 sequencing	 whole	 normal	 and	tumoral	genomes	at	a	reasonable	cost	and	timeframe8,	9.	This	involved	the	generation	of	an	unprecedented	 volume	 of	 sequencing	 data	 and	 the	 necessity	 of	 overcoming	 huge	bioinformatics	 challenges	 in	 terms	 of	 data	 storage,	 quality	 control,	 alignment,	 assembly	and	annotation.	During	the	last	years,	the	development	of	computational	tools	has	allowed	the	 implementation	 of	 next-generation	 sequencing	 (NGS)	 in	 routine	 research.	While	 the	first	 studies	analyzed	a	 short	number	of	patients10,	big	 consortia	as	The	Cancer	Genome	Atlas	Research	Network	(TCGA),	the	International	Cancer	Genome	Consortium	(ICGC)	and	the	 Cancer	 Genome	 Project	 (CGP)	 among	 others	 have	 allowed	 the	 characterization	 of	hundreds	of	 tumors	of	different	 types11,	12.	These	studies	have	shown	that	 few	genes	are	frequently	mutated	in	each	cancer	type,	confirming	those	previously	described	as	well	as	revealing	 new	 ones13.	 However,	 the	 number	 of	 low	 frequency	 mutated	 genes	 has	substantially	 increased,	 suggesting	 the	 presence	 of	 genetic	 heterogeneity	 across	 tumors	with	the	same	origin	(known	as	 inter-tumor	heterogeneity).	Furthermore,	recent	studies	are	 moving	 from	 whole-exome	 sequencing	 (WES)	 to	 whole-genome	 sequencing	 (WGS),	since	it	has	been	shown	that	mutations	in	non-coding	regions	may	have	direct	tumorigenic	effects	 or	 lead	 to	 genetic	 instability14,	15.	 Additionally,	 a	meta-analysis	 considering	 about	7,000	primary	tumors	of	30	different	cases	analyzed	by	WES	and	WGS,	revealed	that	the	combination	 of	 somatic	 mutations	 found	 in	 a	 tumor	 lead	 to	 a	 specific	 ‘mutational	signatures’	and	identified	21	recurrent	cathegories16.	While	some	of	these	signatures	were	related	to	the	age	of	the	patient,	the	exposure	to	mutagenics	or	defects	in	DNA	repair,	the	
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INTRODUCTION	 		 	biological	 processes	 that	 originate	 the	 majority	 of	 them	 remain	 unknown.	 This	 study	highlighted	 the	 diversity	 of	 mutational	 processes	 underlying	 cancer	 development	 and	showed	a	potential	utility	in	order	to	understand	cancer	aetiology.	
1.1.2 Applications	of	NGS	in	cancer:	use	in	the	clinic	The	widespread	characterization	of	cancer	genomes	has	increased	the	number	of	clinically	relevant	 biomarkers	 for	 cancer-risk	 assessment,	 diagnosis	 and	 treatment,	 including	 the	tailoring	 of	 therapeutic	 strategies	 based	 on	 actionable	 molecular	 alterations	 and	resistance	 mechanisms17.	 However,	 large-scale	 genome	 sequencing	 studies	 are	 still	unaffordable	not	only	from	an	economical	point	of	view,	but	also	because	of	the	limitations	to	apply	their	results	into	the	clinic.	It	is	important	to	note	that	few	of	described	mutations	have	been	functionally	validated	and	the	prediction	of	their	consequence	continues	being	a	real	challenge	nowadays.		Nowadays,	 the	 implementation	 of	 NGS	 technologies	 into	 the	 clinic	 is	 mainly	 based	 on	targeted	 sequencing	of	 specific	 genes	panels,	due	 to	 the	 cost	 and	 the	 complexity	of	data	analysis	are	sifnigicantly	lower.	A	clear	example	of	this	was	indicated	in	the	2015	National	Comprehensive	 Cancer	 Network	 guidelines,	 which	 recommends	 the	 use	 of	 NGS	 gene	panels	 for	 patients	 with	 hereditary	 ovarian	 cancer	 without	 mutations	 in	 the	 high-penetrance	 genes18.	 The	 use	 of	 this	 kind	 of	 panels	 allows	 the	 simultaneous	 analysis	 of	multiple	 genes	 in	 several	 samples	 with	 a	 low	 DNA	 input	 and	 a	 high	 sensitivity.	Additionally,	 these	 platforms	 can	 be	 applied	 in	 the	 analysis	 of	 formalin-fixed	 paraffin-embedded	(FFPE)	samples,	favouring	their	utility	in	the	clinical	setting.	Nevertheless,	the	selection	 of	 suitable	 genes	 for	 panel	 design,	 the	 need	 of	 additional	 validation,	 together	with	long-term	storage	and	retrieval	of	data	are	still	challenging19.		
1.1.3 New	 challenges	 for	 NGS:	 unraveling	 intratumor	 genetic	
heterogeneity	Intratumor	 phenotypic	 heterogeneity	 has	 been	 observed	 by	 pathologists	 since	 the	 early	days	of	cancer	knowledge,	which	 led	to	propose	the	existence	of	a	genetic	heterogeneity	implicated	 in	 the	 clonal	 evolution	 of	 tumors20-22.	However,	 it	 has	 not	 been	 until	 the	 last	years,	with	the	development	of	NGS	technologies,	that	intratumor	heterogeneity	(ITH)	at	a	genomic	 point	 of	 view	 has	 been	 well	 demonstrated	 and	 deeply	 characterized.	 Initial	sequencing	studies	comparing	subsets	of	regionally23,	24	and	temporally25	separated	areas	from	the	same	tumor	confirmed	the	existence	of	 ITH	not	only	 in	the	primary	 lesions	but	also	in	metastatic	regions.	In	fact,	ITH	has	been	described	in	numerous	solid	tumor	types,	including	 pancreatic24,	 26,	 renal25,	 27,	 lung28-30,	 breast31-33,	 colorectal34,	 35,	 glial36-38	 and	prostate39,	 40	 cancers,	 among	 others;	 as	 well	 as	 hematologic	 malignancies41-46.	 Several	
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INTRODUCTION	 		 	studies	 have	 been	 also	 reported	 about	 gynecological	 cancers,	 including	 ovarian	 and	endometrial	carcinomas47.	Since	these	types	of	cancer	are	the	focus	of	this	thesis,	they	will	be	discuss	in	depth	in	the	next	sections	1.3.1.10	and	1.3.2.9.		The	 analysis	 of	 multiple	 samples	 along	 tumor	 development	 has	 revealed	 different	phylogentic	evolution	patterns.	Thus,	some	tumors	showed	a	monophyletic	evolution26,	48-50,	with	metastatic	 regions	more	closely	related	among	 them	than	 to	 the	primary	 tumor,	but	 polyphyletic	 patterns	 were	 also	 found24,	 40	 and	 revealed	 that	 distinct	 metastatic	samples	could	arise	from	different	subclones	of	the	primary	tumor.	The	 clinical	 implication	 of	 ITH	 remain	 a	 controversial	 issue	 nowadays,	 being	 necessary	further	 studies	 to	 analyze	 its	 real	 impact	 on	 cancer	 progression,	 risk	 of	 relapse	 and	treatment	response	and	resistance51.	Nevertheless,	recent	studies	have	suggested	that	ITH	could	 be	 an	 independent	 prognostic	 factor	 of	 disease	 progression	 and	 survival43,	 52,	although	the	underlying	mechanisms	are	yet	to	be	determined.	Additionally,	it	is	a	fact	that	ITH	 also	 supposes	 a	 challenge	 for	 cancer	 diagnosis.	 Considering	 that	 molecular	characterization	 of	 multiple	 tumor	 regions	 is	 not	 affordable	 in	 a	 diagnostic	 laboratory,	supplementary	tools	should	be	developed	to	overcome	this	problem.	In	this	sense,	the	use	of	 alternative	 samples	 as	 liquid	 biopsies,	 such	 as	 circulating	 tumor	 DNA	 (ctDNA)	 and	circulating	tumor	cells	(CTCs),	has	been	proposed	as	a	novel	approach	to	capture	ITH53-55.		
1.2 Female	reproductive	system	
The	 female	 reproductive	 system	 is	 composed	 of	 internal	 and	 external	 sex	 organs56:	 i)	internal	organs	are	those	included	within	the	pelvis,	counting	the	vagina,	uterus,	fallopian	tubes	 and	 ovaries;	 and	 ii)	 external	 organs	 or	 genitals	 make	 up	 the	 vulva,	 which	 is	connected	to	the	uterus	at	the	cervix	(Figure	1).		Ovaries	 are	 the	 female	gonads	as	well	 as	 endocrine	glands,	 located	alongside	 the	 lateral	wall	of	the	uterus.	They	are	composed	by	an	epithelial	layer	that	covers	the	cortex	(outer	part	consisting	of	ovarian	follicles	and	stroma)	and	the	medulla	(inner	part	composed	of	supporting	stroma	and	neurovascular	structures).		The	 uterus	 is	 a	 hollow	 muscular	 organ	 in	 which	 the	 fetus	 develops	 during	 gestation.	Anatomically,	 the	uterus	 can	be	divided	 into	 fundus,	 corpus	and	cervix.	The	walls	of	 the	uterus	are	made	up	of	three	tissue	layers:	
• Perimetrium:	external	thin	layer	composed	of	a	serous	membrane	continuous	with	the	peritoneum	that	protects	the	uterus.		
• Myometrium:	 middle	 layer	 formed	 by	 three	 smooth	 muscle	 fibers	 layers,	responsible	for	uterine	contractions.	
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• Endometrium:	 inner	mucous	epithelial	membrane,	highly	vascularized,	 that	 lines	the	hollow	lumen	of	the	uterus.	This	layer	changes	throughout	the	menstrual	cycle	and	it	becomes	thick	and	rich	of	blood	vessels	when	prepare	for	pregnancy.			
	
Figure	 1	 Female	 reproductive	 system.	 Scheme	 of	 the	 female	 reproductive	 system.	 The	 name	 of	 internal	organs	 are	 indicated	 in	 the	 left	 side.	 Uterus	 parts	 are	 described	 in	 the	 right	 side.	 Figure	 adapted	 from	http://www.wisegeekhealth.com.	
1.3 Gynecological	cancers	
Gynecological	 cancers	 are	 those	 originated	 in	 the	 female	 reproductive	 organs,	 including	uterine,	 ovarian,	 cervical,	 vulvar	 and	 vaginal	 cancers57.	 Although	 cervical	 cancer	 is	 the	most	frequent	gynecologic	cancer	in	the	world,	uterine	and	ovarian	cancers	are	the	most	common	in	the	developed	countries58.	Regarding	the	American	Cancer	Society	estimation,	there	will	be	approximately	105,890	new	cases	diagnosed	and	about	30,890	deaths	from	gynecologic	cancers	in	the	United	States	during	2017	(Table	1).		
	
Table	1	Estimated	new	cases	and	mortality	from	gynecologic	cancers	in	the	United	States	during	2017	
Cancer	Type	 New	cases*	 Deaths*	
Uterine	 61,380	 10,920	
Ovarian	 22,440	 14,080	
Cervical	 12,820	 4,210	
Vulvar	 6,020	 1,240	
Vaginal	 4,810	 1,150	*Data	obtained	from	American	Cancer	Society	
1.3.1 Ovarian	cancer	
1.3.1.1 Epidemiology	of	ovarian	cancer	Ovarian	 cancer	 (OC)	 is	 the	 second	 most	 common	 gynecological	 cancer	 in	 developed	countries58.	About	3,300	new	cases	are	diagnosed	annually	 in	Spain,	 representing	5%	of	female	 cancers	behind	breast,	 colorectal,	 uterine	 and	 lung	 cancer59.	The	5-years	 relative	
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INTRODUCTION	 		 	survival	rate	for	these	tumors	is	around	45%,	although	it	strongly	depends	on	the	stage	at	diagnosis	(Figure	2).			
Figure	2	Five-year	relative	overall	survival	rate	
depending	 on	 stage	 at	 diagnosis	 in	 ovarian	
cancer.	 Percentage	 of	 cases	 with	 relative	 overall	survival	of	at	least	five	years	depending	on	stage	at	diagnosis	 in	 ovarian	 cancer.	 Localized:	 tumor	confined	entirely	to	ovary.	Regional:	extended	into	surrounding	 organs	 or	 tissues.	 Distant:	 spread	 to	parts	of	 the	body	remote	 from	the	ovary.	Adapted	from	http://seer.cancer.gov/.		While	92%	of	localized	tumors	survive	5	years	before	diagnosis,	this	percentage	decreases	to	29%	in	distant	tumors58.	Due	to	the	majority	of	the	patients	are	diagnosed	at	advanced	stages,	of	which	around	75%	will	recur	after	surgery	and	chemotherapy,	OC	is	associated	with	a	greater	number	of	deaths,	being	the	most	lethal	gynecological	cancer.	
1.3.1.2 Types	of	ovarian	cancer	Ovarian	 cancers	 are	 divided	 into	 epithelial,	 germ	 cell	 and	 sex-cord	 stromal	 tumors,	depending	on	the	cell	type	that	gives	rise	to	the	tumor.	The	majority	of	OCs	(about	90%)	are	epithelial	 tumors,	which	start	 in	 the	epithelial	 surface	 layer	covering	 the	ovary	or	 in	the	distal	fallopian	tubes60.	Germ	cell	and	stromal	tumors	are	rare	subtypes,	originated	in	the	 cells	 that	 generate	 the	 eggs	 or	 in	 the	 stromal	 cells	 that	 produce	 female	 hormones,	respectively57.	All	 these	 tumor	 subtypes	 can	be	 subdivided	 into	benign	 (non-cancerous),	borderline	(low	malignant	potential,	without	stromal	invasion)	or	malignant	tumors.	Most	of	 them	are	benign	and	confined	 into	 the	ovary,	while	borderline	and	malignant	 tumors	can	spread	to	other	parts	of	the	body57.	Epithelial	 ovarian	 tumors,	 also	 known	 as	 carcinomas,	 are	 the	most	 common	OCs.	 Based	not	only	 in	histopathology	characteristics	but	also	 in	molecular	 features,	 five	main	 types	can	 be	 identified61:	 high-grade	 serous	 ovarian	 carcinomas	 (HGSOC),	 that	 are	 the	 most	common	 accounting	 for	 about	 70%	 of	 the	 cases,	 endometrioid	 (EOC,	 10%),	 clear	 cell	(CCOC,	 10%),	 mucinous	 (MOC,	 3%)	 and	 low-grade	 serous	 ovarian	 carcinomas	 (LGSOC,	<5%).	Their	clinical	and	molecular	characteristics	are	summarized	in	Table	2,	and	will	be	expounded	on	the	next	sections.		 	
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Table	2	Clinical	and	molecular	features	of	the	most	common	ovarian	cancer	types		 HGSOC	 EOC	 CCOC	 MOC	 LGSOC	
Risk	factors	
BRCA1/2	alterations	 Lynch	syndrome	 Unknown	 Unknown	 Unknown	
Precursor	
lesions	
Tubal	intraepithelial	carcinoma	 Atypical	endometriosis	 Atypical	endometriosis	
Cystadenoma,	borderline	tumor	
Serous	borderline	tumors	
Pattern	of	spread	
Very	early	transcoelomic	spread	
Usually	confined	to	pelvis	
Usually	confined	to	pelvis	
Usually	confined	to	ovary	 Transcoelomic	spread	
Frequently	
mutated	genes	
BRCA,	TP53	 PTEN,	ARID1A	 HNF1,	ARID1A	 KRAS,	HER2	 BRAF,	KRAS	
Chemosensitivity	 High	 High	 Low	 Low	 Intermediate	
Prognosis	 Poor	 Favorable	 Intermediate	 Favorable	 Intermediate	HGSOC:	 high-grade	 serous	 ovarian	 carcinoma,	 EOC:	 endometrioid	 ovarian	 carcinoma,	 CCC:	 clear	 cell	 ovarian	 carcinoma,	MOC:	mucinous	ovarian	carcinoma,	LGSOC:	low-grade	serous	ovarian	carcinoma.	Adapted	from	Prat	et	al.,	201261.	
1.3.1.3 Risk	factors	in	ovarian	carcinoma	Several	 well-established	 risk	 factors	 have	 been	 identified	 in	 epithelial	 ovarian	 tumors.	These	include	age,	obesity,	use	of	menopausal	hormone	therapy,	endometriosis,	diabetes	and	 family	 history	 of	 breast	 and/or	 OCs,	 among	 others62-67.	 By	 contrast,	 the	 use	 of	 oral	contraceptives,	a	late	menarche,	tubal	ligation	and	hysterectomy,	parity	and	breastfeeding	have	been	associated	with	a	lower	risk	of	OC68-72.		On	 the	 other	 hand,	 around	 5	 to	 15%	 of	 the	 OC	 cases	 are	 related	 with	 hereditary	syndromes	 (Table	 2),	 the	majority	 of	 them	 caused	 by	 germline	mutations	 in	BRCA1	 or	
BRCA2	 genes	 and	 related	 with	 HGSOC73,	 74.	 Additionally,	 a	 smaller	 percentage	 of	 them,	mostly	with	endometrioid	histology,	can	be	 linked	 to	other	 inherited	conditions,	 such	as	Lynch	 syndrome,	 also	 known	 as	 hereditary	 nonpolyposis	 colorectal	 cancer	 (HNPCC)75	(molecular	basis	are	expounded	in	the	1.3.2.7	section).		
1.3.1.4 Clinical	manifestations	and	diagnosis	Ovarian	cancer	may	cause	several	symptoms,	including	bloating,	pelvic	or	abdominal	pain,	irregular	 menstruation	 or	 postmenopausal	 vaginal	 bleeding,	 urinary	 symptoms,	 loss	 of	appetite	 and	 fatigue59.	 However,	 these	 symptoms	 appear	 more	 frequently	 when	 the	disease	has	spread,	which	suppose	a	clinical	problem.	The	 standard	 diagnosis	 protocol	 for	 OC	 begins	 with	 medical	 examination	 followed	 by	imaging	 tests	 as	 ultrasounds,	 computed	 tomography	 (CT)	 scans,	 magnetic	 resonance	imaging	(MRI)	and/or	Positron	emission	tomography	(PET)	scans.	A	blood	test	can	be	also	performed	in	order	to	detect	cancer	antigen-125	(CA-125),	a	protein	used	as	a	biomarker	for	ovarian	tumors76.	However,	CA-125	has	limited	specificity	since	it	can	be	increased	in	
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INTRODUCTION	 		 	other	 tumor	 types	 and	even	 in	benign	 conditions	 such	 as	 endometriosis,	 fibroids,	 pelvic	inflammatory	disease	or	pregnancy77-79.	The	final	diagnosis	will	be	always	performed	with	a	biopsy	examination	by	the	pathologist,	using	tissue	or	fluid	in	patients	with	ascites	(fluid	accumulated	inside	the	abdomen)80.	
1.3.1.5 Ovarian	cancer	staging	Cancer	 staging	 classifies	 tumors	 regarding	 its	 extension,	 considering	 factors	 as	 primary	tumor	location,	tumor	size	and	cancer	dissemination.	There	are	numerous	parameters	for	tumor	staging.	Although	TNM	classification	of	malignant	tumor	is	the	system	most	widely	used	for	other	types	of	cancer	(T	defines	the	size	of	the	primary	tumor	and	whether	it	has	invaded	nearby	tissue,	N	indicates	nearby	lymph	nodes	that	are	involved	and	M	refers	to	distant	metastasis),	FIGO	(International	Federation	of	Gynecology	and	Obstetrics)	stage	is	recommended	 in	 gynecologic	 tumors	 typification.	 The	 last	 FIGO	 revision	 for	 ovarian,	fallopian	 tubes	and	primary	peritoneal	 cancers	 staging	 is	 summarized	 in	Supplementary	Table	157.	
1.3.1.6 Standard	treatment	and	new	therapeutic	approaches	for	ovarian	
cancer	The	standard	 treatment	 in	OC	 includes	aggressive	 surgery	 followed	by	a	 combination	of	platinum	 and	 taxane	 chemotherapy81.	 However,	 although	 the	 initial	 response	 rate	 is	higher	 than	 80%,	 platinum	 resistance	 appears	 in	 approximately	 25%	 of	 the	 patients	within	six	months,	and	the	majority	of	patients	ultimately	relapses	due	to	chemo-resistant	disease82,	83.	The	genetic	and	molecular	 factors	that	contribute	to	explain	the	high	rate	of	resistance	 in	 this	 disease	 are	 currently	 unknown,	 although	 it	 has	 been	 shown	 that	 a	defective	status	of	the	DNA	repair	machinery	(especially	BRCA1/2	genes)	correlates	with	a	better	response	to	platinum-based	therapy84.		In	this	sense,	tumors	with	defects	in	DNA	repair	have	been	shown	to	be	more	sensitive	to	the	inhibition	of	other	DNA	repair	proteins	as	PARP85.	This	phenomenom,	consisting	of	cell	death	caused	by	the	simultaneous	perturbation	of	 two	genes,	 is	called	synthetic	 lethality	and	 its	 application	 supposed	 a	 real	 advance	 in	 OC	 treatment86.	 The	 OC	 research	 is	currently	focused	on	the	extension	of	the	use	of	different	PARP	inhibitors	to	other	tumors	with	 sensitizing	molecular	 defects	 resulting	 in	 homologous	 recombination	 repair	 (HRR)	deficiencies87.	 Furthermore,	 clinical	 trials	 including	 anti-angiogenic	 therapies	 to	 the	standard	 treatment	 have	 shown	 a	 significant	 increase	 in	 the	 disease	 free	 survival	 time,	suggesting	 the	 necessity	 of	 anti-angiogenic	 therapies	 maintenance	 until	 disease	progression88.	Nonetheless,	 effective	predictors	of	 response	are	 required	 to	 select	which	
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INTRODUCTION	 		 	group	 of	 patients	would	 benefit	 from	 these	 therapies,	 principally	 due	 to	 the	 substantial	increase	in	the	cost	of	treatment.	
1.3.1.7 Molecular	features	of	High	Grade	Serous	Ovarian	Carcinoma	As	 above	 pointed	 out,	 HGSOC	 represents	 the	 majority	 of	 OC	 cases.	 HGSOCs	 are	 widely	characterized	by	TP53	mutations,	which	appear	in	at	least	96%	of	the	cases89,	90.	TP53	is	a	key	 tumor	 suppressor	 gene	 implicated	 in	 G2	 checkpoint,	 mediating	 cell	 cycle	 arrest,	senescence	 or	 apoptosis	 in	 response	 to	 different	 kinds	 of	 cellular	 stress,	 including	DNA	damage,	activated	oncogenes	or	hypoxia91,	92.	The	majority	of	TP53	mutations	are	missense	substitutions	in	contrast	to	other	tumor	suppressor	genes	that	present	mainly	truncating	mutations93.	This	 type	of	mutations	 leads	 to	nuclear	protein	accumulation	with	a	diffuse	and	strongly	positive	immunohistochemistry	(IHC)	staining.	Nevertheless,	approximately	30%	of	somatic	TP53	mutations	are	nonsense,	frameshift	or	splicing	junction	variants	that	lead	to	complete	absence	of	p53	protein,	also	known	as	null	mutations.	On	the	other	hand,	
TP53	wild-type	tumors	present	a	focal	positive	staining	(less	than	50%	of	the	cells,	usually	less	than	10%)94	(Figure	3).			
	
Figure	 3	 p53	 immunostaining	 patterns	 in	 high-grade	 serous	 ovarian	 carcinomas.	 Immunostaining	 for	p53	 in	 high-grade	 serous	 ovarian	 carcinomas;	 representative	 examples	 for	 the	 different	 patterns	 of	 p53	staining.	a)	TP53	wild-type:	focal	nuclear	expression	(marked	with	arrows)	in	less	than	50%	of	tumor	cells.	b)	
TP53	misense	mutant:	strong	nuclear	overexpression	in	more	than	80%	of	tumor	cells.	c)	TP53	null	mutant:	complete	absence	of	expression.	Magnification	40x.	Images	were	obtained	from	tumor	tissue	samples	from	MD	Anderson	Cancer	Center,	Madrid.		The	majority	of	HGSOCs	are	also	immunoreactive	for	WT1	and	p16	markers,	as	well	as	for	Ki-67	which	indicates	a	high	proliferation	index95,	96.	Moreover,	approximately	two	thirds	of	the	cases	express	estrogen	receptor	(ER)61.	As	mentioned	before,	alterations	in	BRCA1	and	BRCA2	genes,	essential	components	of	the	HRR	of	DNA	double-strand	breaks,	are	also	common	 in	HGSOCs	(Table	 2).	 In	 fact,	more	than	 15%	 of	 the	 cases	 present	 germline	 mutations,	 while	 somatic	 mutations	 or	BRCA1	promoter	methylation	occur	in	an	additional	14-22%	of	the	cases90,	97.	Mutations	in	other	
b	 c	a	
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INTRODUCTION	 		 	members	 of	 the	HRR	 pathway,	 as	PALB2,	RAD51,	RAD50,	BARD1,	CHK2	 and	BRIP1	 have	been	also	detected,	although	in	a	lower	proportion	of	cases98.	However,	the	hallmark	of	HGSOCs	is	the	chromosomal	instability	and	widespread	somatic	copy	number	alterations	(SCNAs),	probably	as	a	consequence	of	the	DNA	repair	disorders	due	to	TP53	or	BRCA1/2	mutations99.	The	first	and	most	common	SCNAs	were	identified	in	
MYC	and	ERBB2	oncogenes100,	101.	
1.3.1.8 TP53:	a	prognosis	marker	in	ovarian	cancer?	Although	somatic	mutations	in	the	TP53	gene	are	the	most	frequent	genetic	alterations	in	human	cancers,	showing	HGSOCs	the	highest	frequency	among	all	the	solid	tumors	with	a	96%89,	90,	93,	102,	the	prognosis	value	of	TP53	alteration	is	a	controversial	issue.	In	this	sense,	numerous	 studies	 have	 tried	 to	 correlate	 TP53	mutational	 status	 with	 different	 clinical	parameters	such	as	overall	survival	or	therapy	response,	but	results	remain	conflicting103.	This	could	be	partially	explained	taking	into	account	that	the	vast	majority	of	studies	has	performed	 IHC	 to	 asses	 p53	 alterations,	 a	 technique	 prone	 to	misclassify	 an	 important	number	of	cases	due	to	the	difficulty	in	distinguishing	wild-type	and	null	tumors	(Figure	
3).	Likewise,	other	analyses	limited	TP53	sequencing	to	those	exons	that	encode	the	DNA	binding	 domain,	 or	 did	 not	 differentiate	 between	 biological	 consequences	 of	 the	mutations104.	 However,	 recent	 studies	 support	 that	 tumors	 with	 TP53	 null	 mutations	present	a	worse	outcome	compared	to	those	in	which	TP53	harbors	mutations	 involving	overexpression,	not	only	in	OCs	but	also	in	leukemia,	breast,	colorectal	and	head	and	neck	cancers94,	105-107.	 Conversely,	 a	 recent	 analysis	 using	 TCGA	 data	 sustains	 that	TP53	 wild-type	tumors	could	have	a	worse	prognosis	than	mutant	tumors,	though	it	is	important	to	note	that	no	differentiation	between	missense	and	null	mutations	was	considered108.	
1.3.1.9 Omics	and	ovarian	cancer:	The	Cancer	Genome	Atlas	The	TCGA	Research	Network	published	in	2011	an	integrated	genomic	analysis	of	HGSOCs	including	 489	 untreated	 stage	 II-IV	 tumors	 and	 their	 corresponding	 normal	 DNA90.	Analyses	of	mRNA	expression,	microRNA	expression,	promoter	methylation	and	DNA	copy	number	alterations	were	performed	in	the	totality	of	the	patients,	while	WES	was	carried	out	in	316	of	them.	As	 expected,	 WES	 analysis	 showed	 that	 TP53	 is	 the	 most	 frequently	 mutated	 gene	 in	HGSOCs	 (96%	 of	 the	 samples),	 whereas	 lower	 prevalence	 but	 statistically	 recurrent	somatic	mutations	were	found	in	eight	further	genes	including	BRCA1	and	BRCA2	(22%	of	the	 cases,	 including	 germline	 and	 somatic	mutations),	RB1,	NF1,	 FAT3,	 CSMD3,	GABRA6	and	 CDK12	 (2-6%)90.	 Moreover,	 113	 significant	 focal	 somatic	 copy	 number	 alterations	(SCNAs)	were	also	found,	supporting	the	relevance	of	chromosomal	instability	in	this	type	
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INTRODUCTION	 		 	of	tumor.	Focal	amplifications	in	CCNE1,	MYC	and	MECOM	(detected	in	more	than	20%	of	tumors)	and	deletions	of	PTEN,	RB1	and	NF1	(observed	at	least	in	2%	of	the	tumors)	were	identified.	 Furthermore,	 promoter	 methylation	 analysis	 showed	 168	 genes	 silenced	 by	epigenetic	 events	 in	HGSOCs	 comparing	with	 normal	 controls,	 including	BRCA1	 in	more	than	10%	of	the	cases,	as	previously	reported97.		Transcriptional	analysis	was	able	to	classify	HGSOC	into	four	tumor	subgroups,	including	‘immunoreactive’,	 ‘diferenciated’,	 ‘proliferative’	and	‘mesenchymal’	subtypes,	although	no	significant	 differences	 in	 survival	 rate	 were	 found	 among	 them.	 Additionally,	 miRNA	expression	 analysis	 identified	 three	 subtypes	 that	 partially	 overlapped	 with	 the	 mRNA	results.	In	this	case,	one	of	the	clusters	presented	a	significantly	longer	survival	time90.		Interestingly,	 a	 system	 biology	 study	 identified	 five	main	 altered	 signaling	 pathways	 in	HGSOCs,	comprising	RB	(67%	of	cases	altered),	PI3K/RAS	(45%	of	cases	altered),	NOTCH	(22%	 of	 cases	 altered),	 HRR	 (51%	 of	 cases	 altered)	 and	 FOXM1	 signaling	 (84%	 cases	altered).	Nonetheless,	 it	 is	 important	 to	notice	 that	samples	analyzed	by	the	TCGA	study	 included	untreated	 primary	 tumors90.	 Given	 that	 the	 majority	 of	 HGSOCs	 recur	 due	 to	 planitum	resistance,	 a	 recent	 publication	 based	 on	 WES	 analysis	 compared	 primary	 refractory,	resistant,	 sensitive	 and	matched	 acquired	 resistant	 tumors	 to	 further	 investigate	 in	 this	sense109.	Inactivation	of	the	tumor	suppressor	genes	RB1,	NF1,	RAD51B	and	PTEN	by	gene	breakage	 was	 shown	 to	 contribute	 chemotherapy	 resistance	 acquisition,	 while	 CCNE1	amplification	was	associated	with	primary	platinum	resistance.	Other	events	implicated	in	platinum	resistance	were	germline	BRCA1/2	mutation	reversion,	loss	of	BRCA1	promoter	methylation,	and	overexpression	of	the	drug	efflux	pump	MDR1109.	
1.3.1.10 	Intratumor	heterogeneity	in	ovarian	cancer	Intratumor	heterogeneity	(ITH)	has	been	extensively	described	in	OCs110-118.	First	studies	based	 on	 loss	 of	 heterozygosity	 (LOH)	 data	 by	 microsatellite	 and	 single	 nucleotide	polymorphism	(SNP)	analyses	demonstrated	widespread	ITH	in	primary	ovarian	tumors,	suggesting	 a	 monoclonal	 origin110.	 This	 process	 was	 also	 found	 between	 metastatic	lesions,	being	clonally	related	with	the	primary	tumor111.	These	studies	proposed	a	model	in	which	OCs	have	a	common	clonal	origin,	evolving	to	polyclonal	 tumors	due	to	genetic	divergence110,	111.	The	role	derived	from	ITH	in	cisplatin	resistance	was	also	described	by	array	 comparative	 genomic	 hybridization	 analysis,	 showing	pre-existing	minor	 resistant	clones	even	before	treatment112.	Further	 analyses	 using	more	 sensitive	 techniques,	 including	WES	 and	 targeted	massive	parallel	 sequencing,	 have	 led	 to	 a	 deeper	 understanding	 of	 ITH	 in	 OC	 with	 a	 single	
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INTRODUCTION	 		 	nucleotide	 resolution.	 The	 majority	 of	 studies	 agreed	 on	 the	 presence	 of	 extensive	genomic	 and	 transcriptomic	 ITH	 in	 OCs,	 showing	 different	 degrees	 of	 heterogeneity	depending	on	the	patient113-117.	These	analyses	also	subscribed	the	presence	of	subclones	in	 the	 untreated	 primary	 tumor	 that	would	 give	 rise	 to	 recurrent	 disease,	 although	 the	possibility	 of	 metastasis-to-metastasis	 spread	 has	 been	 also	 proposed115.	 The	 major	differences	 regarding	 samples	 from	 the	 same	 patients	 were	 found	 between	 distant	metastases	 and	 ovarian	 tumors118.	 Interestingly,	 the	 quantification	 of	 ITH	 may	 have	 a	predictive	 value,	 showing	 a	 decreased	progression	 free	 survival	 and	overall	 survival	 for	patients	with	extensive	ITH115.		All	 of	 these	 findings	 confirm	 that	 ITH	 supposes	 a	 real	 challenge	 in	OC	OCs110-118.	 In	 this	sense,	 the	genetic	analysis	of	ascites	appear	 to	be	a	way	 to	overcome	 ITH,	 since	most	of	somatic	 mutations,	 SCNAs	 and	 methylation	 patterns	 are	 represented	 in	 ascitic	 cells116.	With	 respect	 to	 ctDNA,	despite	 the	 fact	 that	 it	 has	been	proposed	 as	 a	 solution	 in	 other	types	 of	 cancer53,	 119,	 preliminary	 analyses	 with	 this	 source	 of	 genetic	 material	 in	 OC	allowed	 the	 detection	 of	 mutations	 but	 with	 high	 variations	 in	 mutation	 detection	sensitivity	among	patients113.	
1.3.2 Uterine	Cancer	
1.3.2.1 Epidemiology	of	uterine	cancer	Uterine	 cancer	 is	 the	 most	 common	 gynecological	 cancer	 in	 the	 developed	 world,	 with	about	5,000	new	 cases	per	 year	 in	 Spain59,	120.	On	 the	 contrary	 to	OCs,	 uterine	 cancer	 is	usually	 diagnosed	 in	 early	 stages,	 so	 the	 global	 survival	 rate	 is	 higher	 for	 this	 type	 of	tumors.	 In	 this	 sense,	 approximately	more	 than	80%	of	 the	patients	will	 survive	 after	5	years,	although	this	percentage	decreases	to	less	than	20%	in	tumors	in	which	extension	to	distant	sites	is	detected	at	diagnosis	(Figure	4).			
Figure	 4	 Five-year	 relative	 overall	 survival	 rate	
depending	 on	 stage	 at	 diagnosis	 in	 uterine	 cancer.	Percentage	of	cases	with	a	5-year	relative	overall	survival	depending	 on	 stage	 at	 diagnosis	 in	 endometrial	 cancer.	Localized:	 tumor	 confined	 to	 the	 uterus.	 Regional:	extended	 into	 surrounding	 organs	 or	 tissues.	 Distant:	spread	 to	 parts	 of	 the	 body	 remote	 from	 the	 uterus.	Adapted	from	http://seer.cancer.gov/.		
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1.3.2.2 Types	of	uterine	cancer	Uterine	 cancer	 is	mainly	 divided	 into	 two	 subtypes	 regarding	 its	 cellular	 origin:	 uterine	sarcomas	 and	 endometrial	 carcinomas57.	 Uterine	 sarcomas	 are	 originated	 in	 the	muscle	layer	(myometrium)	or	supporting	connective	tissue	of	the	uterus,	representing	less	than	5%	of	uterine	cancers.	These	mesenchymal	tumors	comprise	leiomyomas,	adenosarcomas,	and	 endometrial	 stromal	 sarcomas57.	 The	 most	 common	 type	 of	 uterine	 cancer	 is	endometrial	carcinoma	(EC),	which	originates	 in	 the	epithelial	cells	of	 the	endometrium.	This	thesis	will	be	mostly	focused	on	EC,	given	its	high	prevalence.	EC	 has	 been	 traditionally	 classified	 into	 two	 main	 groups	 with	 different	 clinical,	pathological	and	molecular	features121,	122.	Type	I	or	endometrioid	endometrial	carcinomas	(EECs)	are	the	most	common	ECs	(about	75%),	being	mainly	diagnosed	in	perimenopausal	women.	 EECs	 are	 typically	 estrogen-related	 and	 low-grade	 tumors	with	 good	 prognosis	that	 coexist	 or	 are	 preceded	 by	 endometrial	 hyperplasia.	 In	 contrast,	 type	 II	 or	 non-endometrioid	 endometrial	 carcinomas	 (NEECs)	 are	 high-grade	 aggressive	 tumors	associated	 with	 endometrial	 atrophy	 and	 poor	 prognosis,	 unrelated	 to	 estrogen	 and	diagnosed	in	older	women.	These	comprise	several	histological	subtypes,	being	the	most	common	serous	(SEC)	and	clear	cell	(CCEC)	carcinomas.		However,	this	dualistic	model	presents	several	 limitations123,	124.	For	example,	high-grade	endometrioid	carcinomas,	accounting	for	10-19%	of	type	I	EECs,	seem	to	be	more	similar	to	 type	 II	 cancers	 due	 their	 lack	 of	 association	 with	 endometrial	 hyperplasia	 and	 poor	outcomes125.	 Moreover,	 there	 are	 tumors	 that	 present	 combined	 or	mixed	morphologic	and	 molecular	 features.	 That	 is	 the	 case	 of	 carcinosarcoma	 (CS), also	 known	 as	malignant	 müllerian	 mixed	 tumor	 (MMMT).	 CSs	 are	 uncommon	 biphasic	 neoplasms	formed	by	malignant	epithelial	and	sarcomatoid	components	(with	the	minor	component	representing	at	least	10%	of	the	neoplasm),	with	high	rates	of	recurrence	and	mortality126,	127.	 There	 are	 also	 some	 tumors	 with	 overlapping	 and	 intermediate	 characteristics	between	 EECs	 and	 NEECs	 that	 do	 not	 show	 two	 distinct	 components,	 considered	 as	ambiguous	tumors	(AEC)128,	129.		Clinical	and	molecular	characteristics	of	endometrial	tumors	are	summarized	in	Table	3,	and	will	be	expounded	on	the	following	sections.		 	
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Table	3	Clinical	and	molecular	features	of	the	different	endometrial	carcinoma	subtypes		 EEC	 SEC	 CCEC	 CS	
Clinical	features	
Histological	grade	 Low	 High	 High	 High	 High	
Metastasis	 Uncommon	 Lymph	nodes	Distant	organs	 Lymph	nodes	Peritoneal	Distant	organs	 Lymph	nodes	Peritoneal	-/+	
Lymph	nodes	Peritoneal	Distant	organs	
Prognosis	 Favorable	 Poor	 Poor	 Poor	 Poor	
Molecular	characteristics	
DNA	MMR	loss	 -/+	 -/+	 -	 -/+	 -	
Common	
mutations	
PTEN,	KRAS,	
PIK3CA,	
CTNNB1	
PTEN,	KRAS,	
PIK3CA,	
CTNNB1,	TP53	
TP53,	PIK3CA	 PIK3CA	 TP53,	PIK3CA	
ER/PR	expresssion	 +	 -/+	(frequent)	 -/+	 -	 -/+	
p16	expression	 -	 -	 +	 -	 -/+	
Ki-67	 Low	 High	 High	 Low/High	 High	EEC:	 endometrioid	 endometrial	 cancer;	 SEC:	 serous	 endometrial	 cancer;	 CCEC:	 clear	 cell	 endometrial	 cancer;	 CS:	carcinosarcoma;	ER:	estrogen	receptor;	PR:	progesterone	receptor;	MMR:	mismatch	repair.	+	:	present/high;	–	:	absent/low;	–/+	:	could	be	present	or	absent.	Adapted	from	Murali	et	al.,	2014123.	
1.3.2.3 Risk	factors	in	endometrial	carcinoma	Endometrial	 cancer	 is	 associated	 with	 several	 risk	 factors,	 including	 age,	 overweight,	obesity,	 and	 endometrial	 hyperplasia130,	131.	Multiple	 risk	 factors	 associated	 to	 hormonal	imbalance	 (due	 to	 high	 exposure	 to	 estrogens)	 have	 been	 described	 to	 increase	 uterine	cancer	risk,	 such	as	 long	menstrual	 lifespan,	exposure	 to	hormonal	 replacement	 therapy	or	 nulliparity132-134.	 Medical	 disorders	 as	 diabetes,	 polycystic	 ovarian	 syndrome,	 and	previous	diagnosis	of	breast	or	ovarian	tumors,	which	may	 involve	tamoxifen	treatment,	are	 also	 linked	 to	 a	 higher	 risk135-139.	 Other	 factors	 as	 the	 use	 of	 oral	 contraceptives,	multiparity	and	physical	activity	descrease	the	risk	of	suffering	uterine	cancer140-142.		Approximately	 2-5%	 of	 ECs	 are	 related	 to	 hereditary	 causes,	 most	 of	 them	 to	 Lynch	syndrome,	whose	molecular	basis	are	explained	in	the	1.3.2.7	section.	
1.3.2.4 Clinical	manifestations	and	diagnosis	of	uterine	cancer	The	 most	 common	 clinical	 manifestation	 in	 uterine	 cancer	 is	 the	 abnormal	 vaginal	bleeding	 or	 discharge,	 including	 bleeding	 after	 menopause	 or	 between	 periods.	 Pelvic	pain,	presence	of	a	mass	and	loss	of	weight	can	also	appear	in	later	stages	of	the	disease143.		Diagnostic	procedures	in	endometrial	cancer	are	based	on	ultrasound	test	and	especially	endometrial	tissue	analysis.	Pre-operative	endometrial	tissue	can	be	obtained	by	dilation	and	 curettage	 (D&C),	 hysteroscopy-guided	 biopsy	 or	 aspiration144-146.	 The	 D&C	 is	nowadays	considered	a	poor	diagnostic	procedure	that	may	cause	high	discomfort	in	the	
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INTRODUCTION	 		 	patients144.	 Conversely,	 uterine	 aspirate	 (UA)	 is	 a	 minimally	 invasive	 biopsy	 performed	with	 a	 flexible,	 disposable	 suction	 curette	 or	 pipelle,	 preferentially	 a	 pipelle	 de	 Cornier.	However,	a	failure	rate	of	8%	has	been	reported	in	obtaining	such	samples,	whereas	13%	of	 the	 samples	 turn	 out	 to	 be	 histologically	 inadequate146-148.	 This	 especially	 occurs	 in	postmenopausal	women149.	In	fact,	hysterecopy-guided	biopsies	have	been	reported	to	be	more	 sensitive	 than	 those	 obtained	 by	 aspiration145,	 149,	 150.	 Nonetheless	 the	 use	 of	hysteroscopy	increases	the	risk	of	complications,	such	as	uterine	perforation,	hemorrhage,	potential	damage	to	other	organs,	together	with	stroke	and	intoxication	provoked	by	the	dilation	procedure151.	Although	there	is	no	significant	relation	between	hysteroscopy	and	the	prognosis	of	 the	disease,	 it	has	also	been	associated	with	peritoneal	disemination	of	tumor	cells152.	 In	spite	of	that,	the	diagnostic	value	of	UAs	was	enlarged	due	its	potential	use	in	molecular	diagnosis153,	154.	
1.3.2.5 Stages	and	prognosis	factors	in	uterine	cancer	Endometrial	carcinoma	staging	 is	usually	performed	following	the	FIGO	criteria	as	 in	OC	(1.3.1.5	 section),	 although	 the	 TNM	 system	 is	 also	 employed.	 The	 main	 factors	 for	 an	optimal	 staging	 include	 tumor	 location,	 depth	 of	myometrial	 invasion	 and/or	 lymphatic	invasion,	and	extra-uterine	spread.	Moreover,	the	most	important	prognosis	factors	in	EC	are	 not	 only	 defined	by	 tumor	 staging,	 but	 tumor	histology	 and	 grade	 are	 also	 decisive.	The	last	FIGO	revision	for	ECs	is	summarized	in	Supplementary	Table	257.		
1.3.2.6 Standard	 treatment	 and	 new	 therapeutic	 approaches	 for	
endometrial	carcinoma	Nowadays	 the	 standard	 treatment	 of	 EC	 depends	 on	 tumor	 stage	 and	 histologic	 grade.	This	 includes	 (alone,	 consecutively	 or	 in	 combination)	 surgery,	 radiation,	 hormone	therapy	and	chemotherapy155.	The	use	of	adjuvant	radio	and/or	chemotherapy	is	based	on	the	presence	of	 risk	 factors.	However,	 the	high	rates	of	 treatment	 fail	 in	high	aggressive	and	recurrent	EC	reveal	the	need	of	new	therapeutic	approaches.	Novel	targeted	therapies	have	been	proposed	considering	the	molecular	abnormalities	described	in	EC	(see	1.3.2.7	section)156.	 In	 this	 sense,	 current	 strategies	 are	mainly	 focused	 in	 the	 inhibition	 of	 PI3K	pathway	 through	 mTOR	 inhibitors,	 the	 use	 of	 EGFR	 and	 PARP	 inhibitors,	 and	 more	recently,	immunotherapies157-161.	
1.3.2.7 Molecular	features	of	endometrial	carcinomas	Molecular	alterations	in	EC	have	been	associated	to	the	two	types	traditionally	described,	in	 which	 different	 gene	 expression	 and	 copy	 number	 profiles	 have	 been	 found162-164.	Basically,	EECs	show	microsatellite	instability	(MSI)	and	mutations	in	PTEN,	PIK3CA,	KRAS	
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INTRODUCTION	 		 	and	 CTNNB1;	 while	 NEECs	 are	 characterized	 by	 p53	 alterations,	 loss	 of	 heterozygosity	(LOH)	 through	 extensive	 somatic	 copy	 number	 alterations	 (SCNAs)	 and	 less	 frequent	alterations	 as	ERBB2	 amplifications	 or	 CDKN2A	 (p16)	mutations	 and	 overexpression124.	However,	 no	 mutations	 in	 any	 of	 these	 genes	 have	 been	 exclusively	 detected	 in	 either	tumor	 subtype.	 The	most	 common	 alterations	 found	 in	 EC	 and	 its	 prevalence	 in	 type	 I	versus	type	II	sporadic	tumors	are	summarized	in	Table	4.		
Table	4	Common	molecular	alterations	reported	in	endometrial	carcinoma		 Function	 Alteration	 Type	I	
prevalence	
Type	II	
prevalence	MSI165-167	 DNA	repair	 Methylation,	mutation	 20-30%	 0-2%	
PTEN168,	169	 Tumor	suppressor	 Mutation,	deletion,	methylation,	expression	 52-78%	 0-11%	
PIK3CA170,	171	 Oncogene	 Amplification	 2-14%	 46%	Mutation	 36-52%	 24-42%	
PIK3R1172	 Oncogene	 Mutation	 21-43%	 0-12%	
KRAS173	 Oncogene	 Mutation	 13-26%	 0-10%	
CTNNB1174,	175	 Oncogene	 Mutation	 25-38%	 0-5%	
ARID1A176,	177	 Tumor	suppressor	 Mutation	 25-48%	 11-26%	
TP53173	 Tumor	suppressor	 Mutation	 5-10%	 80-90%	
PPP2R1A178	 Tumor	suppressor	 Mutation	 5-7%	 15-43%	Her2/neu	
(ERBB2)179	 Oncogene	 Amplification,	expression	 0%	 18-80%	
CDKN2A180,	181	 Tumor	suppressor	 Mutation,	methylation,	expression	 10%	 10-40%	
CDH1182	 Tumor	suppressor	 Loss	of	expression	 50%	 80%	MSI:	microsatellite	instability.	Adapted	from	Salvesen	et	al.,	2012183	and	Murali	et	al.,	2014123.	
1.3.2.7.1 Molecular	alterations	associated	to	type	I	EC	As	 mentioned	 before,	 molecular	 alterations	 described	 in	 EEC	 include	 MSI	 and	 somatic	alterations	in	the	genes	mentioned	above.	The	 presence	 of	 MSI	 was	 initially	 described	 in	 patients	 with	 Lynch	 syndrome,	 which	presented	 inherited	germline	mutations	 in	MMR	genes,	 including	MLH1,	MSH2,	MSH6	 or	
PMS2.	 By	 contrast,	 in	 sporadic	 endometrial	 tumors,	 the	 main	 cause	 of	 MSI	 is	 MLH1	promoter	hypermethylation,	although	mutations	in	MMR	genes	are	also	present165-167.		On	the	other	hand,	alteration	of	the	PI3K/AKT/mTOR	pathway	by	activating	mutations	in	
PIK3CA	 or	 PIK3R1	 genes	 and	 inactivation	 of	 the	 tumor	 suppressor	 gene	 PTEN	 are	
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INTRODUCTION	 		 	frequently	found	in	this	tumor	subtype184.	In	fact,	PIK3CA	mutations	seem	to	be	associated	with	 invasion	 and	 adverse	 prognosis	 factors,	 such	 as	 blood	 vessel	 invasion185.	 PTEN	mutations	 have	 been	 also	 detected	 in	 atypical	 and	 non-atypical	 hyperplasia,	 considered	precursos	 lesions,	 which	 indicates	 that	 these	 are	 early	 events	 in	 the	 development	 of	EEC161.	The	same	observation	was	found	in	activating	KRAS	mutations,	considered	in	turn	a	bad	prognosis	factor186,	187.	Alterations	in	Wnt/β-catenin	include	CTNNB1	mutations	and	lack	of	E-caherin	expression,	 though	 the	second	 is	more	common	 in	 type	 II	 tumors174,	175.	Coexistence	 between	 MSI	 and	 PTEN	 and	 KRAS	 mutations	 has	 been	 described,	 while	
CTNNB1	mutations	appear	to	be	independent	of	them124.	Mutations	in	ARID1A,	a	recently	described	 tumor	 suppressor	 gene	 implicated	 in	 chromatin	 remodeling,	 have	 been	 also	found	in	both	EC	types,	although	seem	to	be	predominant	 in	endometrioid	and	clear	cell	carcinoma	histologies176,	177.	Mutations	 in	ARID1A	 frequently	 co-occur	with	alterations	 in	the	 PI3K	 pathway,	 and	 are	 associated	 with	 its	 activation188.	 The	 correlation	 between	
ARID1A	 and	 tumor	 stages	 and	 its	 presence	 in	 28%	 of	 metastatic	 ECs	 suggest	 its	contribution	to	the	progression	of	EECs189.	
1.3.2.7.2 Molecular	alterations	associated	to	type	II	EC	The	main	genetic	and	genomic	alterations	in	NEEC	are	TP53	mutations	and	chromosomal	instability,	 characterized	 by	 widespread	 chromosomal	 gain	 and	 losses90.	 Less	 frequent	mutations	have	been	described	in	PPP2R1A	and	CDKN2A	genes,	implicated	in	the	negative	control	 of	 cell	 growth	 and	 division178.	 In	 addition,	 amplification	 and	 overexpression	 of	
ERBB2,	 a	member	of	 the	 epidermal	 growth	 factor	 (EGF)	 tyrosine	kinase	 receptor	 family	involved	in	cell	proliferation,	have	been	observed	in	serous	and	clear	cell	carcinomas179.		
1.3.2.8 Omics	and	endometrial	cancer:	The	Cancer	Genome	Atlas	The	 description	 of	 classical	 molecular	 alterations	 found	 in	 EC	 was	 mainly	 based	 on	targeted	 and	 unique	 gene	 or	 pathways	 studies.	 However,	 the	 development	 of	 high-throughput	 techniques	 has	 allowed	 the	 expansion	 of	 these	 studies	 to	 a	 large-scale	molecular	 way47.	 Thus,	WES	 analyses	 previous	 to	 the	 TCGA	 revealed	mutations	 in	 new	candidate	genes,	although	their	biological	and	clinical	relevance	have	not	been	elucidated.	A	WES	study	including	11	endometrioid	and	two	mixed	carcinomas	showed	mutations	in	
ARID1A,	 IGFBP1,	 WNT11,	 HER3	 and	 RPS6KC1	 genes188.	 On	 the	 other	 hand,	 three	independent	 studies	 revealed	 frequent	 alterations	 in	 chromatin-remodeling	 and/or	ubiquitin	 ligase	 complex	 genes	 in	 serous	 tumors,	 including	CHD4	 and	FBXW7	mutations	and	CCNE1	amplifications190-192.	In	this	sense,	our	group	have	recently	reported		frequently	mutations	 in	chromatin	remodelling	and	DNA	repair	genes193.	Additional	WES	studies	 in	less	 frequent	uterine	cancer	 types	 including	 sarcomas	and	undifferentiated	 tumors	have	
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INTRODUCTION	 		 	been	recently	carried	out,	revealing	a	low	rate	of	point	mutations	in	sarcomas	and	a	high	molecular	heterogeneity	in	undifferentiated	tumors194,	195.	Nevertheless,	 the	 integrated	 analysis	 performed	 by	 the	 TCGA	 is	 the	most	 complete	 and	influential	 study	 to	 the	 date196.	 A	 total	 of	 373	 endometrial	 carcinomas,	 including	endometrioid	(n=307),	 serous	(n=53)	and	mixed	(n=13)	carcinomas,	were	characterized	at	a	genomic,	transcriptomic	and	proteomic	level.	These	analyses	allow	the	stratification	of	EC	into	four	distinct	molecular	subgropus:	POLE/ultramutated,	MSI/hypermutated,	copy-number	low/endometrioid	and	copy-number	high/serous-like.	The	main	characteristics	of	each	subgroup	are	highlighted	in	Figure	5.			
	
Figure	5	Molecular	classification	of	endometrial	carcinoma	based	on	 the	TCGA	study.	Summary	of	the	new	molecular	subgroups	identified	in	the	TCGA	study196.		The	existence	of	four	distinct	molecular	subgroups	was	 proposed	 based	 on	 somatic	 copy	 number	 alterations	 (SCNAs),	 mutational	 profile	 and	 microsatellite	instability	 (MSI).	 Additional	 classifications	 regarding	 mRNA	 and	 protein	 expression	 as	 well	 as	 DNA	methylation	were	correlated	with	the	integrated	subgroups.		
POLE	
(ultramutated,	
n=17)	
MSI	
(hypermutated,	
n=65)	
Copy-number	low	
(endometrioid,	
n=90)	
Copy-number	high	
(serous-like,	n=60)	
SCNAs	 Few	SNCAs	(clusters	1	and	2)	 Few	SNCAs	(clusters1-3)		 Few	SNCAs	(clusters1-3)		
Extensive	SNCAs	
(cluster	4)	Frequent	MYC,	
ERBB2	and	CCNE1	ampli=ications,	and	alterations	in	LRP1B,	
FGFR3/1	and	SOX17		
Mutation	rate	 232	x	10-6	mutations	per	Mb	 18	x	10-6	mutations	per	Mb	 2.9	x	10-6	mutations	per	Mb	 2.3	x	10-6	mutations	per	Mb	
Prognosis	 Favorable	 Intermediate	 Intermediate	 Poor	
Frequent	
mutations	
POLE,	PTEN,	PIK3R1,	
PIK3CA,	FBXW7,	
KRAS	
RPL22,	KRAS,	PTEN,	
PIK3CA,	PIK3R1,	
ARID1A	
CTNNB1,	
PTEN,	PIK3CA,	
PIK3R1,	ARID1A,		
TP53,	PIK3CA,	
PPP2R1A,	FBXW7	
Other	
molecular	
characteristics	
Increased	frequency	of	CèA	transversions	 MLH1	promoter	methylation	 Infrequent	PTEN	and	KRAS	mutations	
Hystology	and	
grade	
Endometrioid		(grade	1-3)	 Endometrioid		(grade	1-3)	 Endometrioid		(grade	1-2)	 Serous,	mixed	and	high-grade	endometrioid	
mRNA	
expression	 Immunoreactive	 Hormonal		(decreased	MLH1,	increased	PGR)	
	Mitotic	(increased	CCNE1,	
PIK3CA,	MYC,	CDKN2A)		
Protein	
expression	
Cluster	1:		é	ASNS	and	CCNB1	 Cluster	2:	é	p-Akt		and	êPTEN	 Cluster	3:é	RAD50		 	Cluster	4:	é	p53	
Methylation	
MC1:	heavily	methylated	(MLH1	promoter	methylation)	 MC3:	minimal	DNA	methylation	
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INTRODUCTION	 		 	Additionally,	 novel	 classifications	 were	 also	 performed	 based	 on	 mRNA	 expression	(n=333),	protein	expression	(n=293)	and	DNA	methylation	(n=373).	Interestingly,	clusters	obtained	 from	 mRNA	 sequencing,	 named	 ‘mitotic’,	 ‘immunoreactive’	 and	 ‘hormonal’,	strongly	correlated	with	the	integrated	clusters	explained	above.	Similar	results	were		also	found	in	the	protein	expression	and	DNA	methylation	analyses	(Figure	5).	Furthermore,	these	 data	were	 integrated	 to	 identify	 recurrently	 altered	 pathways,	 being	 RTK/RAS/β-catenin	and	PI3K	pathways	consistently	affected.	Finally,	the	TCGA	study	revealed	a	high	genomic	alterations	concordance	between	high-grade	serous	ovarian	carcinomas,	serous	endometrial	carcinomas	and	basal-like	breast	carcinomas.	Moreover,	 a	 recent	 study	 has	 expanded	 and	 reanalyzed	 the	 TCGA	 data	 with	 improved	bioinformatics	methods50,	 identifying	a	 total	of	49	 frequently	mutated	genes,	21	of	 them	not	previously	described	in	EC	(Supplementary	Table	3).	 Interestingly,	some	of	them	are	involved	in	the	estrogen	receptor	pathway	(including	NRIP1	and	ESR1).	
1.3.2.9 Intratumor	heterogeneity	in	endometrial	cancer	Given	 the	significance	of	 ITH	 from	the	clinical	point	of	view,	 it	 is	 important	 to	study	 the	relevance	of	 this	phenomenon	 in	EC.	Despite	 that	 the	majority	of	 large-scale	 sequencing	analyses	have	been	based	on	primary	EC,	a	recent	study	including	not	only	primary	tumor	but	also	pre-malignant	and	metastatic	lesions	have	revealed	the	genomic	evolution	of	EC50.	In	this	analysis,	atypical	hyperplasia,	considered	as	precursor	tumoral	lesions,	showed	at	least	one	mutated	gene,	mainly	PTEN	or	PIK3CA.	However	no	recurrent	metastasis-specific	driver	mutations	were	 identified.	Primary	 tumors	and	paired	metastasis	 (n=26)	 showed	similar	 levels	 of	 alterations,	 although	 only	 an	 average	 of	 48%	of	mutations	 and	 56%	of	SCNAs	were	common	between	paired	samples.	This	ITH	was	also	found	in	those	cases	in	which	multiple	metastasis	regions	were	analyzed	(n=7).	In	the	majority	of	these	cases,	the	metastatic	 regions	were	more	 closely	 related	 to	 each	 other	 than	 to	 the	 primary	 tumor,	suggesting	 a	 monophyletic	 evolution.	 Although	 bioinformatics	 analysis	 revealed	 the	presence	 of	 subclonal	 populations	 in	 the	 primary	 tumor	 from	 which	 metastasis	 would	arise,	 cases	 with	 multiple	 primary	 tumor	 regions	 were	 not	 included	 in	 this	 study	 to	confirm	this	hypothesis.	In	this	regard,	additional	studies	covering	multiple	regions	of	the	primary	tumor	are	needed	to	better	understand	ITH	in	EC.		
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2 OBJECTIVES	Previous	 studies	 have	 reported	 the	 presence	 of	 intratumor	 genomic	 and	 genetic	heterogeneity	 (ITH)	 in	 gynecological	 cancers,	 mainly	 in	 ovarian	 carcinomas.	 However,	little	 is	known	about	endometrial	 carcinoma	as	well	 as	 the	 implications	 that	 ITH	entails	into	 the	 clinic.	Due	 to	 the	 interest	 of	 our	 group	 in	 translational	medicine	 and	molecular	diagnosis,	 as	 well	 as	 the	 application	 of	 new	 technologies	 based	 on	 next	 generation	sequencing	 into	 the	 clinical	 practice,	 the	 following	 objectives	 were	 set	 for	 the	 present	thesis:		 1. Decoding	 ITH	 in	 the	 TP53-null	 high	 grade	 serous	 ovarian	 carcinoma	 subtype:	multiple	samples	analysis	in	a	patient.		2. Implementing	 new	 massive	 sequencing	 protocols	 for	 endometrial	 cancer	diagnosis:	mutational	profile	of	uterine	aspirates.		 3. Characterizing	 ITH	 in	 endometrial	 carcinoma:	 phylogenetic	 evolution	 analysis	regarding	the	mutational	distribution	in	metastatic	tumors.		 4. Deciphering	 ITH	 of	 an	 ambiguous	 endometrial	 carcinoma	 by	 exome	 analysis:	advancing	in	the	translation	of	clinical	research	into	the	practice.			
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3 MATERIALS	AND	METHODS	
3.1 Human	samples	
For	 this	 thesis,	 different	 groups	 of	 formalin	 fixed	 paraffin	 embedded	 (FFPE)	 and	 frozen	samples	 have	 been	 analyzed	 in	 three	 independent	 projects:	WES	 in	 ovarian	 carcinoma,	targeted	 massive	 sequencing	 in	 uterine	 aspirates	 and	 WES	 in	 metastatic	 endometrial	carcinomas.	 Samples	 were	 collected	 at	 the	 MD	 Anderson	 Cancer	 Center	 (Madrid),	 the	Arnau	 de	 Vilanova	 University	 Hospital	 (Lleida),	 the	 Vall	 d’Hebron	 University	 Hospital	(Barcelona),	 the	 Bellvitge	 University	 Hospital	 (Barcelona),	 the	 Catalan	 Institute	 of	Oncology	(Barcelona)	and	the	Medical	University	(Lublin).	Tissue	samples	were	obtained	with	the	support	of	MD	Anderson	Foundation	Biobank	(record	number	B.0000745,	ISCIII	National	 Biobank	 Record),	 the	 Xarxa	 Catalana	 de	 Bancs	 de	 Tumors	 and	 Plataforma	 de	Biobancos	 ISCIII	 (PT13/0010/0014,	 B.000609).	 Samples	 were	 retrospectively	 selected	following	 the	 study	 criteria	 and	 the	 procedures	 established	 in	 the	 actual	 Spanish	 Law	14/2007	on	Biomedical	Research	and	 the	1716/2011	Royal	Decree	on	Biobanks.	All	 the	specimens	 were	 collected	 under	 patient	 informed	 consent	 and	 each	 project	 had	 the	approval	of	Ethics	and	Scientific	Committees	of	the	corresponding	institutions.	
3.1.1 Ovarian	samples		For	the	ovarian	carcinoma	study,	a	total	of	12	samples	were	obtained	from	a	50-years-old	patient	diagnosed	with	a	 recurrent	High	Grade	Serous	Ovarian	Carcinoma	(HGSOC).	The	description	of	the	samples	is	included	in	Table	5.	
	
Table	5	Ovarian	cancer	samples	characteristisc	
Sample	 Type	of	Tissue	 Surgery	 Anatomical	location	 Type	of	Study	
P1	 Frozen	 Primary	 Ovary	 WES	+	Sanger	
P2	 FFPE	 Primary	 Rectum	 Sanger	
P3	 FFPE	 Primary	 Right	intra-pelvic	dissemination	 Sanger	
P4	 FFPE	 Primary	 Left	intra-pelvic	dissemination	 Sanger	
P5	 FFPE	 Primary	 Thin	mesentery	 Sanger	
P6	 FFPE	 Primary	 Hepatic	flexure	 Sanger	
IR1	 Frozen	 Recurrence	 Pararectal	dissemination	 WES	+	Sanger	
IR2	 FFPE	 Recurrence	 Pararectal	dissemination	 Sanger	
ER1	 Frozen	 Recurrence	 Ileum	 WES	+	Sanger	
ER2	 FFPE	 Recurrence	 Mesentery	first	jejunal	loop	 Sanger	
ER3	 FFPE	 Recurrence	 Ileum	 Sanger	
ER4	 FFPE	 Recurrence	 Left	sigmoid	 Sanger	
N	 Frozen	 Recurrence	 Mesothelium	 WES	+	Sanger	P:	Primary	Tumor,	 IR:	 intrapelvic	 recurrence,	ER:	 extrapelvic	 recurrence,	WES:	Whole-exome	 sequencing,	 Sanger:	 Sanger	sequencing	
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3.1.2 Endometrial	samples	Two	subset	of	patients	were	analyzed	in	two	different	projects	of	endometrial	cancer	(EC).		
3.1.2.1 Uterine	Aspirates	project	In	 this	 study,	 the	 potential	 use	 of	 uterine	 aspirates	 (UAs)	 in	 genetic	 diagnosis	 as	 a	 low	invasive	biopsy	was	analyzed	and	compared	with	its	paired	hysterectomy	sample.	Cancer	samples	as	well	as	pre-malignant	and	bening	lesions	were	included	(Table	6,	Table	7).		
Table	6	Endometrial	samples	analyzed	in	the	uterine	aspirate	project	
Diagnosis	 n	(%)	Endometrial	Cancer	 62/99	(61.4)	Atypical	Hyperplasia	 10/99	(9.9)	Non-Atypical	Hyperplasia	 7/99	(6.9)	Leiomyoma	 7/99	(6.9)	Normal	Endometrium	 13/99	(12.9)		
Table	7	Pathological	features	of	the	endometrial	cancer	samples	analyzed	in	the	uterine	aspirate	
project	
		 n	(%)	
Tumor	subtype	(n=62)	 	Endometrioid	Endometrial	Carcinomas	 44	(71.0)	Serous	Endometrial	Carcinomas	 9	(14.5)	MMMT	 9	(14.5)	
Endometrioid	endometrial	carcinomas:	grade	(n=44)	 	1	 12	(27.3)	2	 8	(12.9)	3	 24	(54.5)	
Endometrioid	endometrial	carcinomas:	FIGO	stage	(n=44)	 	IA-B	 32	(72.7)	IIA-B	 6	(13.6)	IIIC	IVA-B	 4	(9.1)	2	(4.5)	Serous	endometrial	carcinomas:	grade	(n=9)	 	3	 9	(100)	
Serous	endometrial	carcinomas:	FIGO	stage	(n=9)	 	IA	 2	(22.2)	IIA	 1	(11.1)	IIIA-C	 6	(66.7)	
Carcinosarcomas:	grade	(n=9)	 	3	 9	(100)	
Carcinosarcomas:	FIGO	stage	(n=9)	 	IA-B	 6	(66.7)	II	 2	(22.2)	IIIC	 1	(11.1)	
Carcinosarcomas:	Epithelial	component	(n=9)	 	Endometrioid		 2	(22.2)		Serous		 6	(66.7)		Clear	Cell	 1	(11.1)		
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3.1.2.2 WES	in	metastatic	EC	project	Multiple	 tumor	 regions	 from	 patients	 diagnosed	 with	 metastatic	 EC	 were	 analyzed	 in	order	 to	 study	 intratumor	 heterogeneity	 (ITH).	 For	 this	 purpose,	 at	 least	 three	 samples	from	each	 tumor	patient	were	 analyzed	by	WES.	A	 total	 of	 11	EC	 cases	 (Table	 8)	were	moleculary	grouped	according	to	the	TCGA	classification196	as	copy-number	low	(CN-low,	n=3),	 microsatellite	 unstable	 (MSI,	 n=4)	 and	 serous	 like	 (n=4)	 carcinomas.	 Genetic	variants	detected	in	this	analysis	were	validated	by	targeted	massive	parallel	sequencing	in	the	original	samples	as	well	as	in	additional	samples	from	the	same	patients	(Table	9).		
Table	8	Summary	of	endometrial	cancer	cases	analyzed	in	the	WES	project	
Patient	 Histology	 Grade	 FIGO	
Myometrial	
infiltration	
Lymph	
node	
invasion	
POLE	
Status	
MSI	Status*	
TCGA	
Classification**	
	EEC-1	 Endometrioid	 2	 IIIC	 100%	 Yes	(5/42)	 WT	 Negative	 CN-low	EEC-2	 Endometrioid	 2	 IIIC	 75%	 Yes	(1/1)	 WT	 Negative	 CN-low	EEC-3	 Endometrioid	 2	 IB	 80%	 No	 WT	 Negative	 CN-low	EEC-4	 Endometrioid	 2	 IA	 40%	 No	 WT	 Positive-Low	 CN-low	EEC-5	 Endometrioid	 3	 IV	 100%	 -	 WT	 Positive-High	 MSI	EEC-6	 Endometrioid	 3	 IB	 75%	 No	 WT	 Positive-High	 MSI	EEC-7	 Endometrioid	 3	 IB	 <50%	 No	 WT	 Positive-High	 MSI	SEC-1	 Serous	 3	 IIIB	 95%	 -	 WT	 Negative	 Serous-like	SEC-2	 Serous	 3	 IIIA	 80%	 -	 WT	 Negative	 Serous-like	SEC-3	 Serous	 3	 IIIA	 <50%	 No	 WT	 Negative	 Serous-like	AEC	 Ambiguous	 3	 IIIC	 95%	 Yes	(11/36)	 WT	 Negative	 Serous-like	*	MSI	 status	was	 analyzed	 following	 the	3.8	 section.	 **Molecular	 classification	 based	 on	 the	 previously	 published	 TCGA	data196,	 including	 MSI	 (hypermutated),	 copy-number	 low	 (CN-low,	 endometrioid)	 and	 copy-number	 high	 (serous-like)	subgroups.			 	
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Table	9	Summary	of	primary	tumor	(T),	metastatic	(M)	and	normal	(N)	endometrial	samples	analyzed	
per	patient	in	the	WES	project	
Patient	 Sample	Name	 Type	of	Tissue	 Surgery	 Anatomical	location	 Type	of	Analysis	EEC-1	 EEC-1_N	 Blood	 Primary	 Blood	 WES+Validation	EEC-1	 EEC-1_T1	 Frozen	 Primary	 Fundus	 WES+Validation	EEC-1	 EEC-1_T2	 Frozen	 Primary	 Left	parametrium	 WES+Validation	EEC-1	 EEC-1_M	 Frozen	 Primary	 Right	pelvic	node	 WES+Validation	EEC-1	 EEC-1_T3	 FFPE	 Primary	 Left	pelvic	node	 Validation	EEC-1	 EEC-1_T4	 FFPE	 Primary	 Uterus	 Validation	EEC-1	 EEC-1_T5	 FFPE	 Primary	 Intern	iliac	node	 Validation	EEC-1	 EEC-1_M2	 FFPE	 Primary	 Right	primitive	Node	 Validation	EEC-2	 EEC-2_T1	 Frozen	 Primary	 Uterus	 WES+Validation	EEC-2	 EEC-2_T2	 Frozen	 Primary	 Uterus	 WES+Validation	EEC-2	 EEC-2_N	 Frozen	 Primary	 Non-tumoral	tissue	 WES+Validation	EEC-2	 EEC-2_M	 Frozen	 Primary	 Ovary	 WES+Validation	EEC-2	 EEC-2_T3	 FFPE	 Primary	 Uterus	 Validation	EEC-2	 EEC-2_T4	 FFPE	 Primary	 Uterus	 Validation	EEC-2	 EEC-2_T5	 FFPE	 Primary	 Uterus	 Validation	EEC-2	 EEC-2_T6	 FFPE	 Primary	 Uterus	 Validation	EEC-2	 EEC-2_T7	 FFPE	 Primary	 Uterus	 Validation	EEC-2	 EEC-2_M2	 FFPE	 Primary	 Ovary	 Validation	EEC-2	 EEC-2_M3	 FFPE	 Primary	 Ovary	 Validation	EEC-2	 EEC-2_M4	 FFPE	 Primary	 Ovary	 Validation	EEC-3	 EEC-3_T1	 Frozen	 Primary	 Uterus	 WES+Validation	EEC-3	 EEC-3_T2	 Frozen	 Primary	 Uterus	 WES+Validation	EEC-3	 EEC-3_N	 Frozen	 Primary	 Non-tumoral	tissue	 WES+Validation	EEC-3	 EEC-3_M	 Frozen	 Recurrence	 Node	 WES+Validation	EEC-3	 EEC-3_T3	 FFPE	 Primary	 Uterus	 Validation	EEC-3	 EEC-3_T4	 FFPE	 Primary	 Uterus	 Validation	EEC-3	 EEC-3_T5	 FFPE	 Primary	 Uterus	 Validation	EEC-3	 EEC-3_M2	 FFPE	 Recurrence	 Iliac	node	 Validation	EEC-3	 EEC-3_M3	 FFPE	 Recurrence	 Iliac	node	 Validation	EEC-4	 EEC-4_T1	 Frozen	 Primary	 Uterus	 WES+Validation	EEC-4	 EEC-4_T2	 Frozen	 Primary	 Uterus	 WES+Validation	EEC-4	 EEC-4_N	 Frozen	 Primary	 Non-tumoral	tissue	 WES+Validation	EEC-4	 EEC-4_M	 Frozen	 Recurrence	 Epiplon	 WES+Validation	EEC-4	 EEC-4_T3	 FFPE	 Primary	 Uterus	 Validation	EEC-4	 EEC-4_M2	 FFPE	 Recurrence	 Peritoneum	 Validation	EEC-4	 EEC-4_M3	 FFPE	 Recurrence	 Peritoneum	 Validation	EEC-4	 EEC-4_M4	 FFPE	 Recurrence	 Peritoneum	 Validation	EEC-5	 EEC-5_T1	 Frozen	 Primary	 Depth	tumor	 WES+Validation	EEC-5	 EEC-5_T2	 Frozen	 Primary	 Superficial	tumor	 WES+Validation	EEC-5	 EEC-5_N	 Frozen	 Primary	 Non-tumoral	tissue	 WES+Validation	EEC-5	 EEC-5_M	 Frozen	 Primary	 Peritoneun	 WES+Validation	EEC-5	 EEC-5_T3	 FFPE	 Primary	 Uterus	 Validation	EEC-5	 EEC-5_T4	 FFPE	 Primary	 Uterus	 Validation	EEC-5	 EEC-5_T5	 FFPE	 Primary	 Uterus	 Validation	EEC-5	 EEC-5_T6	 FFPE	 Primary	 Uterus	 Validation	EEC-6	 EEC-6_T1	 Frozen	 Primary	 Depth	tumor	 WES+Validation	EEC-6	 EEC-6_T2	 Frozen	 Primary	 Superficial	tumor	 WES+Validation	EEC-6	 EEC-6_N	 Frozen	 Primary	 Non-tumoral	tissue	 WES+Validation	EEC-6	 EEC-6_M	 Frozen	 Primary	 Ovary	 WES+Validation	EEC-6	 EEC-6_T3	 FFPE	 Primary	 Uterus	 Validation	EEC-6	 EEC-6_T4	 FFPE	 Primary	 Uterus	 Validation	EEC-6	 EEC-6_T5	 FFPE	 Primary	 Uterus	 Validation	EEC-6	 EEC-6_T6	 FFPE	 Primary	 Uterus	 Validation	EEC-6	 EEC-6_M2	 FFPE	 Primary	 Ovary	 Validation	EEC-6	 EEC-6_M3	 FFPE	 Primary	 Ovary	 Validation	EEC-6	 EEC-6_M4	 FFPE	 Primary	 Ovary	 Validation	EEC-6	 EEC-6_M5	 FFPE	 Primary	 Ovary	 Validation	
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N:	 normal,	 T:	 primary	 tumor,	 M:	 metastasis,	 WES:	 whole-exome	 sequencing,	 Validation:	 targeted	 massive	 parallel	sequencing	using	Ion	Torrent	System		 	
Patient	 Sample	Name	 Type	of	Tissue	 Surgery	 Anatomical	location	 Type	of	Analysis	EEC-7	 EEC-7_T1	 Frozen	 Primary	 Uterus	 WES+Validation	EEC-7	 EEC-7_T2	 Frozen	 Primary	 Uterus	 WES+Validation	EEC-7	 EEC-7_M	 Frozen	 Recurrence	 Diaphragm	 WES+Validation	EEC-7	 EEC-7_N	 Frozen	 Recurrence	 Blood	 WES+Validation	EEC-7	 EEC-7_T3	 FFPE	 Primary	 Uterus	 Validation	EEC-7	 EEC-7_M2	 FFPE	 Primary	 Diaphragm	 Validation	EEC-7	 EEC-7_M3	 FFPE	 Primary	 Diaphragm	 Validation	EEC-7	 EEC-7_M4	 FFPE	 Primary	 Diaphragm	 Validation	EEC-7	 EEC-7_M5	 FFPE	 Primary	 Diaphragm	 Validation	SEC-1	 SEC-1_T1	 Frozen	 Primary	 Uterus	 WES+Validation	SEC-1	 SEC-1_T2	 Frozen	 Primary	 Uterus	 WES+Validation	SEC-1	 SEC-1_T3	 Frozen	 Primary	 Uterus	 WES+Validation	SEC-1	 SEC-1_T4	 Frozen	 Primary	 Uterus	 WES+Validation	SEC-1	 SEC-1_N	 Frozen	 Primary	 Non-tumoral	uterus	 WES+Validation	SEC-1	 SEC-1_M	 Frozen	 Primary	 Ovary	 WES+Validation	SEC-1	 SEC-1_T5	 Frozen	 Primary	 Uterus	 Validation	SEC-1	 SEC-1_T6	 Frozen	 Primary	 Uterus	 Validation	SEC-1	 SEC-1_T7	 Frozen	 Primary	 Uterus	 Validation	SEC-1	 SEC-1_M2	 FFPE	 Primary	 Ovary	 Validation	SEC-1	 SEC-1_M3	 FFPE	 Primary	 Ovary	 Validation	SEC-1	 SEC-1_M4	 FFPE	 Primary	 Tube	 Validation	SEC-2	 SEC-2_T1	 Frozen	 Primary	 Uterus	 WES+Validation	SEC-2	 SEC-2_T2	 Frozen	 Primary	 Uterus	 WES+Validation	SEC-2	 SEC-2_T3	 Frozen	 Primary	 Uterus	 WES+Validation	SEC-2	 SEC-2_N	 Frozen	 Primary	 Non-tumoral	uterus	 WES+Validation	SEC-2	 SEC-2_M1	 Frozen	 Primary	 Ovary	 WES+Validation	SEC-2	 SEC-2_T4	 Frozen	 Primary	 Uterus	 Validation	SEC-2	 SEC-2_M2	 Frozen	 Primary	 Ovary	 Validation	SEC-2	 SEC-2_M3	 FFPE	 Primary	 Ovary	and	tube	 Validation	SEC-2	 SEC-2_M4	 FFPE	 Primary	 Ovary	 Validation	SEC-3	 SEC-3_T1	 Frozen	 Primary	 Uterus	 WES+Validation	SEC-3	 SEC-3_T2	 Frozen	 Primary	 Uterus	 WES+Validation	SEC-3	 SEC-3_M1	 Frozen	 Primary	 Ovary	 WES+Validation	SEC-3	 SEC-3_M2	 Frozen	 Primary	 Ovary	 WES+Validation	SEC-3	 SEC-3_N	 Frozen	 Primary	 Non-tumoral	uterus	 WES+Validation	SEC-3	 SEC-3_T3	 FFPE	 Primary	 Uterus	 Validation	SEC-3	 SEC-3_T4	 FFPE	 Primary	 Uterus	 Validation	SEC-3	 SEC-3_M3	 FFPE	 Primary	 Tube	 Validation	AEC	 AEC_T1	 Frozen	 Primary	 Superficial	tumor	 WES+Validation	AEC	 AEC_T2	 Frozen	 Primary	 Superficial	Tumor	 WES+Validation	AEC	 AEC_N	 Frozen	 Primary	 Non-tumoral	tissue	 WES+Validation	AEC	 AEC_M	 Frozen	 Primary	 Node	 WES+Validation	AEC	 AEC_T3	 FFPE	 Primary	 Uterus	 Validation	AEC	 AEC_T4	 FFPE	 Primary	 Uterus	 Validation	AEC	 AEC_T5	 FFPE	 Primary	 Uterus	 Validation	
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3.2 Samples	processing	
3.2.1 Tissue	fixation	and	paraffin	embedding	Tissue	samples	from	surgery	were	immediately	processed	by	the	pathologist	and	fixed	in	neutral	 tamponated	 formalin	 (PanReac-AppliChem).	 Then,	 samples	 were	 included	 in	paraffin	blocks	for	their	analysis	and	conservation,	after	several	steps	of	dehydration	with	increasing	ethanol	(PanReac-AppliChem)	concentrations.	Paraffin	blocks	were	cut	with	a	RM2255	 microtome	 (Leica,	 Germany)	 into	 sections	 of	 4µm	 and	 counterstained	 with	hematoxylin	and	eosin	(H&E).	Two	independent	pathologists	evaluated	the	histology	and	tumor	cell	percentage	of	each	sample.		
3.2.2 Tissue	freezing	procedure	Tissue	samples	for	frozen	conservation	were	processed	in	less	than	30	minutes	since	the	surgical	 procedure.	Representative	 zones	of	 the	 tumor	 (about	5mm2)	with	 viable	 tissue,	avoiding	 ischemia	areas,	were	selected	by	 the	pathologist.	After	resection,	 samples	were	included	 in	 a	 vinyl	 cryomold	 (Sakura,	 CA,	 USA),	 embedded	 in	 Optimal	 Cutting	Temperature	(OCT)	(Sakura,	CA,	USA)	and	frozen	by	immersion	in	isopentane	(VWR,	PA,	USA)	 (-56°C	 to	 -62°C).	 Frozen	 tissue	 blocks	 were	 stored	 at	 -80°C	 until	 use	 by	 the	corresponding	 Biobank.	 Tissue	 sections	 (5-10µm)	 were	 obtained	 using	 a	 HM525NX	cryostat	(ThermoFisher,	Germany)	and	counterstained	with	H&E	to	be	evaluated	by	two	independent	pathologists.	
3.2.3 Tissue	Microarrays		Tissue	microarrays	(TMA)	were	performed	with	a	'Quick	Ray'	manual	tissue	microarrayer	and	premade	recipient	blocks	with	120	holes	(10x12)	of	1mm	diameter	(IHC	World,	MD,	USA).	 Two	 different	 representative	 tumor	 regions	 from	 each	 case	 were	 selected.	 The	marked	tissue	was	punched	with	a	Quick-Ray	needle	(1mm)	and	delivered	to	the	intended	hole	 of	 the	 recipient	 block.	 After	 compleating	 all	 the	 samples,	 the	 recipient	 block	 was	transfered	to	the	embedding	mold	and	incubated	at	60°C	for	30	minutes	or	until	it	turned	completely	 transparent.	 Paraffin	 at	 64°C	was	 added	 to	 the	 block	 and	 the	 cassette	 array	was	placed	on	top	of	the	paraffin.	The	block	was	solidified	in	a	cold	plate	and	cut	(3-5µm)	in	a	RM2255	microtome	(Leica).	
3.2.4 Uterine	aspirate	processing	Uterine	aspirates	were	collected	with	a	Cornier	pipelle	by	clinicians	and	transported	to	the	laboratory	 immediately.	 Samples	 were	 transferred	 to	 a	 1.5ml	 Eppendorf	 tube	 and	maintained	on	ice	until	processing	(less	than	one	hour).	Aspirates	larger	than	700μl	were	
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MATERIALS	AND	METHODS	 		 	split	up	into	two	tubes	after	homogenization.	Aspirate	samples	were	diluted	in	a	1:1	ratio	with	 PBS	 1X	 and	 shook	manually	 by	 inverting	 the	 tube	 several	 times.	 Then,	 they	 were	centrifuged	for	20	minutes	at	2500g,	4°C.	Supernatant	and	pellet	were	separated	using	a	micropipette	and	both	were	stored	at	-80°C	until	use.	In	some	of	the	cases,	uterine	pellets	were	 processed	 as	 FFPE	 samples	 to	 generate	 blocks	 as	 previously	 described	 (see	3.2.1	section).	
3.2.5 Immnohistochemisty	analysis	Immunostaining	 was	 performed	 on	 2-4μm	 FFPE	 tissue	 sections.	 After	 deparaffinization	(60°C	 during	 1	 hour),	 PT	 Link	module	 (Dako,	 Denmark)	was	 used	 for	 antigen	 retrieval.	Immunohistochemistry,	 amplification	 and	 visualization	 of	 immune	 complexes	 were	performed	 in	 an	 Autostainer	 (Dako,	 Denmark),	 using	 EnVision	 FLEX+	 (Dako,	 CA,	 USA).	Primary	antibodies	used	in	the	different	projects	are	included	in	Supplementary	Table	4.	
3.3 DNA	extraction	and	quantification	
DNA	was	 extracted	 from	 several	 FFPE	 or	 frozen	 tissue	 sections	 (10-15μm)	 and	 uterine	aspirate	 pellets.	 Tissue	 was	 resuspended	 into	 Tris-HCl	 50mM	 pH8	 and	 digested	 with	Proteinase	 K	 (10mg/ml	 of	 Proteinase	 K,	 recombinant,	 PCR	 grade,	 Roche),	 followed	 by	phenol	 (Sigma-Aldrich)	 extraction	 and	 ethanol	 (PanReac-AppliChem)	 precipitation.	Additionally,	 DNA	 from	 blood	 samples	 was	 obtained	 using	 DNeasy	 Blood	 &	 Tissue	 Kit	(Qiagen),	 according	 to	 the	manufacturer’s	 protocols.	 DNA	 quantification	was	 performed	using	 NanoDrop	 2000	 Spectrophotometer	 and	 Qubit	 3.0	 Fluorometer	 with	 the	 Qubit	dsDNA	BR	Assay	Kit	(ThermoFisher).	DNA	quality	was	evaluated	using	electrophoresis	in	agarose	 gel	 (Agarose	D1	 Low	EEO,	 Conda-Pronadisa)	 and	 visualized	with	 the	 Chemidoc	XRS+	Molecular	Image	(BioRad).		
3.4 Targeted	massive	parallel	sequencing	
Targeted	 massive	 parallel	 sequencing	 was	 performed	 using	 IonTorrent	 System	(ThermoFisher)	 and	 following	 manufacturer’s	 protocols.	 Sequencing	 workflow	 is	summarized	in	Figure	6.	
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Figure	6	Scheme	of	targeted	massive	parallel	sequencing	protocol	summary.	Targeted	massive	parallel	sequencing	 was	 performed	 using	 IonTorrent	 technology	 (ThermoFisher)	 and	 following	 manofacturer’s	protocol.	Briefly,	after	library	construction	with	Ion	Ampliseq	kit	(A),	a	template	with	a	mix	of	libraries	were	generated	using	Ion	OneTouch	2	and	Ion	OneTouch	ES	(B).	Samples	were	runned	in	the	Ion	PGM	system	and	analyzed	by	the	Torrent	Suite	Software	v.4.2.1	(C).	
3.4.1 Library	construction	For	 library	preparation,	 10ng	of	DNA	quantified	 according	 to	Qubit	 protocol	were	used.	Multiplex	 PCR	 for	 preparation	 of	 amplicon	 libraries	 was	 performed	 using	 the	 Ion	AmpliSeq	 Library	 Kit	 2.0	 and	 Ion	 AmpliSeq	 Cancer	 Hotspot	 Panel	 v2	(https://www.thermofisher.com/order/catalog/product/4475346)	 or	 Custom	 Panels	(Supplementary	 Table	 5),	 which	 included	 the	 specific	 oligonucleotides	 designed	 for	 the	genes	 of	 interest	 in	 each	 project.	 The	 following	 conditions	 were	 used	 in	 an	 AB	 2720	Thermal	 Cycle	 (ThermoFisher):	 99,	 2min;	 cycle	 99°,	 2min/60°C,	 4min;	 10°C,	 hold.	 The	number	 of	 cycles	 used	 in	 the	 PCR	 amplification	 depended	 on	 the	 tissue	 type	 and	 the	number	of	primers	used	in	the	reaction	(Table	10).	After	PCR	amplification,	primers	were	partially	digested	using	FuPa	reagent	(50°,	10min;	55°,	10min;	60°,	10min;	10°,	hold	for	up	to	1	hour).	 Ion	P1	Adapter	 and	 Ion	Xpress	Barcode	X	were	 combined	and	 ligated	 to	 the	amplicons	 (22°,	 30min;	 72°,	 10min;	 10°,	 hold),	 in	 order	 to	 identify	 each	 sample	 with	 a	specific	 barcode.	 Libraries	 were	 purified	 and	 then	 quantified	 using	 the	 Ion	 Library	TaqMan	 Quantitation	 Kit	 and	 ViiA	 7	 system	 (ThermoFisher).	 Fo	 this	 purpose,	 libraries	were	diluted	(1:50)	to	reach	a	concentration	within	the	range	of	the	E. coli DH10B Control	
A)   Library	construction		(3.4.1	section)	 B)	Template	preparation	(3.4.2	section)	 C)	Run	Sequence	(3.4.3	section)	
D)	Data	analysis	(3.4.4	section)	Partially	digest	primer	sequences	
Genomic	DNA	
Amplify	targets	using	Ion	AmpliseqTM	Primer	Pool	
Ligate	adapters	Barcode	P1	
Barcoded	library	
Dilute	library	to	a	100	pM	concentration	
Combine	libraries	with	different	barcode	number	in	the	same	proportion	
1	 2	 3	
1+	
2+	
3	
Prepare	template-positive	ISP	during	the	emulsion	PCR	in	the	Ion	OneTouchTM	2		
ISP	
ISP	
Enrich	the	template-ISPs	in	the	Ion	OneTouchTM	ES		
Enriched	ISPs		+	Sequencing	primers		+	Polymerase		
Alignment	to	Hg19	human	reference	genome		
Variant	calling		
Mutation	selection:	PROVEAN	dbSNP	IGV	visualization	
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MATERIALS	AND	METHODS	 		 	Library	standards.	This	Control	Library	is	a	validated,	pre-quantified,	ready-to-use	control	that	was	diluted	serially	(from	6.8pM	to	0.00068pM),	generating	a	standard	curve	to	the	qPCR.	 Relative	 concentration	 of	 the	 sample	 libraries	 to	 the	 Control	 Libraries	 were	obtained	 from	 the	 qPCR	 analyses.	 Libraries	 were	 stored	 at	 -20°C	 in	 LoBind	 tubes	(Eppendorf)	until	use.		
Table	10	Number	of	cycles	used	in	the	multiplex	PCR	amplification	for	targeted	massive	parallel	
sequencing	
Primer	pairs	per	pool	
Number	of	cycles	
Standard	DNA	 FFPE	DNA	12-24	 21	 24	25-48	 20	 23	49-96	 19	 22	97-192	 18	 21	193-384	 17	 20	385-768	 16	 19	
3.4.2 Template	preparation	Template	preparation	and	enrichment	were	performed	using	Ion	PGM	Template	OT2	200	Kit	 (uterine	 aspirates	 project)	 or	 Ion	 PGM	 Hi-Q	 OT2	 Kit	 (EC	WES	 project)	 and	 the	 Ion	OneTouch	2	System.	Libraries	were	diluted	in	nuclease-free	water	to	a	final	concentration	of	 100pM	 and	 combined	 at	 the	 same	 proportion.	 Two	 µl	 of	 combined	 libraries	 were	diluted	in	23µl	of	water,	obtaining	a	final	volume	of	25µl.	Diluted	libraries	were	used	for	the	preparation	of	template-positive	Ion	PGM	Hi-Q	Ion	Sphere	Particles	(ISPs)	according	to	the	 manufacturer’s	 protocol.	 In	 summary,	 an	 emulsion	 PCR	 was	 perfomed	 in	 the	 Ion	OneTouch	2	followed	by	an	enrichment	executed	by	the	Ion	OneTouch	ES.	Enriched	ISPs	could	be	stored	at	2°C	to	8°C	for	up	to	3	days.		
3.4.3 Run	Sequence	Ion	PGM	Sequencing	200	Kit	v2	(uterine	aspirates	project)	or	Ion	PGM	Hi-Q	Sequencing	Kit	(EC	WES	 project)	 and	 Ion	 PGM	 System	 (ThermoFisher)	 were	 used	 for	 Next-Generation	Sequencing	 according	 to	 the	 manufacturer’s	 protocols.	 Enriched	 ISPs	 were	 centrifuged	and	 mixed	 with	 sequencing	 primers	 and	 sequencing	 polymerase.	 A	 range	 of	 12-16	libraries	were	run	in	316	or	318	v2	chips	to	reach	the	optimum	coverage,	with	at	least	100	reads	per	base	(100x).	
3.4.4 Bioinformatics	analysis	Alignment	 to	 Hg19	 human	 reference	 genome	 and	 variant	 calling	were	 performed	 using	Torrent	Suite	Software	v.4.2.1	(ThermoFisher).	All	samples	were	sequenced	and	analyzed	in	 equal	 conditions.	 Variants	 with	 a	 Phred-score	 quality	 value	 less	 than	 100	 were	
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MATERIALS	AND	METHODS	 		 	considered	as	low	quality	(LQ)	variants	(http://129.130.90.13/ion-docs/Technical-Note---Quality-Score_6128102.html).	Prediction	of	the	genomic	variant	impact	on	the	biological	function	of	the	corresponding	protein	was	performed	using	PROVEAN	(Protein	Variation	Effect	 Analyzer)	 Genome	 Variants	 tool	 (http://provean.jcvi.org/index.php)197.	 Genetic	variants	 with	 a	 damaging	 or	 deleterious	 consequence	 predicted	 by	 at	 least	 one	 of	 the	PROVEAN	 predictors	 (PROVEAN197	 or	 SIFT198)	 were	 selected	 and	 visually	 checked	with	the	 Integrative	 Genomics	 Viewer	 (IGV)	 v.2.3.40,	 Broad	 Institute199.	 Variants	 with	 global	minor	 allele	 frequencies	 higher	 than	 0.05	 were	 considered	 Single	 Nucleotide	Polymorphisms	 (SNPs)	 and	 were	 rejected	 (data	 from	 dbSNP,	http://www.ncbi.nlm.nih.gov/SNP/).	
3.5 Whole-exome	sequencing	
Whole-exome	sequencing	was	performed	 in	 collaboration	with	Sistemas	Genómicos,	 S.L.	(Paterna,	Valencia,	Spain)	and	the	MSKCC	Integrated	Genomics	Operation	(NY,	USA).		
3.5.1 Library	construction	DNAs	 from	 tumor	 samples	with	 at	 least	 90%	 of	 tumor	 cells	were	 selected	 after	 testing	their	quality	and	integrity	as	previously	described	(section	3.3).	Library	construction	was	perfomed	using	1µg	of	DNA	and	the	 last	version	of	SureSelectXT	Human	All	Exon	+	UTR	(71	Mb)	 enrichment	 kit	 (Agilent)	 (V4	 in	 the	 ovarian	 cancer	 and	 V5	 in	 the	 endometrial	cancer	 projects),	 following	manufacturer’s	 protocols	 and	 recommendations.	 The	 quality	and	quantity	of	the	libraries	were	analyzed	using	Bioanalyzer	2100	High	Sensitivity	assay	(Agilent)	and	real-time	PCR	in	LightCycler	480	(Roche),	respectively.	
3.5.2 Template	preparation	An	 in-emusion	 PCR	 was	 performed	 for	 fragment	 clonal	 amplification,	 followed	 by	 an	enrichment	process	and	chemical	modification	that	allowed	sample	loading	in	the	reaction	chamber.	 Quality	 and	 quantitiy	 of	 the	 microspheres	 from	 each	 library	 were	 estimated	using	the	parameters	from	the	workflow	analysis.	
3.5.3 Sequencing	process	
3.5.3.1 Ovarian	cancer	project	Sequencing	 reactions	 were	 performed	 to	 get	 read	 pairs	 in	 SOLiD	 high-throughput	sequencing	platform	and	a	mean	coverage	value	of	50	reads	per	base	 (50x).	Parameters	from	SOLiD	Experimental	 Tracking	 System	 software	were	used	 to	 calculate	 quality	 data	(https://tools.thermofisher.com/content/sfs/brochures/cms_057557.pdf).	
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3.5.3.2 Endometrial	cancer	project	Prior	 to	 clusters	 generation	 in	 cbot	 (Illumina),	 a	 pool	 of	 the	 libraries	 was	 performed.	Libraries	were	read	by	paired-end	sequencing	in	an	Illumina	HiSeq	2500	system	to	a	mean	coverage	value	of	50	reads	per	base	(50x).	
3.5.4 Bioinformatics	analysis	
3.5.4.1 Ovarian	cancer	project:	variant	analysis	Exomes	 alignment	 to	 Hg19/GRCh37	 human	 reference	 genome	 was	 performed	 using	Bioscope	 (http://solidsoftwaretools.com).	 Picard-tools	 (http://picard.sourceforge.net)	and	 SAMtools200	 (http://samtools.sourceforge.net/)	 were	 used	 for	 the	 post-alignment	sequence	filtering,	removing	that	sequences	with	a	mapping	quality	lower	than	1	and	PCR	duplicates.	 Variant	 calling	 was	 performed	 using	 a	 combination	 of	 three	 different	algorithms:	 SAMTools,	 GATk	 (http://www.broadinstitute.org/gatk/)	 and	 Bioscope.	 The	identified	 Single	 Nucleotide	 Variants	 (SNVs)	 were	 annotated	 using	 the	 ‘Application	Programming	 Interfaces’	 (APIs)	 from	 Ensembl	 v64201	 and	 several	 ‘custom’	 scripts.	Biological	consequence	of	the	genomic	variant	in	the	corresponding	protein	was	analyzed	through	 SIFT198,	 Condel202	 and	 Polyphen203	 computational	 predictors.	 Variants	 were	considered	mutations	 with	 negative	 consequence	 in	 the	 protein	 when	 one	 of	 the	 three	predictors	showed	a	damaging	effect.	
3.5.4.2 Ovarian	cancer	project:	functional	analysis	In	order	to	determine	the	biological	pathways	affected	by	genetic	variants	identified	in	the	ovarian	cancer	WES	study,	a	 functional	analysis	was	performed	using	David	protocols204,	205.	 Genetic	 variants	 were	 annotated	 using	 different	 biological	 databases	 as	 Biocarta	(http://www.biocarta.com/),	 Gene	 Ontology	 (http://geneontology.org/),	 KEGG	(http://www.genome.jp/kegg/pathway.html)	 and	 Reactome	(http://www.reactome.org/).	 An	 adjust	 p-Value	 threshold	 of	 0.2	 was	 used	 for	 the	selection	 of	 functional	 categories.	 Correlation	 between	 genes	 and	 functional	 categories	was	represented	through	Cytoscape	tool206.	
3.5.4.3 Endometrial	cancer	project:	variant	analysis	Bioinformatics	 analyses	were	performed	as	previously	described207-209.	Reads	 from	WES	and	 targeted	massive	 parallel	 sequencing	were	 aligned	 to	 the	 human	 reference	 genome	Hg19/GRCh37	 using	 Burrows-Wheeler	 Aligner	 (BWA)210.	 Somatic	 genetic	 variants	were	identified	 using	MuTect211	 for	 SNVs,	 and	 Strelka212	 and	 VarScan	 2213	 for	 small	 insertion	and	deletions	(indels).	The	potential	functional	effect	of	each	non-synonymous	SNV	was	in	
silico	 analyzed	 as	 previously	 described209,	 using	 a	 combination	 of	multiple	 predictors	 as	
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MATERIALS	AND	METHODS	 		 	shown	 in	 Figure	 7.	 Somatic	 copy	 number	 alterations	 (SCNAs),	 including	 loss	 of	heterozygosity	 (LOH),	were	analyzed	using	TITAN214.	The	 cancer	 cell	 fraction	 (CCF)	was	calculated	using	ABSOLUTE	and	manually	reviewed	as	recommended43,	196,	215.		
	
Figure	7	Decision	trees	followed	to	define	pathogenicity	in	mutations	in	the	endometrial	cancer	WES	
project.	The	possible	pathogenicity	of	each	mutation	was	define	based	on	the	above	decision	trees,	depending	on	the	type	of	consequence	generate	 for	each	variant.	According	to	these	trees,	mutations	were	classified	as	passenger,	potentially	pathogenic,	likely	pathogenic	or	pathogenic.	
3.5.4.4 Endometrial	cancer	project:	mutational	signatures	Somatic	 mutations	 occur	 as	 a	 consequence	 of	 diverse	 processes	 such	 as	 mutagen	exposures	 or	 defective	 DNA	 repair216.	 The	 specific	 combinations	 of	mutation	 types	 that	occur	 in	 a	 tumor	 sample	 are	 defined	 as	 mutational	 signature16,	 217,	 218.	 	 The	 mutational	signature	of	each	endometrial	tumor	sample	included	in	this	project	was	obtained	by	the	analysis	 of	 the	 mutational	 context	 as	 previously	 described16,	 209.	 Briefly,	 SNVs	 were	categorized	into	C>A,	C>G,	C>T,	T>A,	T>C	or	T>G	and	then	subcategorized	according	to	the	nucleotides	preceding	(5')	and	succeeding	(3')	the	mutated	base.	The	mutational	patterns	found	 in	our	 samples	were	 compared	 to	 the	previously	published	by	Alexandrov	et	al16,	after	 performing	 a	 normalization	 according	 to	 the	 frequency	 of	 nucleotide	 changes	observed	in	the	respective	sequencing	platforms.	
3.5.4.5 Endometrial	cancer	project:	TumorTracer	Server	TumorTracer	 server	 was	 used	 to	 determine	 the	 origin	 of	 an	 specific	 tumor	 sample	regarding	its	molecular	profile219.	Briefly,	WES	data	was	analyzed	by	the	server	in	order	to	compare	the	number	of	nonsynonymous	mutations,	the	mutational	signature	and	the	copy	number	 profile	 with	 a	 set	 of	 232	 specific	 cancer	 genes.	 Public	 data	 from	 the	 COSMIC	
Missense	Mutations	 Likely		Pathogenic	Potentially	Pathogenic	Cancer	Gene	(All	3)?	FATHMM	or	Chasm?	Pathogenic	by	Mutation	Taster	or	Chasm?	 Passenger	Passenger	
YES	 YES	
YES	
NO	 NO	NO	
In-frame	Mutations	
Pathogenic	by	Mutation	Taster	or	Chasm?	
YES	
NO	
(HaploinsufGicient	or	LOH)	and	Cancer	Gene?	Passenger	
YES	
NO	
Pathogenic	HaploinsufGicient	or	LOH	or	Cancer	Gene?	 YES	NO	
Potentially	Pathogenic	Passenger	
Frame	Shift,	Splice	Site	or	Truncating	Mutations	
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MATERIALS	AND	METHODS	 		 	database	were	used	to	train	random-forest	classifiers	to	discriminate	among	the	tissue	of	origin.	Based	on	these	data,	the	classification	score	was	defined	as	the	proportion	of	trees	from	 the	 validation	 dataset,	 that	 is,	 the	 fraction	 of	 samples	 with	 similar	 molecular	alterations	 that	your	 input	 sample.	On	 the	other	hand,	 the	confidence	score	 represented	the	 difference	 between	 the	 individual	 classification	 scores	 for	 the	 two	 highest-scoring	tissues.	
3.5.4.6 Endometrial	cancer	project:	in	silico	prediction	of	drug	treatment	In	order	 to	 identified	potential	effective	drugs	according	 the	mutational	profile	obtained	by	WES	 analysis,	 we	 perfomed	 an	 in	 silico	 study	 using	 different	 compounds	 databases:	CTD	 (http://ctdbase.org/)	 and	 STITCH	 (http://stitch.embl.de/)220-222.	 These	 databases	contain	peer-reviewed	information	about	the	effect	of	a	particular	drug	in	a	specific	gene	or	 signaling	 pathway,	 providing	 the	 correlationship	 between	 chemicals	 and	 proteins	 on	the	human	 context.	 In	 this	 analysis	we	 included	 the	mutational	 status	of	 each	 identified	gene	 in	 the	WES	 study	 of	 the	 ambiguous	 endometrial	 case	 (4.4	 section).	 The	 identified	drugs	were	 used	 to	 treat	 patient	 derived	 xenografts	 (PDX)	models	 originated	 from	 this	patient	 (see	 3.11	 section).	 The	 significance	 was	 performed	 using	 the	 non-parametric	Mann-Whitney	test.	
3.6 Phylogenetic	analysis	
3.6.1 Ovarian	cancer	project:	phylogenetic	analysis	Phylogenetic	 analysis	 was	 carried	 out	 using	 a	 hierarchical	 cluster	 based	 on	 mutational	pattern	 identified	 in	 the	 WES	 study	 of	 the	 ovarian	 cancer	 patient.	 The	 unsupervised	analysis	was	 performed	 using	 the	 SPSS	 17.0	 statistical	 program	 (SPSS	 Inc.,	 Chicago,	 IL)	assuming	Euclidean	distances	between	mutations.		
3.6.2 Endometrial	cancer	project:	phylogenetic	analysis	Maximun	 parsimony	 phylogenetic	 trees	 were	 generated	 using	 CCF	 values	 (in	 the	 WES	analysis)	 or	 binary	 presence/absence	 matrices	 (in	 the	 massive	 targeted	 sequencing	analysis)	 based	 on	 the	 non-synonymous	 somatic	 mutations	 of	 each	 tumor	 region,	 as	previously	described209.	Briefly,	the	R	package	Phangorn	was	used	to	performed	Neighbor-joining	method	and	Hamming	distance,	optimized	using	the	parsimony	Ratchet	method223.		 	
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3.7 PCR	and	Sanger	sequencing	
A	 percentage	 of	 genetic	 variations	 (SNVs	 and	 INDELs)	 detected	 by	 WES	 or	 targeted	massive	parallel	sequencing	in	the	different	projects	were	validated	by	Sanger	sequencing	as	a	second	independent	method.		
3.7.1 Primer	design	and	PCR	conditions	Primers	 for	 the	 selected	 variant	 validation	 were	 designed	 using	 Primer3Plus	(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi)	 and	 aligned	 to	Hg19/GRCh37	 genomic	 reference	 using	 Blast	 (http://blast.ncbi.nlm.nih.gov/Blast.cgi)	 to	test	their	specifity.		Forward	and	reverse	primers	were	designed	to	have	a	similar	melting	temperature	(Tm)	and	a	CG	content	between	40	and	60%.	In	order	to	stablish	the	optimal	PCR	 annealing	 temperature	 for	 each	 pair	 of	 primers,	 a	 gradient	 PCR	 protocol	 was	performed.	 A	 total	 of	 100ng	 of	DNA	were	mixed	with	 diluted	 primers	 (10X,	 2.5µl),	 PCR	master	 mix	 (M750B,	 Promega)	 (2X,	 12.5µl)	 and	 H2O	 in	 a	 final	 volume	 of	 25µl.	 The	following	protocol	was	run	in	a	T100TM	Thermal	Cycle	(Bio-Rad):	5min	at	94°C;	40	cycles	of	45s	at	94°C,	45s	at	a	range	of	55-59°C	and	45s	at	72°C;	and	7min	at	72°C.	PCR	products	were	analyzed	by	electrophoresis	using	2.5%	agarose	gels	(Agarose	D1	Low	EEO,	Conda-Pronadisa)	 stained	 with	 SybrSafe	 (ThermoFisher)	 and	 visualized	 in	 a	 Chemidoc	 XRS+	Molecular	 Image	 (BioRad).	 The	 annealing	 temperature	 resulting	 in	 the	 most	 efficient	amplification	was	chosen	for	each	pair	of	primers,	and	it	is	shown	in	Supplementary	Table	6.	
3.7.2 Sequencing	and	data	anlysis	Sequencing	 reactions	were	 prepared	with	 BigDye	 Terminator	 v3.1	 Cycle	 Sequencing	 kit	(Applied	Biosystems).	The	sequencing	mix	 included	20	ng	of	DNA	from	the	PCR	product	per	each	100	bases	of	amplicon	 length	and	1µl	of	primer	 (5pM).	Products	were	purified	using	gel	columns	with	the	Optima	DTR	96	Well	Plates	(EdgeBio),	in	order	to	eliminate	the	dye	 terminators,	 dNTPs	 and	 primers	 non-included	 during	 the	 reaction,	 to	 avoid	 they	interfere	 in	 the	 sequencing	 signal.	 Sequencing	products	were	 analyzed	 in	 a	 3730xl	DNA	Analyzer	 (96-capillary,	 ThermoFisher).	 Sequencing	 analyses	 were	 performed	 at	 the	Genomic	Unit	of	the	Madrid	Science	Park.		 	
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3.8 Microsatellite	instability	study	
Microsatellite	 instability	 (MSI)	was	 determined	 in	 the	 EC	 samples	 analyzed	 in	 the	WES	project,	 following	 the	 recommended	 criteria196,	 224,	 225.	 As	 an	 initial	 approach,	immunohistochemistry	 analyses	 of	 MLH1,	 MSH2,	 MSH6	 and	 PMS2	 proteins	 were	performed	(see	3.2.5	section).	Loss	of	expression	of	at	least	one	mismatch	repair	protein	was	considered	to	classify	the	case	as	MSI	positive224.	After	that,	5	microsatellite	markers	including	 two	 mononucleotide	 (BAT25	 and	 BAT26)	 and	 three	 dinucleotide	 (D2S123,	D5S346	 and	D17S250)	 repeat	markers	were	 analyzed	by	PCR	amplification	 followed	by	fragment	 analysis.	 PCR	was	performed	as	previously	described	 (section	3.7.1),	 and	PCR	conditions	 are	 included	 in	 Supplementary	 Table	 6.	 Fragment	 analysis	 was	 performed	using	 a	 3730	 DNA	 Analyzer	 (Applied	 Biosystem)	 at	 the	 Genomic	 Unit	 of	 the	 Madrid	Science	Park.	Cases	with	instability	detected	in	more	than	one	microsatellite	marker	were	classified	as	MSI-High.	MSI	status	of	EC	patients	(Table	8)	is	based	on	results	indicated	in	
Table	11.		
Table	11	MSI	analysis	by	IHC	and	microsatellite	markers	PCR	study	
	 IHC	 Microsatellite	markers	
	 MLH1	 MSH2	 MSH6	 PMS2	 D2S123	 D5S346	 D17S250	 Bat25	 Bat26	
EEC-1	 +	 +	 +	 +	 n.a.	 n.a.	 n.a.	 n.a.	 n.a.	
EEC-2	 +	 +	 +	 +	 n.a.	 n.a.	 n.a.	 n.a.	 n.a.	
EEC-3	 +	 +	 +	 +	 n.a.	 n.a.	 n.a.	 n.a.	 n.a.	
EEC-4	 -	 +	 +	 -	 -	 -	 -	 +	 -	
EEC-5	 -	 +	 +	 -	 +	 +	 -	 +	 +	
EEC-6	 -	 +	 +	 -	 -	 -	 -	 +	 +	
EEC-7	 -	 +	 -	 -	 +	 +	 -	 +	 +	IHC:	 +	 :	 expression,	 -	 :	 loss	 of	 expression.	Microsatellite	markers:	 +	 :	 instability,	 -	 :	 not	 presence	 of	 instability,	 n.a.	 :	 not	analyzed.	Red	color	marks	the	abnormal	status.	
3.9 Comparative	genomic	hybridization	(CGH)	
Comparative	 Genomic	 Hybridization	 (CGH)	 was	 accomplished	 adapting	 the	 methods	described	by	Kallioniemi	et	al.226.	Nick	 translation	kit	 (Abbot	Molecular	 Inc)	was	used	 to	label	tumor	and	normal	DNA.	A	total	of	200ng	of	labeled	DNA	per	sample	was	hybridized	to	 normal	 female	metaphase	 cells	 in	 the	 presence	 of	 20-35mg	 of	 Cot-1	DNA	 for	 3	 days.	After	washes,	chromosomes	were	counterstained	with	DAPI	in	an	antifade	solution	(Abbot	Molecular	 Inc).	 For	 the	 visualization,	 a	 Leica	 DM4500	 epifluorescence	 microscope	equipped	with	 a	 CCD	 camera	was	 used.	 At	 least	 15	metaphase	 cells	 per	 condition	were	analyzed	in	each	case	using	the	CytoVision	System	with	version	7.3.1	high-resolution	CGH	
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MATERIALS	AND	METHODS	 		 	analysis	 software	 (Leica	 Biosystems,	 UK).	 An	 average	 of	 normal	 cases	 were	 used	 as	 a	dynamic	standard	reference	for	comparing	the	CGH	profiles.	Along	the	mean	ratio	profiles,	the	 99.5%	 confidence	 interval	 of	 each	 mean	 ratio	 profile	 value	 was	 compared	 to	 the	corresponding	99.5%	standard	reference	intervals.	Chromosome	regions	with	no	overlap	between	the	two	intervals	were	considered	as	being	altered.		
3.10 	Fluorescence	in	situ	hybridization	(FISH)		
To	 perform	 fluorescence	 in	 situ	 hybridization	 the	 same	 metaphase	 chromosomes	 were	prepared	directly	form	the	samples	used	for	CGH.	Slices	were	incubated	at	90°C	for	10min,	washed	several	times	with	ethanol	for	dehydration	and	denatured	at	75°C	for	1min	in	the	presence	of	a	probe.	Gene-specific	probes	for	PML	(locus	15q22)	and	RARA	(locus	17q21.1,	control	 gene)	 (Vysis,	Downers	Grove,	 IL)	were	use	 for	detection	of	 gene	 amplication.	At	least	100	interphase	nucleis	were	analyzed	per	sample.	
3.11 	Patient	 Derived	 Xenograft	 (PDX):	 generation	 and	
treatment	
Patient	 derived	 xenograft	 (PDX)	were	 obtained	 from	 the	 Biomedical	 Research	 Group	 in	Gynaecology	(Vall	d’Hebron	Institute	of	Research).	All	animal	procedures	were	performed	according	 to	protocols	 approved	by	 the	Animal	Experimentation	Ethics	Committee	 from	the	Vall	d’Hebron	University	Hospital.	Five	patient	PDXs	from	an	ambiguous	endometrial	carcinoma	 (AEC_PDX)	 were	 generated	 using	 fresh	 primary	 tumor	 tissue	 by	subcutaneously	 implantation	 in	 the	 animal	 flanks.	 Regions	 from	 the	 superficial	 tumor	(AEC_PDX1),	 deep	 tumor	 (AEC_PDX2),	 right	 lymphatic	 node	 (AEC_PDX3),	 left	 lymphatic	node	 (AEC_PDX4)	 and	 cervix	 (AEC_PDX5)	 were	 implanted.	 After	 growing	 in	 the	 mice	during	 around	 2	 months,	 tumors	 were	 resected	 and	 processed	 for	 formalin	 fixation	 or	freezing	procedure	(3.2.1	and	3.2.2	sections).	DNA	for	sequencing	analyses	was	extracted	as	previously	described	(3.3	section).	In	order	to	validated	the	potential	effect	of	drugs	 identified	 in	the	 in	silico	 study	(3.5.4.6	section),	 small	 pieces	 of	 the	 AEC_PDX1	 model	 were	 surgically	 transplanted	subcutaneously	 into	female	Swiss	nude	mice,	6	weeks	old,	and	allowed	to	establish.	Two	mice	 of	 this	 second	 generation	 were	 analyzed	 per	 treatment	 condition.	 Mice	 were	randomized	 into	 the	 following	groups:	 treated	with	placebo	(serum	vehicle	where	drugs	were	 diluted),	 EC	 standard	 chemotherapy	 -carboplatin	 (40mg/kg)	 and	 paclitaxel	(15mg/kg)-,	bortezomib	(0.25mg/kg)	as	a	single	agent	and	the	combination	of	bortezomib	
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MATERIALS	AND	METHODS	 		 	(0.25	 mg/kg)	 and	 paclitaxel	 (15mg/kg).	 Bortezomib	 concentration	 that	 induces	 a	 low	toxicity	was	selected	according	to	previous	studies227.	Chemoterapy	was	performed	once	weekly,	and	bortezomib	treatment	was	performed	once	every	three	days;	both	of	them	by	intra-peritoneal	 injection.	 Tumor	 sizes	 were	 measured	 twice	 weekly	 with	 a	 vernier	caliper.		
3.12 	Statistical	analysis	
3.12.1 TCGA	meta-analysis	performed	in	the	ovarian	cancer	WES	project	To	analyze	the	implication	of	TP53	status	in	patient	outcome,	a	meta-analysis	of	the	TCGA	genomic	data	was	performed	using	the	previously	published	data90.	A	total	of	278	patients	with	available	WES	and	m-RNA	sequencing	data	were	 included.	 In	order	 to	differenciate	
TP53	mutated	from	TP53	null	cases,	those	tumors	with	frameshift,	splice	site	or	nonsense	mutations	and	with	an	mRNA	level	lower	than	the	wild-type	cases	(z-score	lower	than	-1)	were	classified	as	TP53	null	tumors	(Figure	8).	The	z-score	value	was	calculated	as	follow:		 𝑧 =  (expression in tumor sample)  −  (mean expression in normal sample)(standard deviation of expression in normal sample) 		Following	these	criteria,	patients	were	subdivided	into	TP53	null	(n=70),	mutated	(n=193)	and	wild-type	 (n=15)	 regarding	 their	TP53	 status.	 The	 comparison	 of	 the	 copy	 number	altered	genome	fraction	between	these	subgroups	was	performed	using	one-way	ANOVA	test	and	Tukey’s	multiple	comparison	test.	Overall	and	progression	free	survival	analyses	were	visualized	using	Kaplan-Meier	method	with	the	SPSS	Statistics	17.0	software	(SPSS	Inc.,	 Chicago,	 IL).	 Log-rank	 (Mantel-Cox)	 test	was	 used	 to	 determine	 the	 significance.	 p-values	less	than	0.05	were	considered	statistically	significant.			
Figure	8	TP53	mRNA	expression	related	to	mutation	type	in	
TCGA	 cohort.	 mRNA	 expression	 of	 the	 selected	 patients	 were	represented	regarding	their	TP53	mutational	status.	Blue	squares	identify	TP53	null	cases,	defined	as	thoses	cases	with	frameshift,	splice	site	or	nonsense	mutations	and	with	a	mRNA	z-score	lower	than	-1	(lower	than	mRNA	level	in	wild	type	cases).					
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3.12.2 Statistical	analysis	performed	in	the	uterine	aspirates	project	Data	 from	 hysterectomy	 tumor	 samples	 and	 uterine	 aspirates	 were	 compared	 using	paired	T-test.	Tests	were	two-tailed	and	95%	confidence	intervals	were	accepted.	p-values	less	 than	 0.05	 were	 considered	 statistically	 significant.	 Correlation	 between	 the	percentages	 of	 tumor	 cells	 and	 Mutation	 Discovery	 Rate	 (MDR)	 values	 were	 analyzed	using	the	Pearson	coefficient.	The	MDR	was	calculated	 for	each	sample	(uterine	aspirate	or	tumor	region)	from	the	same	patient	according	to	this	equation:		 𝑀𝐷𝑅 =  𝑆𝑎𝑚𝑝𝑙𝑒 𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛( 𝐴𝑠𝑝𝑖𝑟𝑎𝑡𝑒 𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛 +  𝑇𝑅1 𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛 +⋯+ 𝑇𝑅𝑛 𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛)  𝑥 100		Statistical	 analyses	 were	 performed	 using	 the	 SPSS	 Statistics	 17.0	 software	 (SPSS	 Inc.,	Chicago,	IL).	
3.12.3 Statistical	 analysis	 performed	 in	 the	 endometrial	 cancer	 WES	
project	Data	comparison	between	the	TCGA	dataset	and	the	patient	series	included	in	this	project	was	 performed	 using	 Mann-Withney	 U	 test.	 Patient	 subgroups	 were	 compared	 by	unpaired	 T-test	 (comparisons	 between	 two	 groups)	 or	 one-way	 ANOVA	 and	 Tukey’s	multiple	 comparison	 test	 (comparisons	 between	 more	 than	 two	 groups).	 Statistical	analyses	were	performed	using	the	SPSS	Statistics	17.0	software	(SPSS	Inc.,	Chicago,	IL).			
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4 Results	
4.1 Decoding	 intratumor	 genetic	 heterogeneity	 in	 a	
recurrent	TP53	null	HGSOC	patient	
Intratumor	heterogeneity	(ITH)	has	been	previously	described	in	ovarian	cancer	and	mostly	in	HGSOC	patients111,	113,	114,	a	disease	characterized	by	a	high	frequency	of	TP53	mutation	among	other	 features90.	 Due	 to	 the	 potential	 relation	 between	 TP53	 status	 and	 patient	 prognosis,	 a	meta-analysis	using	the	TCGA	dataset	was	performed.	Next,	multiple	samples	from	a	recurrent	
TP53	null	HGSOC	were	analyzed	by	WES	and	CGH	analyses,	in	order	to	further	characterize	ITH	in	this	tumor	subtype.		
4.1.1 Meta-analysis	of	the	TCGA	cohort		based	on	the	TP53	mutational	status	There	 are	 numerous	 studies	 that	 correlate	 TP53	 mutation	 status	 with	 clinical	 prognosis,	although	 this	 remains	 controversial	 due	 to	 conflicting	 results.	 While	 many	 of	 them	 provide	evidences	pointing	to	a	worse	prognosis	for	null	mutations,	the	initial	studies	did	not	consider	the	 biological	 consequences	 of	 somatic	 TP53	 mutations,	 and	 none	 of	 them	 include	 a	 broad	cohort	of	patients104.		Due	to	the	availability	of	 the	TCGA	dataset90,	which	 includes	more	tan	300	patients	diagnosed	with	HGSOC,	a	meta-analysis	was	performed	to	compare	overall	and	progression-free	survival	according	 to	 TP53	 status	 (see	 3.12.1	 section).	 Patients	 were	 divided	 into	 TP53	 null	 (n=70),	mutated	(n=193)	and	wild-type	(n=15)	regarding	their	TP53	status.	Interestingly,	although	the	number	 of	 mutations	 identified	 in	 each	 subgroup	 was	 similar,	 significant	 differences	 in	 the	fraction	 of	 copy	 number	 altered	 genome	were	 found	 (Figure	 9a).	 In	 fact,	 the	 null	 subgroup	showed	the	highest	 faction	of	altered	genome.	Tukey’s	multiple	comparison	test	revealed	that	these	differences	were	 found	between	 the	null	 and	 the	wild-type	subgroups.	Additionally,	 the	
TP53	 null	 subgroup	 showed	 an	 intermediate	 clinical	 behavior	 between	 the	 wild-type	 and	mutant	groups,	with	significant	and	nearly	equivalent	differences	between	these	categories	as	is	shown	in	Figure	9b.	Further	studies	to	better	characterized	the	differences	found	in	the	TP53	null	subgroup	should	be	carried	out.	
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Figure	9	TP53	mutational	status	meta-analysis	in	TCGA	ovarian	cancer	cohort.	Clinical	data	obtained	from	the	TCGA	 study90	 were	 subdivided	 into	 three	 subgroups	 depending	 on	 TP53	 mutational	 status	 (see	 3.12.1	 section):,	mutated	 (orange),	 null	 (blue)	 and	 wild-type	 (green)	 carcinomas.	 a)	 Comparison	 of	 the	 fraction	 of	 copy	 number	altered	 genome	 between	 the	 three	 subgroups	 of	 tumors.	 b)	 Kaplan-Meier	 plots	 showing	 the	 association	 between	
TP53	 mutational	 status	 and	 overall	 and	 progression	 free	 survival.	 Significant	 correlation	 was	 performed	 using	 a	Long-rank-p-value	method.	p-values	lower	than	0.05	were	considered	statistically	significant	(*p<0.05).	
4.1.2 Clinical	case	description	and	sample	selection	As	 previously	 mentioned,	 ITH	 has	 been	 further	 characterized	 in	 HGSOCs.	 However,	 none	 of	these	studies	have	considered	the	TP53	null	subgroup	as	an	independent	entity110-118.	In	order	to	 study	 ITH	 in	 a	 TP53	 null	 tumor,	 a	 total	 of	 12	 samples	 from	 a	 50-year-old	 patient	 with	 a	recurrent	HGSOC	were	analyzed	(Figure	10a,	Table	5).	Patient	was	diagnosed	with	a	stage	IIIC	HGSOC	with	extensive	peritoneal	carcinomatosis	in	2009.	The	first-line	treatment	was	based	on	a	 combination	 of	 surgical	 primary	 cytoreduction	 and	 chemotherapy.	 The	 patient	 received	 six	cycles	of	weekly	paclitaxel	and	carboplatin,	with	bevacizumab	every	3	weeks	for	a	total	period	of	 12	 months,	 following	 the	 OCTAVIA	 clinical	 trial	 criteria228.	 After	 a	 23	 months	 period	 of	platinum	 free	 interval,	 the	 patient	 relapsed	 with	 numerous	 intra-	 and	 extra-pelvic	 implants.	Because	 of	 that,	 the	 patient	 underwent	 a	 second	 debulking	 surgery	 withouth	 residual	macroscopic	disease	(Figure	10b).	The	pathologist	examination	found	papillary	patterns	with	frequent	 necrosis,	 nuclear	 expression	 of	 WT1	 confirming	 a	 serous	 histology	 and	 very	 high	proliferative	rate	(90%	as	determined	by	Ki-67	staining),	in	both	primary	and	relapsed	tumor.	Immunohistochemistry	 study	 showed	 lack	 of	 PTEN	 expression	 (suggestive	 of	 mutation)	 and	complete	absence	of	p53	staining	(indicative	of	wild-type	status	or	null	mutation)	(Figure	10c).	To	 validate	 the	 TP53	 status	 of	 this	 tumor,	 Sanger	 sequencing	 of	 TP53	 coding	 region	 was	perfomed,	detecting	a	mutation	in	exon	7	(c.702C>G)	that	resulted	in	a	premature	stop	codon	in	the	position	234	of	the	protein	(p.Tyr234*)	(Figure	10d).	These	results	confirmed	the	TP53	null	status	of	this	tumor.		
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Figure	 10	 Sample	 selection	 and	 clinal	 case	 description	 of	 a	TP53	 null	 HGSOC.	 a)	Anatomical	 location	 of	 the	primary	tumor	(P,	blue)	and	recurrence	samples	(intra-pelvic,	IR	in	green	and	extra-pelvic,	ER	in	red).	b)	Clinical	case	progression.	 Grey	 squares	 indicate	 periods	 of	 treatment	 between	 primary	 tumor	 diagnosis	 and	 recurrence.	 c)	Representative	pictures	of	H&E	staining	(I)	and	IHC	for	WT1	(II),	Ki-67	(III),	PTEN	(IV)	and	p53	(V).	Maginification	20x.	 d)	 Electropherogram	 showing	 TP53	 mutation	 detected	 in	 exon	 7	 (c.702C>G)	 by	 Sanger	 sequencing	 (I)	 and	diagram	with	the	corresponding	consequence	in	p53	protein	(p.Tyr234*)	(II).	NLS:	nuclear	localization	signal.	
4.1.3 	Whole-exome	 sequencing	 revealed	 differences	 in	 the	 mutational	
patterns	of	the	distinct	tumor	regions		WES	analysis	was	carried	out	in	three	frozen	samples	from	the	TP53	null	tumor,	including	one	region	from	the	primary	tumor	(P1),	a	pararectal	recurrence	implant	(IR1),	an	ileac	recurrence	implant	 (ER1),	 and	mesothelium	 as	 a	 reference	 normal	 tissue	 (N)	 (Figure	 10a).	 In	 order	 to	calculate	 the	 quality	 of	 the	WES,	 the	 percentage	 of	 mapped	 reads	 that	 passed	 quality	 filters	(High	Quality	 or	HQ	 reads)	 and	 reads	 ‘on	 target’	 (reads	 aligned	withing	 target	 regions)	were	used	 as	 standard	 quality	metrics.	 All	 the	 samples	 reached	 the	minimum	quality	 criteria,	with	more	 than	 70%	HQ	 reads	 and	more	 than	 60%	 reads	 ‘on	 target’.	Moreover,	 coverage	 analysis	showed	that	more	than	85%	of	exome	positions	had	a	minimum	10x	coverage	(Table	12).	To	calculate	the	false	positive	ratio	of	our	study,	a	selection	of	25	of	 the	variants	 identified	by	WES	were	 reanalyzed	by	Sanger	 sequencing.	Only	 four	of	 them	(ECE1,	GTF2I,	KMT2A,	PCYT2)	were	 not	 detected	 on	 the	 validation	 study,	 revealing	 a	 false	 positive	 rate	 around	16%	 in	 our	WES	analysis	(Supplementary	Table	6,	Figure	11).		
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Table	12	WES	quality	metrics	from	a	TP53	null	HGSOC	case	sequencing	analysis	
Sample	 Number	of	Reads	 %	'HQ'	Reads	 %	Reads	‘on	target’	
%	Exome	positions	with	
coverage	>10	N	 73640690	 70.84	 60.14	 89.12	P1	 73200254	 70.44	 60.42	 90.4	IR1	 62298712	 71.59	 61.68	 91.65	ER1	 71276218	 70.98	 61.22	 93.31		Bioinformatics	analysis	comparing	tumoral	 tissue	with	 the	normal	control	 identified	a	 total	of	102	variants,	99	of	them	single	nucleotide	variants	(SNVs)	and	three	deletions	(Supplementary	Table	7).	Only	the	41%	(42/102)	of	identified	variants	were	present	in	all	the	samples,	whereas	the	rest	of	them	were	specific	of	one	or	shared	between	two	samples	(Figure	11a).	In	order	to	analize	 the	 consequence	 of	 each	 variant	 in	 the	 corresponding	 protein,	 Condel,	 SIFT	 and	Polyphen	computational	predictors	were	used198,	202,	203.	These	analyses	revealed	that	80	of	the	102	 variants	 (78%)	 showed	 a	 probably	 damaging	 or	 deleterious	 consequence	 in	 their	corresponding	 protein	 (Figure	 11b).	 In	 conclusion,	 our	 results	 showed	 a	 clear	 intratumor	genetic	 heterogeneity	 in	 this	 patient,	with	 different	mutational	 profiles	 between	 the	multiple	samples.		
	
Figure	 11	 Variant	 distribution	 identified	 by	 WES	 analysis	 in	 a	 TP53	 null	 ovarian	 tumor.	 a)	 Venn	 diagram	representing	the	number	and	percentage	of	variants	among	different	samples	(P1,	primary	tumor	region:	blue;	IR1,	intrapelvic	recurrence	sample:	green;	ER1,	extrapelvic	recurrence	sample:	red).	b)	Genes	with	probably	pathogenic	variants	identified	by	WES.	Colored	squares	represent	presence	of	the	mutation	in	the	corresponding	sample	(P:	blue,	IR:	green,	ER:	red).	Light	grey	squares	represent	lack	of	mutation	(wild-type	status).	Variants	that	were	re-analyzed	by	Sanger	sequencing	are	marked	with	the	✓ symbol	(in	green)	if	were	validate,	or	marked	with	the	✗ symbol	(in	red)	in	case	they	were	not	detected.	
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4.1.4 CGH	 analysis	 confirmed	 genomic	 ITH	with	 an	 unequal	 distribution	 of	
SCNAs	among	the	different	tumor	regions		HGSOCs	frequently	present	high	chromosomal	 instability	and	numerous	somatic	copy	number	alterations	 (SCNAs)90.	 To	 further	 deep	 on	 the	 genomic	 profile	 of	 this	 tumor,	 comparative	genomic	hybridization	 (CGH)	was	performed	 in	 the	samples	previously	analyzed	by	WES	(P1,	IR1,	ER1	and	N).	A	total	of	18	chromosomal	regions	with	changes	were	identified,	being	more	frequent	the	gain	of	material	than	the	loss	(61%	vs	39%)	(Figure	12a).	
	
Figure	12	Somatic	Copy	Number	Alterations	(SCNAs)	identified	by	CGH	study	in	a	TP53	null	ovarian	tumor.	a)	SCNAs	detected	by	CGH	in	samples	from	the	TP53	null	tumor.	b)	Venn	diagram	representing	the	distribution	of	the	total	 number	 of	 SCNAs	 among	 the	 different	 samples	 (P1,	 primary	 tumor	 region:	 blue;	 IR1,	 intrapelvic	 recurrence	sample:	 green;	ER1,	 extrapelvic	 recurrence	 sample:	 red).	 c)	Circos	diagram	 representing	 the	 gained	 (red)	 and	 lost	(green)	 regions	 in	 the	 three	 indicated	 samples.	 Concentric	 circles	 represent	 P1,	 ER1	 and	 IR1	 samples	 (from	 the	outside	to	the	inside).		Regarding	 SCNAs,	 similar	 results	 to	 those	 previously	 observed	 in	 the	 genetic	 analysis	 were	found.	Only	7	out	of	the	18	chromosomal	regions	(39%)	were	common	to	all	the	samples.	The	common	 changes	 counted	 five	 gains	 (2q32q33,	 3q22q29,	 7q22q32,	 8q12q24	 and	 11q14q22)	and	 two	 lost	 regions	 (6q25q27	 and	 depletion	 of	whole	 chromosome	 4).	 Additionally,	 P1	 and	ER1	samples	shared	5	variations	(gain	of	1p22p35	and	9q31,	and	loss	of	17p13	and	depletion	of	
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RESULTS	 		 	whole	chromosomes	12	and	16),	while	changes	common	to	P1	and	IR1	or	to	IR1	and	ER1	were	not	found.	However,	all	samples	presented	exclusive	alterations	(8p22p23	and	15q22q26	in	P1;	16q24	in	IR1;	and	5p15,	10q22	and	22q13	in	ER1)	(Figure	12b	and	c).	Therefore,	ITH	was	also	found	at	the	genomic	level	between	the	three	analyzed	samples	in	this	patient.		
4.1.5 The	 study	 of	 additional	 tumor	 regions	 allowed	 the	 identification	 of	
genetically	 heterogeneous	 tumor	 subclones	 and	 the	 phylogenetic	
tumor	evolution	To	 better	 understand	 the	 ITH	 previously	 characterized	 in	 a	 TP53	 null	 HGSOC	 patient,	 nine	additonal	FFPE	 samples	 representing	different	 regions	of	 the	primary	 tumor	and	 recurrences	(P2-P6,	 IR2,	ER2-ER4)	were	selected	 for	 further	analysis	 (locations	are	represented	 in	Figure	
10a).	A	selection	of	20	previously	detected	variants	was	re-analyzed	by	Sanger	sequencing	 in	the	four	WES	samples	(N,	P1,	IR1,	ER1)	and	in	nine	additional	FFPE	samples	(Figure	13a).		These	variants	were	selected	 to	 represent	 the	different	 sample	distribution	observed	 in	WES:	nine	ubiquitous	(TP53,	CSMD3,	CTC1,	FAP,	KIF21B,	LAMA2,	SMG7,	UBR3	and	ZFAT),	one	shared	by	P1	and	IR1	(FRMPD1),	four	shared	by	IR1	and	ER1	(HEPHL1,	KIF21A,	OR56B1	and	ZNF664),	three	P1	specific	(CNOT1,	PLXNA1	and	TRERF1),	two	IR1	specific	(ROBO2	and	TFDP1)	and	one	ER1	 specific	 (GPNMB).	 Only	 7	 of	 the	 20	 (35%)	 analyzed	 variants	 were	 common	 to	 all	 the	samples,	 reflecting	 the	 ITH	previously	observed	 in	 the	WES	results.	As	expected,	one	of	 these	variants	was	 the	TP53	 nonsense	mutation,	whose	 ubiquitous	 presence	 is	 consistent	with	 the	founder	 role	 of	 this	 gene	 in	 HGSOCs.	 Conversely,	 variants	 in	 FAP	 and	 ZFAT	 genes,	 initially	common	to	all	samples	according	to	the	WES	analysis,	were	not	shared	when	we	studied	more	samples	by	Sanger	sequencing;	while	FRMPD1	variant,	originally	detected	in	P1	and	IR1	but	not	ER1	samples,	was	detected	in	the	rest	of	the	samples,	appearing	to	be	almost	ubiquitous	in	this	tumor.	 Interestingly,	 the	 majority	 of	 the	 variants	 previously	 considered	 as	 exclusive	 of	 the	recurrence	samples	 (3	of	4,	75%),	were	 identified	 in	 three	of	 the	primary	 tumor	regions	 (P3-P5),	whereas	 only	 ZNF664	 variant	was	 detected	 in	 all	 the	 recurrence	 samples	 but	 not	 in	 the	primary	 tumor	 regions.	 This	 could	 be	 an	 example	 of	 genetic	 variant	 adquisition	 during	 the	development	 of	 the	 recurrent	 disease.	 Finally,	 the	 variants	 previously	 classified	 as	 sample-specific	 remained	being	 exclusive	 of	 the	different	main	 regions	 of	 the	 tumor	 (primary	 tumor,	intrapelvic	or	extrapelvic	recurrence)	although	not	always	restricted	to	an	unique	sample.	Taking	 into	 account	 that	 this	 mutational	 heterogeneity	 could	 be	 consistent	 with	 a	 clonal	composition,	a	hierarchical	clustering	analysis	based	on	the	presence	or	absence	of	the	previous	studied	 variants	was	 carried	 out	 (Figure	 13b).	 The	 phylogenetic	 tree	 generated	 showed	 the	existence	 of	 two	main	 branches,	with	 the	majority	 of	 the	 recurrence	 regions	 clustered	 in	 the	upper	 one	 along	with	 P3,	 P4	 and	 P5	 samples.	 This	 branch	 could	 represent	 a	 primary	 tumor	
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RESULTS	 		 	ancestor	subclone	that	gave	rise	to	the	majority	of	recurrence	implants	(all	of	them	except	ER3).	In	 the	 lower	branch,	 P1	 seemed	 to	be	 the	 closest	 region	 to	 the	normal	 tissue,	 and	P2	 and	P6	could	be	part	of	a	different	subclone	from	which	ER3	would	have	arisen.	These	results	revealed	a	polyphyletic	 evolution	 in	 this	 tumor,	 showing	 the	 importance	of	 taking	 in	 consideration	 the	presence	 of	 different	 subclones	 in	 the	 primary	 tumor	 that	 would	 generate	 the	 recurrence	disease.	Additional	studies	to	further	characterized	these	clones	and	their	instrinsic	featrues	are	necessary	to	better	understand	the	implication	of	ITH	in	recurrent	disease	of	this	patient.	
	
Figure	13	ITH	and	hierarchical	clustering	 in	additional	samples	 from	a	TP53	null	ovarian	tumor.	a)	Twenty	selected	 variants	 previously	 detected	 by	WES	were	 reanalyzed	 in	 a	 total	 of	 12	 tumoral	 samples	 derived	 from	 the	same	patient.	The	presence	or	absence	 in	each	sample	 is	 represented	with	colors	 (P1-P6,	primary	 tumor:	blue;	 IR,	intrapelvic	 recurrence:	 green;	 ER,	 extrapelvic	 recurrence:	 red)	 or	 grey	 squares	 respectively.	 b)	 Phylogenetic	 tree	generated	 by	 hierarchical	 clustering	 based	 on	 the	 mutational	 status	 of	 each	 sample	 (see	 3.6.1	 section)	 c)	Representative	 fluoresce	 in	 situ	 hybridization	 (FISH)	 of	 PML	 (red)	 and	 RARA	 (green,	 used	 as	 control)	 genes	 in	primary	tumor	(P1-P6)	and	recurrence	(IR1-IR2	and	ER1-ER4)	samples.	Magnification	40X.		In	addition	to	the	genetic	study,	genomic	heterogeneity	found	by	CGH	analysis	(Figure	12)	was	partially	 validated	 by	 the	 fluorescence	 in	 situ	 hybridization	 (FISH)	 of	 PML	 (Promyelocytic	
Lekemia)	gene	(15q22)	(Figure	13c).	FISH	analysis	confirmed	PML	gain	in	P1	but	not	in	IR1	and	ER1	 samples,	 in	 accordance	with	 CGH	 data.	 Additional	 FFPE	 samples	 showed	 heterogeneous	copy	number	alterations:	while	P3,	P4,	P5	and	ER2	samples	had	3	or	4	copies;	P2,	P6,	IR2	and	ER4	 presented	 between	 5	 and	 8	 copies.	 Nonetheless,	 ER3	 recurrence	 showed	 a	 potential	deletion	due	to	an	unique	copy	of	PML	per	cell	was	found.	Therefore,	ITH	was	also	proved	at	a	genomic	level.	 
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IR1	 IR2	 ER1	 ER2	 ER3	 ER4	
ER1	
ER4	
P3	
P5	
P4	
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P6	
ER3	
P2	
P1	
	 P1	 P2	 P3	 P4	 P5	 P6	 IR1	 IR2	 ER1	 ER2	 ER3	 ER4	 N	 WES	Classi4ication	
CSMD3	 	 	 	 	 	 	 	 	 	 	 	 	 	 Ubiquitous	
CTC1	 	 	 	 	 	 	 	 	 	 	 	 	 	 Ubiquitous	
FAP	 	 	 	 	 	 	 	 	 	 	 	 	 	 Ubiquitous	
KIF21B	 	 	 	 	 	 	 	 	 	 	 	 	 	 Ubiquitous	
LAMA2	 	 	 	 	 	 	 	 	 	 	 	 	 	 Ubiquitous	
SMG7	 	 	 	 	 	 	 	 	 	 	 	 	 	 Ubiquitous	
TP53	 	 	 	 	 	 	 	 	 	 	 	 	 	 Ubiquitous	
UBR3	 	 	 	 	 	 	 	 	 	 	 	 	 	 Ubiquitous	
ZFAT	 	 	 	 	 	 	 	 	 	 	 	 	 	 Ubiquitous	
CNOT1	 	 	 	 	 	 	 	 	 	 	 	 	 	 Shared	P1+IR1	
PLXNA1	 	 	 	 	 	 	 	 	 	 	 	 	 	 Shared	IR1+ER1	
TRERF1	 	 	 	 	 	 	 	 	 	 	 	 	 	 Shared	IR1+ER1	
FRMPD1	 	 	 	 	 	 	 	 	 	 	 	 	 	 Shared	IR1+ER1	
ROBO2	 	 	 	 	 	 	 	 	 	 	 	 	 	 Shared	IR1+ER1	
TFDP1	 	 	 	 	 	 	 	 	 	 	 	 	 	 P1	Speci8ic	
HEPHL1	 	 	 	 	 	 	 	 	 	 	 	 	 	 P1	Speci8ic	
KIF21A	 	 	 	 	 	 	 	 	 	 	 	 	 	 P1	Speci8ic	
OR56B1	 	 	 	 	 	 	 	 	 	 	 	 	 	 IR1	Speci8ic	
ZNF664	 	 	 	 	 	 	 	 	 	 	 	 	 	 IR1	Speci8ic	
GPNMB	 	 	 	 	 	 	 	 	 	 	 	 	 	 ER1	Speci8ic	
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4.1.6 Biological	 functions	 affected	 by	 genetic	 variants	 were	 defined	 by	
functional	annotation	and	network	analysis		To	 further	 investigate	 the	 potential	 effect	 of	 genetic	 variants	 found	 by	 WES,	 the	 biological	functions	 of	 the	 mutated	 genes	 were	 annotated	 using	 David	 protocols	 (see	 3.5.4.2	 section),	through	 several	 biological	 databases	 as	 Biocarta,	 Gene	 Ontology,	 KEGG	 and	 Reactome	(Supplementary	Table	8).	Cytoscape	tool206	was	used	to	generate	a	functional	network	analysis,	showing	 that	 cell	 adhesion,	 cell	 cycle	 control,	 microtubule-related	 movement	 and	 transport,	lipid	metabolism	and	apoptosis	were	pathways	containing	multiple	mutated	genes	in	this	tumor	(Figure	 14).	 Additional	 functional	 analyses	 should	 be	 performed	 to	 better	 characterize	 the	implications	of	these	gene	mutations	in	the	corresponding	pathways.		
	
Figure	14	Functional	network	analysis	based	on	annotation	study	revealed	signaling	pathways	with	multiple	
mutant	 genes.	 All	 the	 probably	 pathogenic	 variants	 detected	 by	WES	 in	 a	TP53	 null	 tumor	were	 considered	 for		functional	 annotation	 using	David	 protocols	 and	 network	 analysis	 by	 Cytoscape	 tool	 (see	3.5.4.2	 section).	 Results	revealed	 signaling	 pathways	 containing	multiple	mutated	 genes,	 that	were	 annotated	 by	 Biocarta,	 Gene	 Ontology,	KEGG	or	Reactome	databases	and	represented	as	squared	nodes.	Mutated	genes	were	characterized	as	colored	circles	indicating	the	sample	or	samples	in	which	each	one	was	mutated	(see	node	fill	color	mapping).		 	
	59		
RESULTS	 		 	
4.2 Uterine	 aspirates	 as	 a	 diagnostic	 tool:	 capturing	 ITH	 in	
endometrial	carcinoma	
Uterine	aspirates	 (UAs)	are	pre-operative	biopsies	usually	obtained	with	a	pipelle	de	Cornier,	which	suppose	a	low	invasive	and	highly	sensitive	procedure149.	The	use	of	UAs	as	a	molecular	diagnosis	 tool	was	proposed	on	 the	basis	of	differential	gene	expression	profiles153,	154.	 In	 this	thesis,	the	potential	use	of	UAs	to	describe	the	tumor	mutational	profile	before	surgery	and	its	implication	 in	 ITH	 have	 been	 studied.	 For	 this	 purpose,	 targeted	 sequencing	 was	 performed	using	 the	commercial	 Ion	AmpliSeq	Cancer	Hotspot	Panel	v2	 that	analyze	above	2,800	cancer	mutations	of	50	oncogenes	and	tumor	suppressor	genes,	including	some	of	the	most	frequently	altered	genes	 in	endometrial	cancer	(PTEN,	KRAS,	FGFR2,	CTNNB1,	PIK3CA,	FBXW7	and	TP53)	(see	 3.4.1	 section).	 Variants	 were	 annotated	 as	 potential	 mutations	 based	 on	 PROVEAN	analysis197	(Supplementary	Table	9),	as	previously	described	in	the	3.4.4	section.	No	differences	were	 found	 in	 sequencing	 quality	 metrics,	 neither	 between	 frozen	 or	 FFPE	 samples,	 nor	between	paired	primary	tumor	and	UAs	samples	(Supplementary	Table	10).	
4.2.1 Genetic	analysis	of	uterine	aspirates	allowed	tumor	mutation	detection	In	order	to	determine	whether	the	biological	material	 from	UAs	was	valid	 for	the	detection	of	genetic	 variants,	 retrospective	 paired	 samples	 of	 UAs	 and	 hysterectomy	 specimen	 were	analyzed	by	targeted	sequencing	using	the	Cancer	Hotspot	Panel	as	mentioned	above.	Initially,	28	paired-samples	 from	malignant	disorders	and	27	UAs	from	patients	with	bening	 lesions	or	normal	endometrium	were	analyzed	to	determine	their	mutational	status.	Malignant	disorders	included	 21	 tumoral	 samples	 (7	 endometrioid	 endometrial	 carcinomas,	 EECs;	 7	 serous	endometrial	 carcinomas,	 SECs;	 and	 7	 carcinosarcomas,	 CSs)	 and	 7	 samples	 from	 atypical	hyperplasia	(AH)	as	a	precursor	 lesion.	The	27	control	samples	comprised	patients	diagnosed	with	 non-atypical	 hyperplasia	 (NAH)	 (n=7)	 or	 leiomyomas	 (LM)	 (n=7),	 and	 13	 normal	endometria	 (NE)	 (Table	 6).	 In	all	 of	NE	samples	and	 in	3	of	 the	7	NAH	cases,	only	UAs	were	analyzed	due	to	these	patients	did	not	undergo	surgery.	Genetic	variants	were	found	in	20	of	the	21	 (95%)	 UAs	 from	 tumoral	 samples,	 according	 to	 the	 results	 obtained	 in	 the	 paired	hysterectomy	specimens.	Only	 in	one	of	 the	UAs	derived	 from	a	SEC,	we	did	not	observed	the	mutations	found	in	its	corresponding	hysterectomy	sample.	Additionally,	we	observed	that	4	of	the	 7	 (57%)	UAs	 from	 the	 AH	 precursor	 lesions	 showed	mutations,	 although	 only	 in	 2	 cases	these	mutations	were	also	detected	in	their	paired	hysterectomy	specimen.	Conversely,	only	1	of	 the	 27	 (4%)	 control	 samples	 showed	 a	 genetic	 variant	 (Figure	 15).	 Since	 the	 UAs	 that	presented	a	genetic	variant	came	from	a	NE	case,	we	did	not	have	the	possibility	to	compare	it	with	its	corresponding	hysterectomy	specimen.		
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Figure	 15	 Percentage	 of	 samples	 with	
genetic	 variants	 detected	 by	 targeted	
massive	 parallel	 sequencing	 in	 paired	
endometrial	 samples.	Percentage	of	samples	in	which	genetic	variants	were	identified	in	the	targeted	 sequencing	 analysis.	 Paired	 samples	of	 uterine	 aspirates	 (dark	 blue)	 and	hysterectomy	 specimens	 (light	 blue)	 were	included	 in	 the	 study.	 EEC:	 endometrioid	endometrial	 carcinoma,	 SEC:	 serous	endometrial	 carcinoma,	 CS:	 carcinosarcoma,	AH:	 atypical	 hyperplasia,	 NAH:	 non-atypical	hyperplasia,	 LM:	 leiomyoma,	 NE:	 normal	endometrium.	
4.2.2 Uterine	 aspirates	 reproduced	 the	 mutational	 profile	 of	 its	 paired	
hysterectomy	specimen	samples		Once	the	capability	to	detect	mutations	in	UAs	was	demonstrated,	we	estimated	the	potential	of	aspirates	 to	 characterize	 EC	 from	 a	 genetic	 point	 of	 view.	 To	 this	 end,	 we	 analyzed	 the	percentage	of	pathogenic	variants	present	 in	hysterectomy	specimen	that	were	also	 identified	in	the	UA.	A	total	of	62	patients	diagnosed	with	EC	(44	EECs,	9	SECs	and	9	CSs)	and	10	patients	diagnoses	 with	 AH	 were	 studied,	 including	 the	 previously	 analyzed	 cases.	 Histopathological	data	of	these	cases	is	detailed	in	Table	7.	In	this	extended	series,	sequencing	analysis	revealed	the	presence	of	mutations	in	58	of	the	62	(94%)	aspirates	from	cancer	patients	(Supplementary	Table	 11)	 and	 in	 5	 of	 the	 10	 (50%)	 aspirates	 from	 AH	 cases	 (Supplementary	 Table	 12).	Interestingly,	 in	35	out	of	the	44	(80%)	UAs	from	EEC	patients	we	identified	all	the	mutations	detected	 in	 their	 paired	 surgical	 tumor	 tissue	 (Figure	 16).	 In	 fact,	 in	 only	 one	 of	 the	 EEC	patients	 (EEC-19),	 the	 genetic	 analysis	 of	 UAs	 did	 not	 show	 any	 of	 the	mutations	 preoviusly	found	in	its	hysterectomy	specimens.	Conversely,	in	one	other	patient	(EEC-21)	mutations	were	detected	in	the	UA,	whereas	none	of	them	were	identified	in	its	surgical	sample	(Supplementary	Table	11).	Furthermore,	 in	6	of	 the	9	(67%)	SEC	and	 in	7	of	 the	9	(78%)	CS	all	 the	mutations	identified	 in	 the	hysterectomy	were	 also	detected	 in	 the	 corresponding	 aspirate	 (Figure	 16).	Therefore,	 these	 results	 confirmed	 that	 the	 genetic	 analysis	 of	 UAs	 reliably	 reproduce	 the	genetic	status	of	the	tumor	in	a	pre-operative	setting,	at	least	in	the	analyzed	samples.		 	
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Figure	 16	 Percentage	 of	 hysterectomy	 mutations	 identified	 in	 paired	
uterine	 aspirates.	 Percentage	 of	 tumor	mutations	 found	 in	 surgical	 tumor	samples	also	detected	in	UAs	are	represented	for	each	hystology	subgroup	of	patients.	EEC:	endometrioid	endometrial	carcinoma.	SEC:	serous	endometrial	carcinoma.	CS:	carcinosarcoma							Mutations	 identified	 in	 the	 different	 histological	 subgroups	 of	 patients	 were	 consistent	 with	previously	published	 results196.	Briefly,	EEC	carried	mutations	 in	PTEN	 (71%	of	 the	patients),	
PIK3CA	(39%),	CTNNB1	(27%),	TP53	(27%),	FGFR2	(23%)	and	KRAS	(21%).	In	addition,	we	also	detected	 mutations	 in	 less	 commonly	 altered	 genes	 (Figure	 17).	 As	 expected,	 the	 most	frequently	 mutated	 gene	 in	 SEC	 and	 CS	 samples	 was	 TP53	 (78%	 and	 89%	 respectively).	Frequencies	 found	 in	 our	 series	were	 generally	 higher	 than	 those	 previously	 detected	 in	 the	TCGA	 series196.	 These	 differences	 could	 be	 explained	 due	 to	 the	 use	 of	 different	 sequencing	methods.	Thus,	while	TCGA	 study	performed	WES	 (mean	 coverage	 around	 to	50x),	 our	 study	was	 developed	with	 targeted	 sequencing	 allowing	 a	 high	 number	 of	 lectures	 (mean	 coverage	around	to	1000x)	and	consequently	a	more	accurate	detection	of	mutations229.		
	
Figure	 17	 Mutated	 genes	 found	 in	 the	 endometrioid	 endometrial	 carcinomas	 comparing	 with	 the	 TCGA	
series.	Percentage	of	EEC	patients	with	mutations	in	the	indicated	genes.	Comparison	between	our	analyzed	series	(blue)	and	the	TCGA	dataset	(orange).	
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4.2.3 Targeted	 sequencing	 helped	 to	 reduce	 diagnosis	 fail	 rate	 of	 uterine	
aspirates	The	fail	rate	for	pathologic	analysis	of	UAs	distinguishing	the	presence	or	absence	of	malignancy	is	 around	13%,	 either	 due	 to	 a	 small	 proportion	 of	 representative	 tumor	 cells	 or	 to	 the	 poor	quality	of	the	sample146-148.	In	fact,	8	of	the	62	(13%)	EC	aspirates	analyzed	in	our	series	were	considered	 non-diagnosable	 but	 turned	 out	 to	 have	 EC	 on	 the	 corresponding	 hysterectomy	specimens	 (EEC38-44	 and	 CS-9).	 However,	 genetic	 analysis	 of	 these	 aspirates	 revealed	 the	presence	 of	mutations	 in	 7	 of	 the	 8	 (88%)	non-evaluable	UAs	 and	 their	 paired	 hysterectomy	samples,	 showing	a	similar	mutational	profile	 (Supplementary	Table	11).	We	did	not	 find	any	mutations	 in	 the	UA	 from	one	of	 these	patients	 as	well	 as	 in	 its	 paired	hysterectomy	 sample.	These	results	indicated	that	genetic	sequencing	of	UAs	provides	valuable	information	and	could	be	used	as	a	complement	for	pathological	analysis	in	order	to	reduce	its	fail	rate.	
4.2.4 Genetic	analysis	of	uterine	aspirates	captured	the	ITH	found	in	ECs		Comparative	 mutational	 profile	 between	 UAs	 and	 hysterectomy	 specimens	 highlighted	 the	presence	of	additional	mutations,	not	detected	in	their	paired	surgical	samples,	in	11	out	of	the	62	(18%)	aspirates.	These	results	could	be	reflecting	the	presence	of	ITH	in	this	clinical	context.	To	 explore	 this	 hypothesis,	 additional	 tumor	 regions	 from	 24	 of	 the	 EC	 previously	 studied	(EEC1-14,	SEC1-5	and	CS1-5)	were	analyzed	by	targeted	sequencing	(Table	13).		
Table	13	Endometrial	cancer	cases	studied	by	targeted	massive	parallel	sequencing	in	the	ITH	analysis	
Patient	 Tumor	regions	analyzed	
Total	variants	detected	
in	tumor	regions	
Total	variants	detected	
in	uterine	aspirates	
Intratumor	
heterogeneity	EEC-1	 3	 5	 5	 Yes	EEC-2	 2	 3	 3	 Yes	EEC-3	 3	 4	 4	 Yes	EEC-4	 4	 2	 5	 Yes	EEC-5	 3	 2	 2	 Yes	EEC-6	 3	 3	 4	 Yes	EEC-7	 4	 9	 4	 Yes	EEC-8	 4	 2	 2	 No	EEC-9	 4	 4	 4	 Yes	EEC-10	 4	 1	 1	 No	EEC-11	 4	 2	 2	 No	EEC-12	 4	 10	 9	 Yes	EEC-13	 3	 12	 16	 Yes	EEC-14	 4	 3	 3	 No	SEC-1	 3	 1	 1	 No	SEC-2	 3	 1	 1	 No	SEC-3	 3	 1	 1	 No	SEC-4	 3	 1	 1	 Yes	SEC-5	 3	 4	 4	 No	CS-1	 4	 4	 4	 Yes	CS-2	 3	 1	 1	 No	CS-3	 3	 1	 1	 No	CS-4	 3	 1	 1	 No	CS-5	 2	 1	 1	 No	
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Figure	 18	 Intratumor	 heterogeneity	 analyses	 in	 endometrioid	 endometrial	 carcinoma	 samples.	 Results	obtained	 in	 targeted	massive	 parallel	 sequencing	 analyses	 of	multiple	 samples	 derived	 from	 hysterectomy	 tumor	regions	 (TRs)	 and	 paired	 uterine	 aspirates	 (UAs)	 from	 14	 endometrioid	 endometrial	 carcinoma	 (EEC)	 patients	identified	genetic	heterogeneous	(a-j)	and	non-heterogeneous	(k-n)	cases.	Colors	represent	mutant	allel	frequencies	(MAFs).	Squares	marked	with	LQ	identified	Low	Quality	variants	detect	in	the	Ion	PGM	analysis.		The	comparison	of	the	mutational	profile	 in	additional	hysterectomy	regions	of	EECs	revealed	that	 10	 of	 the	 14	 patients	 (71%)	 showed	 different	 mutations	 in	 the	 several	 tumor	 samples	analyzed,	 confirming	 the	presence	of	 ITH	 (Figure	 18a-j).	This	 is	 the	 case	of	EEC-1	patient,	 in	which	three	different	tumor	regions	(TR)	were	analyzed.	Five	mutations	were	detected	in	PTEN,	
TP53	 and	APC	 genes	 in	TR-1,	whereas	 in	 the	other	 two	 tumor	 regions	 (TR-2	and	 -3)	we	only	
b)	EEC-2	
TR-1	 TR-2	 UA	
PTEN	(G129R)	
CTNNB1	(S37C)	 	 LQ	
CDKN2A	(R156L)	
TR-1	 TR-2	 TR-3	 TR-4	 UA	
PTEN	(R130G)	
KRAS	(G13D)	 	 LQ	 		
PIK3CA	(R88Q)	 	 	 	 	
PIK3CA	(C420R)	 	 	 	 	
PIK3CA	(E545D)	 	 	 	 	
d)	EEC-4	
TR-1	 TR-2	 TR-3	 UA	
PTEN	(Q298*)	
APC	(Deletion)	 LQ	 	
e)	EEC-5	
TR-1	 TR-2	 TR-3	 UA	
FGFR2	(S252W)	
PIK3CA	(N345K)	
PIK3CA	(W328*)	 	 	 	
KIT	(P573S)	 LQ	
f)	EEC-6	
TR-1	 TR-2	 TR-3	 TR-4	 UA	
FGFR2	(C385R)	 LQ	
PTEN	(R130*)	
PTEN	(R173C)	
PTEN	(R233*)	
TP53	(R283H)	
TP53	(R273H)	
SMARCB1	(E193*)	
CTNNB1	(S37P)	
CDKN2A	(Del)	
g)	EEC-7	
TR-1	 TR-2	 TR-3	 TR-4	 UA	
PIK3CA	(H1047R)	
CTNNB1	(S33F)	 LQ	
k)	EEC-8	 l)	EEC-10	
TR-1	 TR-2	 TR-3	 TR-4	 UA	
PIK3CA	(H1047R)	
TR-1	 TR-2	 TR-3	 TR-4	 UA	
FGFR2	(S252W)	
FBXW7	(R505C)	
m)	EEC-11	
TR-1	 TR-2	 TR-3	 TR-4	 UA	
PTEN	(R130*)	 LQ	
PTEN	(Deletion)	 LQ	 LQ	
KRAS	(G13D)	 LQ	
RB1	(R556*)	 LQ	 LQ	 LQ	
ERBB2	(V842I)	 LQ	 LQ	
TP53	(R196*)	 LQ	
PIK3CA	(V344M)	 LQ	 LQ	 LQ	
CTNNB1	(S33P)	 LQ	
FBXW7	(R479Q)	
i)	EEC-12	
j)	EEC-13	
TR-1	 TR-2	 TR-3	 UA	
NRAS	(G12D)	
PTEN	(E7*)	 LQ	
PTEN	(R233*)	
PTEN	(F341V)	
ATM	(A1942D)	
HRAS	(R68W)	
HNF1A	(R203H)	 LQ	
KRAS	(G12V)	
TP53	(M237I)	
TP53	(P223S)	
SMAD4	(R496C)	
GNA11	(Deletion)	
GNA11	(G208D)	
GNAS	(R842C)	
PIK3CA	(R88Q)	 LQ	 LQ	
CTNNB1	(S45Y)	
SMO	(R628W)	
ABL1	(K266R)	
CDKN2A	(S114I)	 LQ	
TR-1	 TR-2	 TR-3	 UA	
PTEN	(R233*)	
PIK3CA	(R88Q)	
PIK3CA	(V344M)	
ABL1	(K266R)	
c)	EEC-3	
TR-1	 TR-2	 TR-3	 TR-4	 UA	
FGFR2	(S252W)	
PTEN	(Deletion)	
PIK3CA	(E545K)	
CTNNB1	(S33A)	
h)	EEC-9	
TR-1	 TR-2	 TR-3	 UA	
PTEN	(E7*)	 LQ	
PTEN	(R130Q)	
TP53	(G266E)	 LQ	 LQ	
TP53	(M246I)	
APC	(E1544*)	 LQ	
a)	EEC-1	
TR-1	 TR-2	 TR-3	 TR-4	 UA	
PTEN	(H61R)	
PTEN	(R173C)	
ERBB2	(V842I)	 LQ	
n)	EEC-14	
		 		MAF	>50	%			 		MAF	25-50%			 		MAF	10-25	%			 		MAF	1-10	%			MAF	0%	
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RESULTS	 		 	observed	2	and	3	mutations	respectively.	Interestingly,	these	five	mutations	were	identified	in	the	 paired	 UA,	 with	 higher	 values	 of	 mutant	 allele	 frequency	 (MAF)	 and	 better	 sequencing	quality	(Figure	18a).		On	the	other	hand,	4	of	the	14	EEC	cases	showed	a	similar	mutational	profile	in	all	the	samples	analyzed,	 although	 with	 different	 MAF	 values	 (Figure	 18k-n).	 For	 example,	 mutations	 in	
PIK3CA	and	CTNNB1	were	detected	in	the	four	tumor	regions	and	the	corresponding	aspirate	of	the	 EEC-8	 patient	 (Figure	 18k).	 These	 results	 could	 be	 suggesting	 that	 these	 cases	 did	 not	harbor	significant	ITH,	at	least	in	the	sequenced	tumor	regions.		Contrary	to	EEC,	ITH	was	only	observed	in	1	of	the	5	(20%)	SEC	and	1	of	the	5	(20%)	CS	(Figure	
19).	 This	 low	 proportion	 of	 heterogeneous	 cases	 could	 be	 due	 to	 the	 fact	 that	 chromosomal	instability	is	the	hallmark	of	these	tumors230,	in	which	single	mutations	are	not	so	common.			
	
Figure	19	 Intratumor	heterogeneity	 analysis	 in	non-endometrioid	 endometrial	 carcinoma	 samples.	Results	obtained	by	targeted	massive	parallel	sequencing	of	multiple	tumor	regions	(TRs)	and	paired	uterine	aspirates	(UAs)	from	a)	5	serous	carcinomas	(SEC)	and	b)	5	carcinosarcoma	(CS)	patients.	Colors	represent	mutant	allel	 frequency	(MAF).		In	order	to	define	the	sensitivity	of	mutation	detection	for	each	sample,	the	mutation	discovery	rate	(MDR)	was	calculated	(Figure	20).	MDR	indicates	the	proportion	of	mutations	detected	in	each	sample	with	respect	to	the	total		amount	of	mutations	observed	in	all	samples	analyzed	for	a	given	patient	(see	3.12.2	section).	MDR	value	was	significantly	higher	in	EEC	aspirates	than	in	their	 corresponding	 hysterectomy	 specimens,	 with	 a	 mean	 of	 94%	 for	 UAs	 and	 77%	 for	individual	 tumor	 region	 samples.	 These	 differences	were	 accentuated	when	 low-quality	 (LQ)	mutations	were	not	considered,	decreasing	MDR	value	 in	surgical	 tumor	samples	 to	68%	and	remaining	unaltered	in	UAs	(Figure	20a).	As	expected,	no	significant	differences	were	found	in	SEC	or	CS	samples,	since	are	less	genetic	heterogeneous	tumors,	at	least	at	the	analyzed	genetic	level.	 In	 fact,	 the	main	differences	 in	MDR	values	were	 found	 in	heterogeneous	tumors	due	to	
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TR-1	 TR-2	 TR-3	 UA	
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TR-1	 TR-2	 TR-3	 UA	
TP53	(R248W)	
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a		
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RESULTS	 		 	the	 variability	 in	 the	 mutational	 profile	 of	 each	 sample.	 In	 8	 out	 of	 the	 10	 (80%)	 EEC	heterogeneous	 tumors,	UAs	 showed	 a	 higher	MDR	value	 than	 that	 tumor	 region	 used	 for	 the	pathological	diagnosis	 (TR-1)	 (Figure	 20b).	Only	 in	EEC-7	patient,	MDR	value	was	higher	 for	TR-1	sample	than	for	the	corresponding	aspirate.	Interestingly,	UAs	had	a	higher	MDR	than	at	least	one	tumor	region	in	all	the	heterogeneous	EEC	cases.	These	differences	were	not	related	to	the	proportion	of	 tumor	 tissue	 contained	 in	each	analyzed	 region,	 as	 there	was	no	 significant	correlation	according	 to	Pearson	test	results	 (r	=	0.146).	These	results	confirmed	that	genetic	analysis	of	UAs	detects	a	more	representative	mutational	 landscape	of	the	tumor,	reproducing	in	a	single	sample	the	ITH	found	in	the	multiple	TRs.	
		
Figure	20	Mutation	discovery	rate	(MDR)	in	uterine	aspirates	and	their	respective	hysterectomy	specimens.	Mutation	 discovery	 rate	 (MDR)	 is	 defined	 as	 the	 percentage	 of	 mutations	 detected	 in	 each	 studied	 sample	 with	respect	 to	 the	 totality	 of	mutations	 observed	 in	 all	 analyzed	 samples	 for	 the	 same	patient	 (see	3.12.2	 section).	 a)	MDR	mean	in	EEC,	SEC	and	CS	patients.	b)	Comparison	of	MDR	value	calculated	in	each	sample	of	heterogeneous	EEC	patients.	 Dark	 greys	 represents	 percentage	 of	 variants	 detected	 with	 good	 quality	 and	 light	 grey	 percentage	 of	variants	 identified	with	 low	 quality	 in	 the	 Ion	 PGM	 analysis.	 A:	 uterine	 aspirate,	 TR:	 tumor	 region,	 TR-HQ:	 tumor	region	 considering	 high	 quality	 variants,	 EEC:	 Endometrioid	 Endometrial	 Carcinoma,	 SEC:	 Serous	 Endometrial	Carcinoma,	CS:	Carcinosarcoma.	(*p<0.05,	**0.05<p<0.001).		 	
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4.3 Deciphering	 intratumor	 heterogeneity	 in	 metastatic	
endometrial	carcinomas	
Previous	results	derived	from	the	UAs	project	suggested	that	ITH	seemed	to	be	a	common	event	in	 EECs,	 but	 not	 in	 SECs	 or	 CSs	 (see	 section	 4.2).	 However,	 this	 study	 showed	 several	limitations,	 considering	 that	 targeted	 sequencing	 is	 restricted	 to	 specific	 regions	 and	 only	primary	tumors	were	included.	To	further	investigate	the	implication	of	ITH	in	EC,	a	collection	of	metastatic	and	recurrent	cases	was	analyzed	by	WES.	In	this	sense,	the	current	study	allowed	not	only	 the	analysis	of	 genetic	 changes	as	point	mutations	and	 small	 insertion	and	deletions	(indels),	 but	 also	 big	 genomic	 variations	 as	 somatic	 copy	 number	 alterations	 (SCNAs),	 more	common	in	SECs.	Additionally,	WES	analysis	was	followed	by	a	targeted	sequencing	validation	process,	which	let	us	to	increase	the	number	of	samples	analyzed	in	each	patient.		
4.3.1 Cases	description	and	endometrial	samples	selection	A	series	of	11	patients	diagnosed	with	metastatic	EC	and	complete	follow-up	information	were	included	in	the	study,	counting	7	EEC,	3	SEC	and	one	ambiguous	carcinoma	(AEC)	(Table	8).	As	previously	mentioned,	AECs	 comprise	 those	 tumors	with	overlapping	 characteristics	between	EECs	 and	 NEECs,	 difficulting	 a	 clear	 histologycal	 classificationus128,	 129.	 The	 ultramutated	subgroup	of	EC	related	to	POLE	mutations	was	excluded,	since	it	could	hamper	the	analysis	of	ITH.	 The	 the	 most	 frecuent	 POLE	 mutations	 in	 EC	 were	 analyzed	 by	 Sanger	 sequencing,	accounting	for	about	90%	of	the	mutations	previously	described	in	endometrial	carcinomas231	(Supplementary	 Table	 13).	 Furthermore,	 microsatellite	 instability	 (MSI)	 was	 analyzed	 in	 the	EEC	cases	by	IHC	and	PCR	amplification	of	5	microsatellite	markers	(see	3.8	section).	According	to	 these	 results	 4	 of	 the	 7	 EEC	 showed	MSI	 (EEC4-7),	 being	 3	 of	 them	 classified	 as	MSI-high	cases	(EEC5-7).	After	sample	classification,	the	fresh-frozen	tumor	tissue	and	the	corresponding	germline	DNA	were	analyzed	by	WES,	 including	at	 least	 two	 tumor	 regions	 from	 the	primary	tumor	 and	 one	 from	 the	 metastasis.	 Then,	 the	 validation	 of	 the	 identified	 variants	 was	performed	by	targeted	ampliseq	sequencing,	including	additional	FFPE	samples	from	each	case	to	further	explore	ITH	in	these	patients	(Table	9).	
4.3.2 Whole-exome	 sequencing	 study	 and	 molecular	 classification	 of	
metastatic	EC	samples	A	total	of	48	frozen	samples	from	the	11	patients	(with	a	mean	of	4	samples	per	patient)	were	analyzed	by	WES	to	a	51x	median	depth	(range	=	32-74x).	Bioinformatics	analysis	identified	a	median	of	83	variants	per	 sample	 (range	=	23-1000),	57	of	 them	non-synonymous	mutations	(range	 =	 17-779)	 (Figure	 21a,	 Supplementary	 Table	 14),	 similar	 to	 the	 TCGA	 dataset	 (TCGA	
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RESULTS	 		 	patients	excluding	POLE	mutated	subtype;	median	=	50,	range	=	14-	3810,	Mann-Whitney	U	test	p=	0.76).		
	
Figure	 21	 Summary	 of	 WES	 results	 from	 the	 multiple	 sample	 analysis	 from	metastatic	 ECs.	 a)	 Number	 of	synonymous,	non-synonymous	and	pathogenic	variants	and	b)	number	of	somatic	copy	number	alterations	identified	by	WES	analysis	in	specified	samples.	c)	Frequently	mutated	genes	previously	described	in	endometrial	carcinomas50	(blue	 bold	 font	 indicates	 those	 initially	 described	 by	 the	 TCGA	 consortium196).	 Colored	 squares	 represent	 the	presence	of	mutation	in	at	least	one	sample	of	the	patient.	CN-low	cases	(EEC	1-4)	are	marked	in	orange,	MSI	cases		(EEC	5-7)	in	green,	serous-like	cases	(SEC	1-3)	in	red	and	the	ambiguous	case	(AEC)	in	black.	Grey	squares	indicate	the	absence	of	mutation	(wild-type	status).	
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RESULTS	 		 	The	number	of	SCNAs	widely	varies	depending	on	the	histological	subtype	(median	=	10,	range	=	0-43),	being	significantly	higher	in	the	serous	cancer	patients	and	in	the	ambiguous	carcinoma	case	 than	 in	 the	endometrioid	 tumors	 (P<0.0001)	 (Figure	 21b,	 Supplementary	Table	15).	No	significant	 differences	 were	 found	 between	 the	 number	 of	 somatic	 variants	 neither	 SCNAs	between	 primary	 tumors	 and	 metastasis.	 According	 to	 these	 results,	 tumors	 were	 stratified	based	 on	 the	 TCGA	 classification196	 as	 copy-number	 low/endometrioid	 (EEC1-4),	MSI/hypermutated	(EEC5-7),	and	copy-number	high/serous-like	(SEC1-3	and	AEC)	(Table	8).	At	least	one	of	the	most	frequently	mutated	genes	described	by	the	TCGA	analysis196	was	found	altered	in	all	the	cases,	except	in	the	ambiguous	case	that	presented	a	missense	non-pathogenic	mutation	in	ESR1,	recently	described	as	a	frequently	mutated	gene	in	EC50	(Figure	21c).		Furthermore,	 the	mutational	process	of	each	tumor	region	was	analyzed	(see	3.5.4.4	 section),	and	mutational	signatures	were	defined	for	each	sample	according	to	the	previously	described	by	Alexandrov	 et	al16	 (Supplementary	Table	 16).	While	 the	majority	 of	 CN-low	 samples	were	related	to	signature	1,	associated	to	the	age	of	the	patient,	MSI	tumors	showed	the	signature	6,	linked	to	DNA	MMR	deficiency.	For	the	majority	of	 the	patients,	 the	different	samples	showed	concordant	mutational	signatures,	except	for	EEC-4	and	SEC-3	patients.	In	both	cases,	primary	tumor	 samples	 showed	 signature	 1	while	metastatic	 regions	 had	 the	mutational	 signature	 6.	Nevertheless,	 metastatic	 samples	 did	 not	 have	 the	 correct	 associated	 indels	 to	 be	 properly	classified	 as	 signature	 6,	 so	 this	 should	 not	 be	 considered	 as	 a	 reliable	 signature	 assignation.	Interestingly,	all	the	samples	analyzed	from	the	AEC	case	showed	the	mutational	signature	13,	which	has	not	been	previously	described	in	ECs.	Because	this	case	showed	unusual	histological	and	 molecular	 characteristics,	 it	 was	 analyzed	 separately	 from	 the	 rest	 of	 cases	 and	 will	 be	discussed	in	section	4.4.	
4.3.3 Whole-exome	sequencing	analysis	revealed	different	degrees	of	ITH	in	
metastatic	ECs	The	 comparison	 of	 the	 genetic	 variants	 found	 in	 the	 different	 samples	 from	 each	 patient	revealed	a	mean	of	44%	shared	mutations	(range	=	2-74%)	(Figure	22a),	with	the	MSI	patients	showing	a	significantly	lower	percentage	(mean	=	12%,	p=0.0085).	On	the	other	hand,	a	mean	of	54%	(range	=	4-100%)	of	pathogenic	mutations	were	common	between	all	the	samples	of	each	patient	 (Figure	 22b),	 remaining	 the	 lower	 percentages	 those	 observed	 in	 the	 MSI	 cases.	Interestingly,	the	percentage	of	common	SNCAs	was	very	low	in	all	the	subtypes,	with	a	mean	of	6%	 (range	 =	 0-37%)	 (Figure	 22c).	 However,	 the	 percentage	 of	 common	 genes	 affected	 by	SCNAs	was	significantly	higher	(mean	=	21%,	range	=	0-975;	p=0.048)	(Figure	22d),	especially	in	the	EEC-2	case	that	shared	97%	of	the	affected	genes	but	only	38%	of	SCNAs.			
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Figure	22	Percentage	of	common	genetic	and	genomic	alterations	 found	 in	 the	multiple	sample	analysis	of	
metastatic	 ECs.	 Percentage	 of	 shared	 single	 nucleotide	 variants	 (SNVs)	 (a),	 pathogenic	 SNVs	 (b),	 somatic	 copy	number	 alterations	 (SCNAs)	 (c)	 and	 genes	 affected	 by	 SCNAs	 (d)	 identified	 in	 the	 comparison	 between	 multiple	samples	 in	 each	metastatic	 EC.	 Each	 point	 represents	 a	 patient.	 CN-low	 cases	 are	marked	 in	 orange,	MSI	 cases	 in	green	and	serous-like	cases	in	red.	p-values	lower	than	0.05	were	considered	statistically	significant	(*p<0.05).		These	 results	 suggested	 the	 presence	 of	 not	 only	 genetic	 but	 also	 genomic	 ITH	 between	 the	multiple	 samples	 derived	 from	 metastatic	 EC,	 with	 different	 degrees	 depending	 on	 the	molecular	 subgroup.	Previous	 results	obtained	 in	 the	uterine	aspirates	project	 suggested	 that	ITH	was	mainly	 found	 in	 the	 endometrioid	 histology	 (see	 section	4.2),	 but	 the	 present	WES	analysis	 revealed	 that	 ITH	was	 also	 found	 in	 the	 serous	 tumors.	However,	 this	 heterogeneity	was	more	widespread	at	the	SCNA	level.	Since	numerous	changes	at	the	copy	number	level	are	the	 hallmark	 of	 serous	 tumors,	 we	 thoroughly	 investigated	 its	 distribution	 in	 these	 cases	(Figure	 23).	 While	 most	 of	 the	 genetic	 variants	 were	 shared	 by	 all	 the	 samples,	 the	 genes	affected	by	SCNAs	had	a	diverse	distribution.	In	the	SEC-1	patient,	whereas	43%	of	the	genetic	variants	were	 shared	by	 the	 five	 analyzed	 samples,	 only	10%	of	 the	 genes	 affected	by	 SCNAs	were	 common	 between	 them.	Nevertheless,	 the	 percentage	 of	 common	 variants	 between	 the	primary	tumor	samples	was	similar:	15%	in	the	SNVs	versus	20%	in	the	SCNAs	analysis.	About	the	 SEC-2	 patient	 analysis,	 it	 is	 worth	 mentioning	 the	 high	 number	 of	 SCNAs	 detected	exclusively	 in	 the	 metastatic	 region	 (28%	 of	 the	 total	 SCNAs	 identified).	 Finally,	 the	 SEC-3	patient	 also	 showed	 a	 higher	 number	 of	 shared	 genetic	 variants	 (73%)	 compared	 to	 the	common	SCNAs	(46%).	In	this	case,	an	important	percentage	of	the	SCNAs	were	also	exclusively	
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RESULTS	 		 	observed	 in	 the	 metastatic	 regions	 (50/253,	 20%),	 not	 being	 found	 in	 the	 primary	 tumor	samples	analyzed.			
	
Figure	23	Genetic	and	genomic	changes	distribution	in	the	multiple	sample	analysis	of	metastatic	SECs.	Venn	diagrams	representing	the	number	and	percentage	of	single	nucleotide	variants	(SNVs,	left	panel)	and	genes	affected	by	 somatic	 copy	 number	 alterations	 (SNCAs,	 right	 panel)	 in	 the	 multiple	 samples	 analyzed	 by	 WES	 from	 the	metastatic	serous	endometrial	carcinomas	(SECs).		To	further	characterize	genetic	ITH	in	each	sample,	tumor	purity	and	malignant	cell	ploidy	were	inferred	by	the	calculation	of	the	cancer	cell	fraction	(CCF),	as	previously	described	(see	section	
3.5.4.3).	CCF	represents	the	fractions	of	analyzed	cancer	cells	that	carried	each	mutation,	which	
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RESULTS	 		 	allows	 to	 discriminate	 between	 clonal	 and	 subclonal	 mutations	 in	 each	 specific	 sample.	 The	majority	 of	 the	 detected	 variants	 revealed	 a	 clonal	 status	 (mean	 =	 82%,	 range	 =	 61-93%)	(Supplementary	Table	14),	independently	of	the	histological	or	molecular	subtype	of	the	tumor	or	 the	 anatomical	 location	 of	 the	 sample	 (primary	 tumor	 or	 metastasis).	 In	 this	 sense,	 CCF	values	 showed	 that	most	of	 the	 cancer	 cells	of	 each	 sample	 carried	 the	majority	of	mutations	detected	 by	 WES	 in	 each	 specific	 region,	 whereas	 a	 small	 percentage	 of	 variants	 were	 only	present	 in	 subclonal	 populations	 of	 the	 sample.	 Variants	 distribution	 and	 clonal	 status	 are	represented	in	the	Supplementary	Figure	1	and	Supplementary	Figure	2.			
	
Figure	 24	 Phylogenetic	 trees	 representing	 tumor	 evolution	 in	 metastatic	 ECs.	 Phylogenetic	 trees	 were	generated	 using	 the	 cancer	 cell	 fraction	 (CCF)	mutational	 data	 from	 the	WES	 analysis	 (see	 section	3.6.2).	 Colors	represent	 the	 samples	 in	which	 variants	were	 identified:	 black	 for	 ubiquitous	 variants,	 green	 for	 variants	 shared	between	primary	tumor	and	metastatic	lesions,	purple	for	variants	shared	by	different	primary	tumor	regions,	brown	for	variants	shared	between	the	multiple	metastatic	regions,	blue	for	variants	exclusively	observed	in	primary	tumor	samples	and	orange	for	variants	only	detected	in	the	metastatic	samples.		Tumor	 evolution	 was	 analyzed	 by	 the	 construction	 of	 phylogenetic	 trees	 based	 on	 the	 CCF	values	 for	each	patient	(Figure	 24).	Three	different	patterns	of	evolution	were	observed.	The	majority	of	the	patients	showed	a	monophyletic	pattern,	with	two	main	branches	representing	an	initial	evolution	of	the	metastatic	clone	and	a	subsequent	development	of	additional	primary	tumor	mutations	(EEC-2,	EEC-4,	EEC-5,	EEC-7,	SEC-1	and	SEC-2).	SEC-3	patient	also	showed	two	
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RESULTS	 		 	differentiated	branches	for	the	primary	tumor	and	metastatic	regions,	but	with	a	main	group	of	ubiquitous	variants	that	developed	in	two	branches:	one	of	them	with	shared	variants	between	both	primary	tumor	regions	and	the	other	one	with	the	same	pattern	for	the	metastatic	lesions.	On	 the	 other	 hand,	 in	 the	 EEC-1,	 EEC-3	 and	 EEC-6	 patients	 the	 metastatic	 lesion	 seems	 to	develop	 from	 one	 of	 the	 primary	 tumor	 regions,	 indicating	 the	 presence	 of	 polyphyly.	Altogether,	 these	 results	 suggested	 that	 different	 evolution	 patterns	 are	 found	 in	 EC	progression,	apparently	not	related	to	histological	or	molecular	classification	of	the	tumor.	
4.3.4 Targeted	 sequencing	 broadened	 the	 view	 of	 ITH	 implication	 in	
metastatic	ECs	With	 the	 aim	 of	 validating	 the	 genetic	 variants	 identified	 by	WES,	 a	 subsequent	 study	 using	targeted	massive	parallel	sequencing	was	performed	in	the	previously	analyzed	samples.	A	total	of	596	variants	were	 reanalyzed	 in	 the	validation	process	 (Supplementary	Table	5).	 Selection	criteria	 included	 all	 the	 pathogenic	 variants	 along	with	 additional	 non-pathogenic	 variants	 to	reach	at	least	40%	of	those	detected	by	WES	in	the	CN-low	and	serous	cases	and	10%	in	the	MSI	tumors.	Seven	of	the	596	variants	(1.2%)	could	not	be	analyzed	due	to	a	failure	of	the	primers	in	the	 amplification	 step.	 A	 validation	 ratio	 of	 99%	 was	 found,	 being	 582	 of	 the	 589	 analyzed	variants	detected	as	previously	described	by	the	WES	analysis.	In	order	to	expand	the	study	of	ITH	in	these	cases,	additional	FFPE	samples	from	each	patient	were	 also	 subjected	 to	 ampliseq	 sequencing.	 At	 least	 6	 different	 tumor	 regions	 per	 patient,	accounting	 for	 multiple	 primary	 tumor	 as	 well	 as	 metastatic	 locations	 were	 included	 in	 this	analysis	(mean	=	9,	range	=	7-11)	(Table	9).	Uterine	aspirates	(UAs)	were	also	included	when	available.	Targeted	sequencing	was	performed	to	a	mean	depth	of	1,243x	(range	=	224-5,431x).	No	differences	were	 found	between	 the	sequencing	quality	metrics	of	 frozen	and	FFPE	 tumor	samples	(Supplementary	Table	17).	Targeted	sequencing	results	are	included	in	Supplementary	Table	18.	The	comparison	between	those	variants	 identified	 in	the	multiple	sample	analyzed	by	WES	or	by	 targeted	 sequencing	 revealed	 changes	 in	 the	 ITH	 degree.	 For	 this	 comparison,	 only	 those	variants	included	in	the	validation	process	were	taken	into	account.	Starting	with	the	CN-low	patients	(EEC1-4),	we	observed	that	the	percentage	of	common	SNVs	remains	similar	in	two	of	the	cases	(EEC-1	and	-3)	but	strongly	decreases	in	the	other	two	(EEC-2	and	-4)	(Figure	25a).	In	the	case	of	the	patients	with	MSI	tumors	(EEC5-7),	the	percentage	of	shared	 mutations	 was	 higher	 in	 the	 targeted	 sequencing	 compared	 with	 the	 exome	 study	(Figure	 25b).	This	could	be	partially	explained	by	 the	 fact	 that	 targeted	sequencing	provided	coverage	 values	more	 than	 20-fold	 higher	 than	WES	 analysis.	 In	 that	 light,	 this	methodology	allows	 much	 more	 reliable	 DNA	 sequencing,	 facilitating	 the	 analysis	 of	 DNAs	 as	 unstable	 as	
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RESULTS	 		 	those	of	a	tumor	with	MSI.	On	the	other	hand,	the	three	serous	cases	(SEC1-3)	showed	a	variant	distribution	similar	to	that	found	in	the	WES	analysis,	with	the	majority	of	them	common	to	all	the	samples	(Figure	25c).		
	
Figure	 25	 Comparison	 of	 the	 percentage	 of	 common	 variants	 detected	 by	 WES	 and	 targeted	 sequencing	
validation.	Percentage	of	variants	shared	by	all	analyzed	samples	in	each	CN-low	(a),	MSI	(b)	or	serous	(c)	patients,	by	WES	and	targeted	massive	parallel	sequencing	analyses.	Only	those	variants	considered	in	the	validation	process	were	included	in	this	comparison.		A	 summary	 of	 the	 targeted	 sequencing	 results	 in	 each	 patient	 is	 presented	 in	 the	 following	paragraphs.		In	the	EEC-1	case,	12%	of	the	selected	variants	were	common	to	all	samples	analyzed	by	WES		while	20%	of	them	were	shared	by	the	samples	analyzed	in	the	targeted	sequencing.	This	case	remained	showing	a	high	ITH	rate,	being	genetically	similar	the	T1	and	M2	regions	and	the	T4	and	 M	 samples	 (Figure	 26a).	 Interestingly,	 the	 primary	 tumor	 T5	 region	 did	 not	 show	 the	majority	of	the	variants	detected	in	the	rest	of	the	samples.	This	could	be	suggesting	that	the	T5	region	is	an	early	clone	that	contains	the	initial	mutations	as	those	identified	in	PTEN,	CREBBP	or	SIN3A	genes.	However,	it	did	not	acquire	subsequent	mutations	such	as	that	in	CTNNB1	gene,	which	 was	 observed	 in	 the	 rest	 of	 the	 regions.	 These	 observations	 are	 also	 reflected	 in	 the	phylogenetic	tree	obtained	for	this	patient	(Figure	26b),	mainly	 formed	by	multiple	branches	containing	 between	 different	 primary	 tumor	 and	 metastatic	 regions.	 Interestingly,	 the	metastatic	region	M2	appears	 to	be	similar	 to	 the	primary	 tumor	T1	area,	both	of	 them	being	found	in	an	early	point	of	the	tumor	evolution,	while	T4	and	M	samples,	after	the	acquisition	of	additional	variants,	appeared	at	 the	end	of	 the	tree.	The	oligoclonal	clonal	composition	of	 this	tumor	is	represented	in	its	polyphyletic	evolution.		
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Figure	26	Genetic	 ITH	analysis	 in	 the	EEC-1	patient.	a)	Mutation	Allele	Frequency	(MAF)	heatmap	based	on	the	targeted	 sequencing	 validation	 results.	 b)	 Phylogenetic	 tree	 generated	 according	 to	 the	 presence	 or	 absence	 of	mutations	 in	 the	 validation	 analysis.	 Tumor	 locations:	 T1:	 fundus,	 T2:	 left	 parametrium,	 T3-T5:	 different	 uterine	locations	 from	 the	 primary	 tumor;	 M:	 right	 pelvic	 node,	 M2:	 right	 primitive	 node.	 Metastases	 were	 detected	 and	resected	at	the	moment	of	the	tumor	diagnosis.	Colors	represent	the	samples	in	which	variants	were	identified:	black	for	ubiquitous	variants,	green	 for	variants	shared	between	primary	tumor	and	metastatic	 lesions,	blue	 for	variants	exclusively	observed	in	primary	tumor	samples	and	orange	for	variants	only	detected	in	the	metastatic	samples.	
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RESULTS	 		 	The	 EEC-2	 case	 exhibited	 a	 lower	 degree	 of	 ITH	 compared	 to	 the	 EEC-1	 patient,	 although	different	patterns	of	variant	distribution	were	also	found	(Figure	27a).	While	the	percentage	of	shared	variants	in	the	WES	was	67%,	it	turned	out	to	be	just	20%	in	the	targeted	sequencing.	In	this	patient,	primary	tumor	samples	T3	and	T6	seemed	to	represent	initial	clones	of	the	tumor,	carrying	a	low	percentage	of	the	variants	detected	in	the	rest	of	the	primary	tumor	regions	and	being	located	in	an	initial	point	of	the	tumor	evolution	(Figure	27b).	In	this	case,	the	CTNNB1	mutation	was	 found	 in	all	 the	analyzed	samples,	which	could	 indicate	 its	 initiating	role	 in	this	tumor.	No	differences	were	found	between	the	multiple	metastatic	regions,	all	 localized	in	the	ovary.		
	
Figure	27	Genetic	 ITH	analysis	 in	 the	EEC-2	patient.	a)	Mutation	Allele	Frequency	(MAF)	heatmap	based	on	the	targeted	 sequencing	 validation	 results.	 b)	 Phylogenetic	 tree	 generated	 according	 to	 the	 presence	 or	 absence	 of	mutations	in	the	validation	analysis.	Tumor	locations:	T1-T7:	different	uterine	locations	from	the	primary	tumor;	M-M4:	different	metastatic	regions	localized	in	the	ovary.	Metastases	were	detected	and	resected	at	the	moment	of	the	tumor	 diagnosis.	 UA:	 uterine	 aspirate.	 Colors	 represent	 the	 samples	 in	 which	 variants	 were	 identified:	 black	 for	ubiquitous	 variants,	 green	 for	 variants	 shared	 between	 primary	 tumor	 and	metastatic	 lesions,	 purple	 for	 variants	shared	by	different	primary	tumor	regions,	brown	for	variants	shared	between	the	multiple	metastatic	regions,	blue	for	variants	exclusively	observed	in	primary	tumor	samples	and	orange	for	variants	only	detected	in	the	metastatic	samples.	
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RESULTS	 		 	On	the	other	hand,	EEC-3	and	EEC-4	patients	did	not	show	a	clear	ITH,	sharing	all	the	samples	the	 majority	 of	 the	 analyzed	 variants.	 Interestingly,	 in	 both	 cases	 the	 metastatic	 regions	analyzed	belong	to	a	recurrent	disease,	affecting	lymph	nodes	and	the	peritoneum	in	EEC-3	and	EEC-4	 patients,	 respectively.	 In	 those	 patients,	more	 than	 70%	of	 the	 variants	were	 common	between	primary	 tumor	and	metastatic	 samples,	while	 the	majority	of	 the	remaining	variants	correspond	to	additional	mutations	acquired	by	the	metastatic	regions	(Figure	28a	and	b).	This	can	 be	 observed	 in	 their	 corresponding	 phylogenetic	 trees,	with	 a	 long	 branch	 of	 ubiquitous	shared	 variants	 and	 a	 final	 expansion	 of	 the	 metastatic	 regions	 due	 to	 the	 acquisition	 of	additional	mutations	(Figure	28c	and	d).		
	
Figure	28	Genetic	ITH	analysis	in	the	EEC-3	and	EEC-4	patients.	Mutation	Allele	Frequency	(MAF)	heatmap	based	on	the	targeted	sequencing	validation	results	of	the	EEC-3	(a)	and	EEC-4	(b)	patients.	Phylogenetic	trees	generated	according	to	the	presence	or	absence	of	mutations	in	the	validation	analysis	of	the	EEC-3	(c)	and	EEC-4	(d)	patients.	Tumor	locations	in	the	EEC-3	patients:	T1-T5:	different	uterine	locations	from	the	primary	tumor;	M-M3:	metastatic	regions	localized	in	different	 lymph	nodes.	Tumor	locations	in	the	EEC-4	patient:	T1-T3:	different	uterine	locations	from	 the	 primary	 tumor;	 M-M4:	 metastatic	 regions	 localized	 in	 different	 zones	 of	 the	 peritoneum.	 UA:	 uterine	aspirate.	 Metastases	 were	 detected	 and	 resected	 3	 years	 after	 primary	 tumor	 diagnosis	 in	 both	 cases.	 Colors	represent	 the	 samples	 in	which	 variants	were	 identified:	 black	 for	 ubiquitous	 variants,	 green	 for	 variants	 shared	between	primary	tumor	and	metastatic	lesions,	brown	for	variants	shared	between	the	multiple	metastatic	regions,	blue	 for	 variants	 exclusively	 observed	 in	 primary	 tumor	 samples	 and	 orange	 for	 variants	 only	 detected	 in	 the	metastatic	samples.		
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RESULTS	 		 	Additionally,	UAs	that	were	available	from	this	series	of	patients	were	also	sequenced	(EEC-2_A	and	 EEC-3_A)	 (Figure	 28).	 Interestingly,	 72%	 and	 87%	 of	 the	 total	 analyzed	 variants	 were	detected	in	the	UAs	from	EEC-2	and	EEC-3	patients	respectively.	In	fact,	UA	obtained	from	the	EEC-3	patient	carried	not	only	the	ubiquitous	variants	but	also	part	of	those	mostly	identified	in	the	metastatic	samples.	This	is	the	case	of	the	variant	detected	in	FOLR2	gene	that	was	identified	in	 three	metastatic	regions	(M,	M2	and	M3)	and	the	uterine	aspirate	(UA),	but	not	 in	primary	tumor	lesions.	It	is	worth	mentioning	that	this	aspirate	was	obtained	as	a	pre-operative	biopsy	in	 the	 first	 surgery	 of	 this	 patient,	 being	 the	metastatic	 lesions	 resected	 3	 years	 later.	 These	results	reaffirm	the	effectiveness	of	sequencing	analysis	in	UAs	for	the	genetic	characterization	of	EC.			Regarding	 the	patients	with	MSI	 tumors	 (EEC5-7),	 a	higher	percentage	of	 common	mutations	between	the	multiple	samples	analyzed	in	each	case	was	found	in	the	targeted	sequencing	study	when	compared	to	the	WES	(Figure	25b),	as	previously	mentioned.		This	is	the	case	of	EEC-5	patient,	where	just	20%	of	the	selected	variants	used	for	the	validation	process	were	shared	by	all	the	samples	in	the	WES	analysis,	but	41%	of	them	were	common	by	targeted	 sequencing.	 In	 fact,	 25	 of	 the	87	 (30%)	 variants	determined	 as	 exclusive	 of	 primary	tumor	 samples	 by	WES,	 turned	 out	 to	 be	 also	 detected	 in	 the	 metastatic	 region	 by	 targeted	sequencing.	 Nevertheless,	 an	 important	 degree	 of	 ITH	 was	 found,	 as	 shown	 the	 irregular	distribution	 of	 the	 detected	 variants	 (Figure	 29a).	 The	 phylogenetic	 tree	 of	 this	 tumor	 also	show	this	ITH,	with	multiple	branches	and	subclones,	evolving	the	metastatic	sample	from	the	primary	tumor	region	T3	(Figure	29b),	indicating	the	presence	of	polyphyly.		
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Figure	29	Genetic	 ITH	analysis	 in	 the	EEC-5	patient.	a)	Mutation	Allele	Frequency	(MAF)	heatmap	based	on	the	targeted	 sequencing	 validation	 results.	 b)	 Phylogenetic	 tree	 generated	 according	 to	 the	 presence	 or	 absence	 of	mutations	in	the	validation	analysis.	Tumor	locations:	T1	depth	tumor,	T2	superficial	tumor,	T3-T6:	different	uterine	locations	 from	 the	 primary	 tumor;	M:	metastatic	 tumor	 localized	 in	 the	 peritoneum.	Metastasis	was	 detected	 and	resected	at	the	moment	of	the	tumor	diagnosis.	Colors	represent	the	samples	in	which	variants	were	identified:	black	for	ubiquitous	variants,	green	for	variants	shared	between	primary	tumor	and	metastatic	lesions,	purple	for	variants	shared	 by	 different	 primary	 tumor	 regions,	 blue	 for	 variants	 exclusively	 observed	 in	 primary	 tumor	 samples	 and	orange	for	variants	only	detected	in	the	metastatic	sample.	
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RESULTS	 		 	By	contrast,	EEC-6	analysis	showed	a	high	consistency	between	the	mutational	profile	of	all	the	analyzed	samples,	sharing	67%	of	the	analyzed	variants	(Figure	30a)	versus	38%	found	in	the	WES.	 In	 this	 case,	 two	 main	 branches	 were	 found	 in	 the	 phylogenetic	 tree,	 distinguishing	between	 primary	 tumor	 and	metastatic	 regions	 	 in	 a	monophyletic	 progression	 of	 the	 tumor	(Figure	30b).	
	
Figure	30	Genetic	 ITH	analysis	 in	 the	EEC-6	patient.	a)	Mutation	Allele	Frequency	(MAF)	heatmap	based	on	the	targeted	 sequencing	 validation	 results.	 b)	 Phylogenetic	 tree	 generated	 according	 to	 the	 presence	 or	 absence	 of	mutations	in	the	validation	analysis.	Tumor	locations:	T1	depth	tumor,	T2	superficial	tumor,	T3-T6:	different	uterine	locations	from	the	primary	tumor;	M-M5:	different	metastatic	region	localized	in	the	ovary.	Metastases	were	detected	and	resected	at	the	moment	of	the	tumor	diagnosis.	Colors	represent	the	samples	in	which	variants	were	identified:	black	 for	 ubiquitous	 variants,	 purple	 for	 variants	 shared	 by	 different	 primary	 tumor	 regions,	 brown	 for	 variants	shared	between	the	multiple	metastatic	regions,	blue	for	variants	exclusively	observed	in	primary	tumor	samples	and	orange	for	variants	only	detected	in	the	metastatic	samples.	
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RESULTS	 		 	Nevertheless,	although	the	percentage	of	common	variants	in	EEC-7	patient	was	higher	with	the	targeted	sequencing	than	with	the	WES	(13%	versus	2%),	this	value	remained	very	low.	Three	main	patterns	of	 variant	distribution	were	 found	 in	 this	patient:	 a	 low	percentage	of	 variants	shared	 by	 all	 the	 samples,	 a	 few	 variants	 mostly	 identified	 in	 the	 metastatic	 lesions	 and	additional	variants	mainly	detected	 in	primary	 tumor	regions	(Figure	 31a).	The	phylogenetic	tree	 generated	 for	 this	 tumor	 confirmed	 these	 assumptions,	 showing	 two	 differentiated	branches:	the	first	one	nearer	to	the	trunk	of	the	three	and	composed	by	the	metastatic	regions,	and	the	other	one	with	primary	tumor	regions,	which	have	additional	mutations	(Figure	31b).	It	 is	 important	to	note	that	 in	this	case,	 the	metastatic	 lesions	come	from	a	distant	recurrence	located	 at	 the	 diaphragm	 and	 diagnosed	 7	 years	 after	 the	 primary	 tumor	was	 treated.	 These	results	could	be	 indicating	that	during	tumor	evolution,	an	early	 tumor	subclone	acquired	the	ability	 to	 spread	 prior	 to	 the	 rest	 of	 the	 primary	 tumor	 subclones,	 which	 continued	 gaining	mutations	 not	 present	 later	 in	 the	 recurrence	 samples,	 suggesting	 their	 irrelevant	 role	 in	 the	metastatic	dissemination	of	this	tumor.		
Figure	31	Genetic	ITH	analysis	in	the	
EEC-7	 patient.	 a)	 Mutation	 Allele	Frequency	 (MAF)	 heatmap	 based	 on	the	 targeted	 sequencing	 validation	results.	b)	Phylogenetic	 tree	generated	according	to	the	presence	or	absence	of	mutations	 in	 the	 validation	 analysis.	Tumor	 locations:	 T1-T3:	 different	uterine	 locations	 from	 the	 primary	tumor;	 M-M5:	 different	 metastatic	region	 localized	 in	 the	 diaphragm.	Metastases	were	detected	and	resected	seven	 years	 after	 primary	 tumor	diagnosis.	 Colors	 represent	 the	samples	 in	 which	 variants	 were	identified:	 black	 for	 ubiquitous	variants,	purple	 for	variants	shared	by	different	 primary	 tumor	 regions,	brown	for	variants	shared	between	the	multiple	 metastatic	 regions,	 blue	 for	variants	 exclusively	 observed	 in	primary	tumor	samples	and	orange	for	variants	only	detected	in	the	metastatic	samples.		
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RESULTS	 		 	In	the	case	of	SECs,	the	majority	of	genetic	variants	were	consistenly	shared	among	most	of	the	samples.	Interestingly,	the	rest	of	the	detected	mutations	were	mostly	identified	in	the	primary	tumor	regions,	indicating	an	early	spread	of	the	metastatic	clone	to	the	ovary	and	a	subsequent	development	 of	 the	 primary	 tumor	 in	 the	 uterus	 (Figure	 32a,	 b	 and	 c).	 Although	 some	mutations	were	exclusively	detected	in	the	metastatic	regions,	they	were	a	minority.	This	is	the	case	 of	 the	 variant	 identified	 in	 DCP1B	 gene	 in	 the	 M1	 region	 of	 the	 SEC-2	 patient;	 or	 the	variants	in	CSF1	and	TRIM27	genes	identified	in	the	metastatic	lesions	of	SEC-3,	though	in	this	case	minor	clones	(<1%	MAF)	were	found	in	some	of	the	primary	tumor	locations.	These	results	are	 shown	 in	 the	 phylogenetic	 trees	 of	 each	 case,	 in	 which	 primary	 tumor	 regions	 and	metastatic	samples	appear	separated	in	two	main	branches,	after	a	long	evolution	of	the	tumor	with	most	of	the	variants	ubiquitously	detected	(Figure	32d,	e	and	f).	
	
Figure	32	Genetic	 ITH	analysis	 in	the	serous-like	patients.	Mutation	Allele	Frequency	(MAF)	heatmap	based	on	the	 targeted	 sequencing	 validation	 results	 of	 the	 SEC-1	 (a),	 SEC-2	 (b)	 and	 SEC-3	 (c)	 patients.	 Phylogenetic	 trees	generated	according	to	the	presence	or	absence	of	mutations	in	the	validation	analysis	of	the	SEC-1	(d),	SEC-2	(e)	and	SEC-3	 (f)	 patients.	 In	 the	 three	 SEC	 T	 regions	 correspond	 to	 primary	 tumor	 locations	 in	 the	 uterus,	 while	 the	metastatic	 lessions	 (M)	were	 located	at	 the	ovary	and	ovarian	 tube.	Metastases	were	detected	and	 resected	at	 the	moment	of	the	tumor	diagnosis.	Colors	represent	the	samples	in	which	variants	were	identified:	black	for	ubiquitous	variants,	 purple	 for	 variants	 shared	 by	 different	 primary	 tumor	 regions,	 brown	 for	 variants	 shared	 between	 the	multiple	metastatic	regions,	blue	for	variants	exclusively	observed	in	primary	tumor	samples	and	orange	for	variants	only	detected	in	the	metastatic	samples.	
	In	 conclusion,	 different	 degress	 of	 ITH	 as	 well	 as	 patterns	 of	 clonal	 evolution	 were	 found,	depending	on	 each	 analyzed	EC	patient.	 It	 is	 important	 to	note	 that	 the	 conclusions	 obtained	from	 the	 phylogenetic	 tree	 studies	 should	 be	 carefully	 considered	 since	 they	 are	 based	 on	 a	targeted	sequencing	study,	not	including	complete	results	found	in	the	previous	WES	analysis.	 	
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RESULTS	 		 	
4.4 Genomic	 analysis	 of	 an	 ambiguous	 endometrial	
carcinoma:	 the	 use	 of	 new	 generation	 platforms	 and	
animal	models	in	complex	cases		
4.4.1 Case	description	and	molecular	diagnosis	As	previously	mentioned,	one	of	the	cases	 included	in	the	WES	analysis	of	metastatic	ECs	was	classified	as	an	ambiguous	endometrial	carcinoma	(AEC).	It	has	been	previously	described	that	there	 is	 a	 subset	 of	 tumors	 with	 discordant	 microscopic	 and	 molecular	 characteristics	 that	entails	real	difficulties	to	be	histiologically	classified,	termed	ambiguous	tumors128,	129,	232.	One	of	the	objectives	of	the	present	thesis	involves	the	implementation	of	genetic	and	genomic	studies	in	order	to	better	characterize	and	understand	this	type	of	tumors.		In	 this	case,	 the	hematoxylin	and	eosin	 (H&E)	stainning	of	different	 regions	of	 the	 tumor	was	pointing	out	towards	a	carcinoma	without	readily	identifiable	features	of	any	of	the	cells	types	of	 differentiated	 endometrial	 neoplasms.	 Sheets	 of	 clear,	 mitotically	 active	 tumour	 cells	 with	areas	 of	 necrosis	 were	 also	 observed	 (Figure	 33a).	 Additionally,	 a	 previously	 described	immunohistochemical	panel	of	9	biomarkers	used	for	helping	to	predict	histological	subtype233	was	 analyzed	 in	 this	 tumor	 (Figure	 33b).	 According	 to	 the	 immunophenotype	 of	 this	 tumor,	more	 than	 5	 conditions	 satisfied	 to	 predict	 SEC	 versus	 differentiated	 EEC	 (grade	 1-2).	Nevertheless,	the	tumor	showed	heterogeneity	and	in	other	sections	less	than	5	conditions	were	satisfied,	 not	 being	 able	 to	 discriminate	 between	 SEC	 or	 EEC.	 Therefore,	 the	 histological	diagnosis	was	of	an	AEC.	Additionally	 and	 to	 further	 characterize	 this	 tumor,	 patient	 derived	 xenografts	 (PDXs)	 were	generated	from	this	AEC	(see	3.11	section).	For	this	approach,	different	tumor	regions	from	the	primary	 surgery	 were	 implanted	 in	 five	 different	 mice,	 including	 areas	 from	 the	 superficial	(AEC_PDX1)	 and	 deep	 (AEC_PDX2)	 tumor,	 right	 (AEC_PDX3)	 and	 left	 (AEC_PDX4)	 lymphatic	nodes	 and	 cervix	 implants	 (AEC_PDX5).	 After	 tumor	 growth,	 samples	 were	 resected	 and	analyzed	 by	H&E	 staining,	 showing	 similar	 histology	 that	 the	 previously	 found	 in	 the	 patient	(Figure	33c).			
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Figure	33	Histological	and	immunohistochemistry	profile	of	an	ambiguous	endometrial	carcinoma	(AEC).	a)	Representative	H&E	images	of	different	regions	from	the	primary	tumor	(I-II)	and	metastatic	lesions	(III)	of	the	AEC.	Magnification	 at	 20x	 in	 the	 upper	 panel	 and	 histological	 details	 of	 the	 images	 in	 the	 lower	 panel	 (40x).	 b)	Immunophenotype	of	the	AEC	based	on	a	9-protein	(ER,	p53,	p16,	PTEN,	FOLR1,	HMGA2,	IMP2,	 IMP3	and	CYC	E1-clycin	 E1)	 biomarker	 signature	 previously	 described233	 to	 facilitate	 the	 discrimination	 between	 SEC	 and	differentiated	EEC.	Magnification	40x.	c)	Representative	H&E	images	of	the	multiple	patient	derived	xenografts	(PDX)	samples	obtained	 from	superficial	 tumor	 (AEC_PDX1),	deep	 tumor	 (AEC_PDX2),	 right	 lymphatic	node	 (AEC_PDX3),	left	lymphatic	node	(AEC_PDX4)	and	cervix	implants	(AEC_PDX5)	of	this	patient.	Magnification	40x.			
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RESULTS	 		 	In	order	to	characterize	this	tumor	at	a	molecular	level	and	for	better	understanding	its	clinical	behavior,	 we	 studied	 it	 by	WES	 to	 identify	 somatic	 mutations	 and	 copy	 number	 alterations.	Regarding	its	controversial	origin,	we	analyzed	its	genetic	profile	using	the	TumorTracer	server	(see	3.5.4.1	section)219,	which	compare	our	tumor	genomic	features	with	a	dataset	of	more	than	200	 tumors.	These	 results	 indicated	 that	 endometrium	was	 the	 tissue	of	origin	 in	 this	 tumor,	showing	the	highest	classification	score	(0.548)	(Figure	34a).	A	confidence	score	of	0.246	was	obtained	for	the	endometrial	cancer	diagnosis.	For	this	score,	a	predictive	positive	value	of	79%	was	 obtained	when	 comparing	 to	 the	 TumorTracer	 dataset,	 with	 11	 of	 the	 14	 positive	 cases	properly	 classified	 (Figure	 34b).	 These	 results	 supported	 the	 pathological	 diagnosis	 of	 this	tumor.	
	
Figure	 34	TumorTracer	 results	 based	 on	WES	 analysis	 of	 the	 ambiguous	 endometrial	 carcinoma	 (AEC).	 a)	TumorTracer	 classification	 score	 identified	 the	 endometrium	 as	 the	 most	 probable	 tissue	 of	 origin.	 	 b)	Representations	 of	 the	 number	 of	 tumors	 from	 the	 TumorTracer	 datased	 incorrectly	 (grey)	 or	 correctly	 (blue)	classified	depending	on	the	confidence	score	(see	3.5.4.1	section	for	further	information).	TumorTracer	classification	and	confidence	scores	obtained	for	our	patient	are	marked	with	a	red	arrow.		 	
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4.4.2 WES	 analysis	 revealed	 uncommon	 results	 in	 the	 molecular	
characterization	of	the	ambiguous	endometrial	carcinoma	Although	this	case	was	molecularly	classified	as	an	endometrial	carcinoma	by	the	TumorTracer	server,	WES	results	revealed	it	did	not	show	any	of	the	most	common	mutated	genes	in	EC.	In	fact,	the	mutational	signature	13,	which	is	characterized	by	C>G	and	C>T	changes	and	has	been	attributed	 to	 the	 AID/APOBEC	 family	 of	 cytidine	 deaminases217,	 was	 identified	 in	 the	 three	samples	analyzed	by	WES	(T1,	T2	and	M)	(Supplementary	Table	16).	This	mutational	signature	has	 been	 previouly	 detected	 in	 bladder	 and	 breast	 cancer16,	 but	 to	 our	 knowledge	 it	 has	 not	been	described	in	endometrial	carcinomas	until	now.		Genetic	and	genomic	variants	distribution	between	analyzed	samples	of	the	AEC	were	studied.	As	previously	observed	in	other	cases,	the	percentage	of	common	SNVs	was	considerably	higher	compared	 to	 the	 shared	 genes	 altered	 by	 SCNAs	 (81%	 versus	 10%)	 (Figure	 35a	 and	b).	 In	contrast,	37%	of	the	genes	affected	by	SCNAs	were	common	to	primary	tumor	samples	(T1	and	T2).	This	similarity	between	the	primary	tumor	regions	was	reflected	in	the	phylogenetic	tree	obtained	for	this	patient,	which	showed	two	main	branches,	one	of	them	including	the	primary	tumor	samples	an	the	other	one	the	metastatic	sample	(Figure	35c),	indicating	a	monophyletic	evolution	programme.	The	low	presence	of	ITH	at	the	genetic	level	was	also	revealed	by	the	CCF	study,	that	identified	80%	of	variants	in	a	clonal	status.	CCF	heatmap	(Figure	35d)	also	showed	three	main	 subgroups	of	 variants	 distribution:	 the	main	 subgroup	was	 composed	by	 variants	common	to	all	samples,		the	second	one	comprised	those	variants	shared	by	the	primary	tumor	samples	(T1	and	T2),	while	the	rest	of	variants	were	identified	in	a	single	sample	(T1,	T2	or	M).	Moreover,	 only	 24	 of	 the	 variants	 identified	 by	 WES	 were	 mutations	 with	 a	 potentially	pathogenic	consequence	 in	 the	corresponding	protein,	and	only	one	(in	 the	ATM	gene)	with	a	pathogenic	consequence	(Supplementary	Table	14,	Figure	35d).	As	previously	mentioned,	none	of	 the	 genes	 carrying	 these	 variants	 are	 considered	 frequently	mutated	 in	 EC.	Nonetheless,	 a	copy-number	 gain	 of	 the	 gene	 CCND1	 was	 found	 in	 all	 samples.	 CCND1	 gene	 codifies	 for	 the	cyclin	D	protein,	which	have	been	described	to	be	amplified	in	26%	of	ECs234,	235.		
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Figure	 35	WES	 results	 obtained	 in	 the	 analysis	 of	 the	 ambiguous	 endometrial	 carcinoma.	 a)	Venn	diagram	representing	 the	 genetic	 variant	 distribution	 found	 in	 the	WES	 analysis	 of	 an	 ambiguous	 endometrial	 carcinoma	(AEC).	b)	Venn	diagram	showing	the	somatic	copy	number	alteration	distribution	found	in	the	WES.	c)	Phylogenetic	tree	symbolizes	 tumor	evolution	based	on	the	WES	results	(see	3.6.2	section).	d)	Heatmap	 indicating	the	presence	(blue)	or	 absence	 (grey)	of	 the	mutations	 identified	by	WES.	Different	blue	 colors	 indicate	 the	 cancer	 cell	 fraction	(CCF)	value	obtained	for	each	variant	(see	3.5.4.3).	Loss	of	heterozigosity	(LOH)	is	represented	by	a	diagonal	white	line	 in	 the	 corresponding	 variant	 box.	 The	 boxes	 of	 those	 variants	 identified	 as	 clonal	 are	 labeled	 with	 a	 yellow	square.	Genes	with	a	probably	pathogenic	consequence	are	indicated	in	the	heatmap.	ATM	gene,	marked	in	red,	was	the	only	one	with	a	totally	pathogenic	mutation.	
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4.4.3 WES	 results	 validation	 in	 additional	 tumor	 samples	 and	 genetic	
analysis	of	patient	derived	xenografts	(PDX)	models	To	further	characterize	the	ITH	in	the	AEC,	a	selection	of	86	of	the	variants	identified	in	the	WES	were	 analyzed	 in	 a	 validation	 process	 using	 targeted	 ampliseq	 sequencing	 (Supplementary	Table	 5).	 These	 variants	were	 selected	 in	 order	 to	 include	 all	 the	 potentially	 pathogenic	 and	additional	non-pathogenic	variants	to	cover	40%	of	those	detected	by	WES.	In	addition	to	those	samples	previously	analyzed	by	WES,	three	additional	FFPE	primary	tumor	samples	as	well	as	the	uterine	aspirate	tissue	were	included	in	the	analysis	(Table	9).		Bioinformatics	 analysis	 revealed	 a	 higher	 degree	 of	 genetic	 ITH	 in	 the	 targeted	 sequencing	analysis	 than	 that	 previously	 observed	 in	 the	 WES.	 Only	 17%	 of	 the	 variants	 were	 shared	between	all	the	samples	in	the	validation	process,	against	69%	observed	in	the	selected	variants	from	WES.	 This	 is	mainly	 due	 to	 the	 fact	 that	 primary	 tumor	 region	 T4	 only	 showed	 a	 small	percetange	 of	 the	 variants,	 probably	 indicating	 that	 it	 is	 an	 initial	 clone	 of	 the	 tumor.	 On	 the	other	hand,	primary	tumor	regions	T1	and	T2	and	the	metastatic	lesion	(M)	appeared	at	the	end	of	the	three,	showing	the	final	part	of	the	tumor	evolution	(Figure	36a	and	b).	Besides,	a	81%	of	the	 analyzed	 variants	were	detected	 in	 the	UA	 sample,	 confirming	 its	 utility	 capturing	 ITH	of	endometrial	tumors	(Figure	36a).		Additionally,	 five	 tumor	 samples	 from	patient	 derived	 xenografts	 (PDX)	were	 included	 in	 the	targeted	 sequencing	 process	 in	 order	 to	 investigate	 its	 reliability	 representing	 the	 genomic	landscape	of	the	patient’s	tumor	(Figure	33c).	A	total	of	79	of	the	86	analyzed	variants	(81%)	were	also	 found	 in	 the	 five	PDX	samples	(Figure	 36a).	Only	11	variants	were	not	detected	 in	any	PDX	sample,	while	 the	other	5	variants	were	present	 in	 some	of	 them.	These	partially	or	non-detected	 variants	 were	 previously	 found	 in	 the	 patient	 primary	 tumor	 regions	 with	 a	heterogeneous	 distribution.	 Therefore,	 these	 results	 suggested	 that	 PDX	models	 could	 be	 not	representing	the	genetic	ITH	found	in	the	different	tumor	samples	of	this	patient.	
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Figure	36	Targeted	sequencing	results	obtained	in	the	multiple	samples	analysis	of	the	AEC	patient	and	PDX	
models.	 a)	 Mutation	 Allele	 Frequency	 (MAF)	 heatmap	 based	 on	 the	 targeted	 sequencing	 validation	 results.	 b)	Phylogenetic	 tree	 generated	 according	 to	 the	 presence	 or	 absence	 of	mutations	 in	 the	 validation	 analysis.	 Tumor	locations:	T1-T5:	different	uterine	locations	from	the	primary	tumor;	M:	lymphatic	node.	Metastasis	was	detected	and	resected	 seven	 years	 after	 primary	 tumor	 diagnosis.	 UA:	 uterine	 aspirate.	 Colors	 represent	 the	 samples	 in	 which	variants	were	identified:	black	for	ubiquitous	variants,	green	for	variants	identified	in	primary	tumor	and	metastasis	regions,	 purple	 for	 variants	 shared	 by	 different	 primary	 tumor	 regions,	 blue	 for	 variants	 exclusively	 observed	 in	primary	tumor	samples	and	orange	for	variants	only	detected	in	the	metastatic	sample.	
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4.4.4 WES	analysis	in	patient	derived	xenografs	(PDX)	and	comparison	to	the	
patient	mutational	profile	Since	 targeted	 sequencing	 used	 in	 the	 validation	 of	 the	 patient	 WES	 study	 showed	 genetic	homogeneity	between	the	different	PDXs,	WES	analysis	was	also	perfomed	in	those	PDXs	and	in	a	normal	mouse	tissue	used	as	control	(see	3.11	section).		Bioinformatics	analysis	of	PDX	WES	identified	a	total	of	393	variants	(Supplementary	Table	19).	Interestingly,	only	197	of	the	393	(50%)	variants	had	been	previously	observed	in	the	patient	samples,	being	most	of	 them	common	to	all	 the	PDX	samples	(187/197,	95%).	(Figure	37).	A	total	of	36	variants	of	 the	233	 (15%)	previously	detected	 in	 the	WES	of	 the	patient	were	not	identified	 in	 the	 PDX	 samples,	 the	 majority	 of	 them	 non-common	 between	 patient	 samples	(25/36,	69%).		From	the	new	variants	detected	in	the	PDX	samples,	only	41%	of	them	were	shared	by	all	the	samples	(Figure	37).	These	results	confirmed	that	PDX	samples	carried	the	majority	of	variants	previously	 identified	 in	 the	 patient,	 although	 not	 those	 with	 a	 heterogeneous	 	 distribution.	Moreover,	 the	 number	 of	 variants	 considerably	 increased	with	 the	 tumor	 growth	 during	 the	PDX	generation.	Consequently,	the	genetic	profile	of	the	PDX	samples	significantly	differs	from	the	original	one	found	in	the	patient.			
	
Figure	 37	WES	 variants	 identified	 in	 the	 patient	 derived	 xenografts	 (PDXs)	 obtained	 from	 an	 ambiguous	
endometrial	 cancer	 (AEC)	 patient.	 Circle	 chart	 showing	 the	 percentage	 of	 variants	 detected	 in	 the	WES	 of	 PDX	samples.	Red	colors	represent	those	variants	newly	identified	in	the	PDX	models,	while	blue	colors	represent	those	previously	detected	in	the	patient	study.	Dark	red	or	dark	blue	colors	marked	those	variants	shared	by	the	five	PDX	analyzed	samples.		
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4.4.5 Personalized	 treatment	 based	 on	 WES	 data	 obtained	 from	 an	
ambiguous	endometrial	carcinoma:	validation	in	a	preclinical	model	Finally,	we	 analyzed	 the	mutational	 profile	 found	 in	 the	 AEC	 in	 a	 pharmacological	 context	 in	order	to	evalutate	the	potential	relationship	between	the	mutational	status	and	available	drugs.	For	 this	 purpose	 we	 performed	 an	 in	 silico	 study	 using	 different	 drug	 databases	 (CTD	(http://ctdbase.org/)	and	STITCH	(http://stitch.embl.de/)220-222).	This	analysis	(3.5.4.6	section)	revealed	 different	 treatments	 which	 could	 have	 a	 potential	 effect	 regarding	 the	 molecular	alterations	identified	in	this	case,	reporting	bortezomib	and	paclitaxel	as	the	most	appropiated	(Figure	38a).	Small	pieces	of	the	AEC_PDX1	model	were	surgically	transplanted	subcutaneously	into	a	second	generation	of	mice.	PDX	models	were	treated	following	the	in	silico	study	results	with	bortezomib	as	a	single	agent	(0.25mg/kg)	and	a	combination	of	bortezomib	plus	paclitaxel,	in	comparison	to	the	standard	treatment	used	in	this	type	of	cancer	(15mg/Kg	paclitaxel	–PTX-	and	50	mg/kg	 carboplatin	 –CBTP-)	 and	placebo.	 For	 testing	 effectiveness	of	 these	 treatments	two	mice	were	used	in	each	condition	as	indicated	in	3.11	section.	Mice	were	treated	during	30	days	 with	 specified	 drugs	 and	 tumor	 growth	 were	 monitored	 twice	 weekly	 during	 70	 days	(Figure	38b).	Although	these	are	preliminary	data,	we	observed	a	statistical	tendency	(p=0.11)	towards	 decreased	 tumor	 growth	 in	 the	 bortezomib-PTX	 when	 compared	 to	 standard	 PTX-CBPT	treatment,	suggesting	the	applicability	of	this	treatment	in	this	particular	clinical	context	as	well	as	the	potential	utility	of	this	in	silico	study	based	on	WES	data.		
	
Figure	 38	 In	 silico	 study	 of	 drug	 treatment	 based	 on	 WES	 results	 and	 its	 application	 in	 PDX	 models.	 a)	Selection	of	treatment	regarding	the	in	silico	study	based	on	information	available	in	CTD	(http://ctdbase.org/)		and	STITCH	 databases	 (http://stitch.embl.de/)	 and	 mutated	 genes	 found	 in	 AEC.	 b)	 Tumor	 growth	 representation	 of	PDXs	 obtained	 from	 AEC	 treated	with	 indicated	 drug	 conditions	 during	 30	 days.	 Tumor	 volumes	were	measured	twice	weekly.	(Mann-Whitney	test,	p=0.11).		Data	show	the	mean	of	2	independent	mice	for	each	treatment;	bars,	s.d.	PTX:	paclitaxel,	CBPT:	carboplatin.		
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5 DISCUSSION	The	presence	of	intratumor	heterogeneity	(ITH)	at	a	phenotypic	level	has	been	described	since	 the	 early	days	of	 cancer	 research,	 leading	 to	 a	wide	 investigation	 about	 the	 clonal	origin	 of	 human	 neoplasms	 as	 well	 as	 the	 role	 of	 molecular	 heterogeneity	 in	 cancer	progression20-22,	236.	The	development	of	high-throughput	techniques,	and	especially	next-generation	 sequencing	 (NGS),	made	 a	 real	 difference	 in	 the	 knowledge	 about	 ITH237-239.	Thereby,	 different	 methodological	 approaches	 have	 provided	 deeper	 insights	 into	 ITH.	The	use	of	bioinformatics	tools	to	infer	the	subclonal	population	of	an	individual	biopsy	of	tumor215,	240,	241	was	followed	by	the	implementation	of	multiregion	analyses23-25	and	more	recently	of	single-cell	sequencing242,	243.		While	the	majority	of	studies	revealed	a	branched	evolution	within	tumor,	supporting	its	complex	 structure	 based	 on	 multiple	 genetically	 diverse	 subclones,	 linear	 patterns	 of	tumor	evolution	have	been	also	found42,	46.	In	these	cases,	the	acquisition	of	advantageous	mutations	 give	 rise	 to	 new	 clones	 that	 replace	 the	 previous	 ones,	 producing	 a	 relative	homogeneity	when	a	single	biopsy	is	analyzed.		
	
	
Figure	 39	 Examples	 of	 tumor	 evolution	 types.	 Three	 different	examples	of	evolution	patterns	are	represented	in	the	graphic.	Left	panels	show	the	tumor	development	prior	to	the	sample	analysis	(past).	Middle	panels	 represent	 the	 specific	 moment	 when	 the	 sample	 is	 obtained	 for	sequencing	analysis	(present).	Right	panels	show	the	possible	evolution	of	each	 tumor	 (future).	 Tumors	 1	 and	 2	 show	 a	 branched	 pattern,	 while	tumor	3	displays	a	linear	evolution.	Although	tumor	1	and	2	may	have	the	same	 present	 heterogeneity	 distribution,	 their	 past	 and	 future	progression	have	different	 patterns.	 Colored	 shapes	 represent	 subclonal	populations	of	the	tumors.	Modified	from	Hiley	et	al239.			Different	 examples	 of	 tumor	 evolution	 are	 schematized	 in	 Figure	 30.	 Regarding	 these	patterns,	 while	 tumor	 1	 and	 2	 have	 a	 branched	 distribution,	 tumor	 3	 shows	 a	 lineal	progression	along	the	time.	However,	if	we	only	analyze	the	current	status	of	each	clinical	case	with	a	single	biopsy	throughout	 the	development	of	 the	tumor,	sequencing	analysis	may	 suggest	 a	 similar	 pattern	 and	 clonal	 composition	 in	 tumors	 1	 and	 2,	 although	 they	have	 a	 different	 history	 of	 evolution239.	 These	 differences	 found	 in	 tumor	 evolution	
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DISCUSSION	 		 	highlight	the	importance	of	analyzing	the	spatial	as	well	as	temporal	growth	of	the	tumors	and	their	dynamic	acquisition	of	alterations.		Numerous	studies	have	shed	light	on	the	extent	of	tumor	diversity,	including	several	solid	tumor	types	such	as	pancreatic24,	26,	renal25,	27,	lung28-30,	breast31-33,	colorectal34,	35,	glial36-38	and	prostate39,	40,	among	others;	as	well	as	hematologic	malignancies41-46.		Similar	 analyses	 have	 been	 also	 reported	 about	 gynecological	 cancers47,	 most	 of	 them	focused	on	ovarian	carcinomas,	which	have	the	highest	mortality	rates	among	this	kind	of	tumors58.	 However,	 there	 are	 other	 tumor	 subtypes	 less	 explored,	 as	 it	 is	 the	 case	 of	endometrial	carcinoma	(EC)50,	which	is	the	most	common	gynecological	malignancy	in	the	developed	 countries,	 but	 have	 a	 better	 prognosis	 compared	 to	 ovarian	 carcinomas58,	120.	Interestingly,	 several	 studies	 have	 analyzed	 ITH	 in	 tumor	 progression	 in	 other	 tumor	types,	 exposing	 heterogeneous	 patterns	 in	 driver	 and	 targetable	 mutations	 between	primary	tumor	and	metastatic	or	recurrent	disease24,	25,	28,	38,	115.	In	this	regard,	it	has	been	demonstrated	 that	 oncologic	 treatment	 could	 act	 as	 a	 selection	 pressure	 in	 some	malignancies42,	244,	245.	Nevertheless,	 genomic	 instability	 is	 considered	 the	major	 cause	 of	cancer	 heterogeneity	 nowadays,	 leading	 to	 an	 increased	 mutation	 rate	 and	 generating	distinct	 genomic	 footprints	 known	 as	 mutational	 signatures16,	 246.	 Although	 genomic	instability	 is	 present	 in	 most	 solid	 tumors	 and	 hematopoietic	 malignancies,	 multiple	pathways	 have	 been	 implicated	 in	 its	 development,	 including	 defects	 in	 DNA	 repair	mechanisms,	DNA	replication	or	chromosome	segregation	among	others246,	247.			To	characterize	the	occurrence	of	ITH	in	different	gynecological	cancers	and	to	assess	its	implication	 in	 metastatic	 and	 recurrent	 disease,	 in	 this	 thesis	 we	 have	 focused	 in	 the	following	specific	objectives:	a)	ITH	analysis	in	a	TP53-null	ovarian	carcinoma	patient,	b)	endometrial	 ITH	 characterization,	 c)	 application	 of	 exome	 studies	 for	 deeping	 on	 an	ambiguous	 endometrial	 carcinoma	 and	d)	 implementation	 of	 genetic	 analysis	 in	 uterine	aspirates	for	capturing	ITH	existent	in	endometrial	tumors.		The	presence	of	ITH	has	been	extensively	described	in	ovarian	cancers,	especially	in	high	grade	 serous	 ovarian	 carcinomas	 (HGSOCs)110-118,	 where	 TP53	 mutations	 are	 broadly	present89,	 90.	 Mutation	 in	 TP53	 is	 considered	 the	 main	 cause	 of	 the	 widespread	 genetic	instability	 found	 in	HGSOCs61.	Despite	 the	majority	of	 them	are	missense	mutations	 that	lead	 to	 protein	 accumulation;	 around	 30%	 of	 somatic	 variants	 are	 considered	 null	mutations,	 including	 nonsense,	 frameshift	 or	 splicing	 junction	 variants	 that	 cause	 the	complete	absence	of	 the	protein94.	 In	 this	 sense,	while	 it	has	been	described	 that	not	all	
TP53	missense	mutations	have	equivalent	consequences	in	the	protein	function248,	little	is	
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DISCUSSION	 		 	known	 about	 null	mutations.	 Furthermore,	 during	 the	 last	 years	 the	 potential	 impact	 of	
TP53	 mutational	 status	 as	 a	 prognosis	 factor	 have	 been	 widely	 analyzed,	 though	conflicting	results	make	it	still	a	controversial	issue103.		On	 the	basis	 of	 these	precedents,	we	 first	 performed	a	meta-analysis	using	 the	 genomic	data	 generated	 by	 the	 TCGA	 consortium90,	 classifying	 patients	 regarding	 their	 TP53	mutational	status	in	mutated,	null	or	wild-type	tumors.	This	analysis	revealed	significant	differences	 in	 the	 fraction	 of	 copy	 number	 alterations	 between	 the	TP53-null	 and	wild-type	 tumors,	which	could	be	suggesting	 the	existence	of	diverse	mechanisms	underlying	genomic	 instability	 or	 at	 least	 a	 different	 level	 of	 effect	 (Figure	 9a).	However,	 although	from	the	genomic	instability	point	of	view	TP53	altered	ovarian	cases	seem	to	be	similar,	
TP53-null	 subgroup	 showed	 an	 intermediate	 overall	 and	 progression	 free	 survival	between	mutated	and	wild-type	tumors	(Figure	9b).		Consequently,	 we	 aimed	 to	 analyze	 ITH	 in	 the	 TP53-null	 tumor	 subgroup,	 less	characterized	than	the	TP53-mutated	tumors.	For	this	purpose,	whole-exome	sequencing	(WES)	 and	 comparative	 genomic	 hybridization	 (CGH)	 analyses	 were	 performed	 on	multiple	 regions	 from	 a	 patient	 diagnosed	 with	 a	 TP53-null	 recurrent	 HGSOC.	 As	previously	 reported	 in	 other	 ovarian	 cancer	 studies113-117,	 significant	 heterogeneity	was	found	 not	 only	 at	 the	 genetic	 level	 but	 also	 at	 the	 somatic	 copy	 number	 alterations	(SCNAs)	 (Figure	 11a	 and	 12a).	 This	 divergence	 was	 consistent	 among	 the	 analyzed	samples,	being	the	recurrence	regions	as	similar	between	them	as	with	the	primary	tumor.	Mutational	 analysis	 by	 Sanger	 sequencing	 of	 the	 selected	 variants	 in	 additional	 tumor	samples	 from	 the	 same	 patient	 revealed	 the	 clonal	 composition	 and	 phylogenetic	evolution	 of	 this	 carcinoma	 (Figure	 13a	 and	 b).	 These	 results	 were	 consistent	 with	 a	situation	 in	which	 the	primary	 tumor	 is	 composed	by	mutational	 heterogeneous	 clones,	with	 some	 of	 them	 giving	 rise	 to	 the	 recurrence	 lesions.	 In	 this	 case,	 ITH	 seemed	 to	 be	intrinsic	to	the	primary	tumor	and	not	a	consequence	of	the	therapy,	which	is	consistent	with	previously	published	data113.	Hierarchical	 clustering	of	 tumor	 regions	based	on	 the	presence/absence	 of	 mutations	 allowed	 to	 dissect	 the	 tumor	 clonal	 evolution	 (Figure	
13b).	 This	 analysis	 showed	 that	 different	 recurrence	 regions	 were	 closely	 related	 to	distinct	and	specific	primary	tumor	subclones,	which	suggests	an	polyphyletic	evolution	as	it	 has	 been	 previously	 described	 in	 other	 tumor	 types24,	40.	 However,	 these	 conclusions	could	 be	 biased	 because	 this	 study	 was	 performed	 using	 preselected	 variants.	 Next,	 to	assess	 the	biological	pathways	 that	could	be	altered	 in	 this	 tumor,	 functional	annotation	and	 network	 analysis	 were	 carried	 out	 using	 the	 mutational	 profiles	 (Figure	 14).	Functions	 intrinsic	 to	 tumor	 growth	 and	 spread,	 such	 as	 cell	 proliferation,	 cell	 cycle	control	 and	 cell	 adhesion	 appeared	 consistently	 mutated,	 while	 other	 less	 expected	
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DISCUSSION	 		 	pathways,	 such	 as	 microtubule-based	 movement	 and	 lipid	 metabolism	 could	 also	 be	affected.	 Microtubule	 function	 is	 essential	 for	 chromosomal	 partitioning	 and	segregation249,	thus,	alterations	in	microtubule	cytoskeleton	might	be	in	part	responsible	for	 the	 wide	 genomic	 and	 chromosomal	 aberrations	 that	 HGSOCs	 usually	 show90.	 Lipid	metabolism	 is	 frequently	 altered	 in	 cancer	 disease250,	 and	 interestingly,	 some	 of	 the	specific	detected	mutations	have	been	previously	involved	in	tumor	progression	in	other	tumor	 types251-255.	 In	 this	 sense,	 our	 study	 revealed	 that	 these	 gene	 alterations	 were	mainly	shared	between	the	three	samples	analyzed	by	WES	(P1,	ER1	and	IR1),	suggesting	a	 founder	and	clonal	role	 for	 lipid	metabolism	deregulation	 in	 this	HGSOC.	Furthermore,	since	TP53	has	been	shown	to	be	a	key	regulator	of	lipid	metabolism256,	altogether,	these	results	suggested	that	lipid	metabolism	could	be	considered	as	a	therapeutic	target	in	this	specific	 TP53-null	 patient,	 although	 additional	 functional	 validation	 are	 required	 to	confirm	this	possibility.	Likewise,	a	large	comparison	between	clonal	evolution	patterns	in	
TP53	 wild-type,	 null	 and	mutated	 cases	may	 help	 in	 the	 understanding	 of	 the	 different	clinical	outcome	of	these	patients.		With	respect	to	endometrial	 carcinomas	 (ECs),	 little	is	known	about	ITH.	The	majority	of	 the	previous	 large-scale	sequencing	analyses	 in	ECs	have	been	performed	on	primary	tumor	 samples	 and	 were	 focused	 on	 the	 molecular	 characterization	 of	 this	 type	 of	tumors188,	 190-196.	 In	 these	 studies,	 the	 classical	 dualistic	 model	 of	 EC	 dividing	 in	endometrioid	(EEC)	and	non-endometrioid	(mostly	represented	by	serous	histology,	SEC)	subtypes122,	 was	 complemented	 by	 the	 new	 molecular	 classification	 established	 by	 the	TCGA	study196.	This	classification	includes	POLE/ultramutated,	MSI/hypermutated,	copy-number	 low/endometrioid	 and	 copy-number	 high/serous-like	 subgroups.	 Most	importantly,	this	categorization	implies	different	clinical	outcomes122.			Regarding	 ITH	 in	 tumor	 progression	 and	 EC	 evolution,	 only	 one	 study	 has	 been	published	 to	 date,	 in	 which	 atypical	 hyperplasia	 as	 a	 premalignant	 lesions,	 and	 paired	samples	 of	 primary	 tumor	 and	 metastasis	 were	 analyzed50.	 In	 this	 study,	 multiregion	analysis	 showed	 that	 metastatic	 samples	 were	 very	 homogeneous	 among	 them	 and	usually	 arose	 from	 a	 common	 ancestral	 subclone	 that	 was	 not	 detected	 in	 the	 primary	tumor	biopsy,	but	it	is	important	to	mention	that	this	work	only	included	one	sample	from	the	 primary	 tumor,	 which	 could	 be	 insufficient	 for	 understanding	 the	 phylogenetic	evolution	of	EC.		Therefore,	 to	 have	 a	 wider	 and	more	 precise	 picture	 of	 EC	 evolution,	 in	 this	 thesis	 we	performed	WES	analysis	 including	multiple	regions	not	only	 from	the	metastatic	disease	but	 also	 from	 the	 primary	 tumor.	 Accordingly,	 we	 analyzed	 a	 total	 of	 10	metastatic	 EC	
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DISCUSSION	 		 	patients	 that	were	histologically	 classified	as	EEC	 (n=7)	and	SEC	 (n=3),	 and	molecularly	subdivided	 regarding	 TCGA	 criteria196	 as	 copy-number	 low/endometrioid	 (EEC1-4),	MSI/hypermutated	 (EEC5-7)	 and	 copy-number	 high/serous-like	 (SEC1-3).	 At	 least	 two	regions	from	the	primary	tumor	and	one	from	the	metastatic	lesion	were	included	in	the	WES,	although	additional	tumor	samples	were	further	analyzed	by	targeted	sequencing.	Our	WES	analysis	 revealed	 that	 less	 than	half	of	mutations	 (44%)	were	shared	between	multiple	samples	of	each	EC	patient,	a	result	 that	 is	similar	to	the	ITH	observed	 in	other	tumor	types	like	renal	cancers25,	27,	but	clearly	different	to	the	higher	homogeneity	found	in	pancreatic	 or	 lung	 carcinomas	 (where	 around	70%	of	 the	 variants	were	ubiquitously	detected)24,	28,	29.	This	suggests	that	single-region	sequencing	might	not	be	sufficient	in	EC,	because	 the	 majority	 of	 mutations	 would	 not	 be	 represented.	 Remarkably,	 different	degrees	 of	 ITH	 between	 the	 multiple	 molecular	 subgroups	 were	 found,	 being	 these	percentages	 significantly	 lower	 in	 the	 MSI	 subgroup	 (mean	 =	 12%).	 Although	 this	 low	frequency	of	ubiquitous	mutations	might	be	 related	 to	 the	high	 random	mutational	 rate	characteristic	 of	 MSI	 tumors,	 no	 evidence	 supporting	 this	 idea	 have	 been	 previously	described.	In	fact,	tumors	with	similar	somatic	mutation	prevalence	as	small	cell	and	non-small	cell	lung	carcinomas	showed	high	differences	in	the	percentage	of	shared	mutations	(95%	versus	50%,	respectively)16,	30.	Furthermore,	the	majority	of	detected	variants	were	found	 in	a	clonal	 status	 in	each	sample,	as	was	 inferred	by	 the	calculation	of	 the	Cancer	Cell	 Fraction	 (CCF)43,	 suggesting	 that	when	 a	 single	 sample	was	 considered	most	 of	 the	cancer	cells	carried	the	majority	of	variants	detected	in	this	specific	region.	This	could	be	misunderstood	as	an	absence	of	heterogeneity.	However,	clonal	mutations	in	one	region	of	the	tumor	could	be	completely	absent	in	another	tumor	region,	as	previously	reported	in	renal25,	lung28	or	ovarian113	cancers,	among	others. 	Moreover,	our	study	also	revealed	 that	 the	whole	common	SCNAs	 found	among	samples	from	the	same	tumor	was	very	low	(6%),	although	the	percentage	of	shared	genes	affected	by	SCNAs	was	higher	(21%)	(Figure	22).	These	differences	could	be	attributed	to	the	fact	that	the	genomic	coordinates	determined	using	the	exome	data	are	only	an	inference	and	might	 not	 be	 totally	 accurate214.	 Thus,	 these	 could	 show	 variations	 regarding	 specific	SCNAs	but	 including	 the	 same	affected	genes.	Comparing	our	 results	 to	 the	Gibson	et	al.	series50,	similar	observations	were	found	in	terms	of	the	percentage	of	shared	mutations	(44%	versus	 48%)	but	 not	 in	 the	 common	 SCNAs	 (21%	versus	 56%).	Nonetheless,	 it	 is	important	to	remind	that	while	our	series	included	at	least	3	samples	per	patient,	Gibson	
et	al.50	used	paired	samples	of	a	unique	primary	tumor	region	and	a	metastatic	sample.		We	next	 analyzed	 in	detail	 the	 ITH	at	 the	SCNA	 level	 in	 the	 serous	 cancers,	which	are	a	molecular	subgroup	with	extensive	genomic	alterations196.	The	three	cases	included	in	our	
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DISCUSSION	 		 	series	showed	more	ITH	at	the	SCNAs	than	at	the	genetic	level	(Figure	23).	Interestingly,	the	metastatic	samples	showed	an	important	fraction	of	the	non-shared	SCNAs,	suggesting	that	 big	 genomic	 changes	may	 have	 an	 important	 role	 in	 the	metastatic	 disease.	 These	findings	 coincided	 with	 the	 previous	 observed	 in	 metastatic	 pancreatic	 tumors,	 where	genomic	instability	increased	during	metastatic	progression26.		On	the	other	hand,	no	differences	were	found	in	the	number	of	genetic	alterations	when	between	 primary	 tumor	 and	 metastatic	 lesions,	 and	 no	 clear	 evidences	 of	 metastasis-specific	 exomic	mutations	were	 either,	 as	 previously	 reported	 in	 endometrial	 and	 other	cancer	 types24,	 50.	 These	 results	 might	 indicate	 that	 genetic	 mutations	 do	 not	 have	 an	essential	 role	 in	metastasis	development,	 or	 at	 least	 that	 there	 is	not	 a	 common	genetic	mechanism	 to	 generate	 them	 in	 ECs.	 It	 is	 also	 important	 to	 note	 that	 other	 genomic	alterations,	 as	 chromotripsis	 or	 big	 genomic	 changes,	 could	 be	 participating	 in	 the	metastasis	 development	 as	 recently	 observed	 in	 pancreatic	 cancers257,	 and	 should	 be	further	analyzed	in	the	EC	clinical	context.	Concerning	 tumor	 progression,	 Gibson	 et	al.50	 found	 a	 high	 proportion	 of	monophyletic	evolution	 in	 EC.	 In	 fact,	 in	 6	 of	 their	 7	 (86%)	 cases	 the	 metastatic	 lesions	 were	 more	closely	 related	 to	 each	 other	 than	 to	 the	 primary	 tumor,	 which	 suggest	 a	 common	evolution	 of	 the	metastatic	 regions	 from	 an	 ancestral	 clone.	 By	 contrast,	 only	 one	 case	showed	a	metastatic	region	closer	at	the	mutational	level	to	the	primary	tumor	than	to	the	other	 metastasic	 regions,	 as	 occur	 in	 polyphyletic	 tumor	 progression.	 However,	 in	 our	series	we	observed	monophyly	in	7	of	the	10	patients	(70%)	and	polyphyletic	evolution	in	the	 remaining	 (30%)	 analyzed	 cases	 (Figure	 24).	 These	 discrepancies	 found	 in	 the	phylogenetic	 patterns	 between	 both	 studies	 could	 be	 due	 to	 the	 absence	 of	 multiple	regions	 from	 the	 primary	 tumor	 in	 the	 Gibson	 et	 al.	 study50.	 In	 fact,	 when	 additional	tumoral	 samples	were	 analyzed	by	 targeted	 sequencing,	 the	phylogenetic	patterns	were	better	clarified	(Figure	26-32).	For	example,	the	phylogenetic	tree	obtained	for	the	EEC-1	patient	(Figure	26)	showed	a	clear	polyphyletic	evolution,	being	one	metastatic	lesion	(M)	genetically	 related	 to	 specific	 primary	 tumors	 regions	 (T4	 and	 T2),	 and	 the	 other	metastatic	area	(M2)	close	to	T1	region.	This	seems	to	be	a	case	of	tumor	with	a	complex	metastatic	 seeding,	 known	 as	 oligoclonal	 evolution	 (Figure	 40a),	 which	 had	 not	 been	previously	 described	 in	 EC	 but	 is	 frequent	 in	 other	 tumor	 types	 as	 pancreatic24	 or	prostate40	tumors.		Nevertheless,	the	most	common	phylogenetic	pattern	found	in	our	study	was	that	in	which	metastatic	lesions	were	closely	related	and	arise	from	one	branched	subclone	of	the	tumor	(EEC-2,	-3,	-4,	-6	and	-7,	and	SEC-1-3).	This	homogeneity	between	metastatic	samples	was	also	found	in	the	Gibson	et	al.	series50	as	well	as	in	pancreatic26	and	prostate48	metastatic	
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DISCUSSION	 		 	tumors,	 and	 brain	metastasis	 from	 lung,	 breast	 or	 renal	 carcinomas49.	 In	 our	 study,	 the	subclone	that	leads	to	the	metastasis	could	arise	directly	from	a	primary	tumor	region,	as	seems	to	occur	in	EEC-2-4	cases	(Figure	27-28,	Figure	40b),	or	from	a	common	ancestor	as	in	EEC-6-7	and	SEC-1-3	patients	(Figure	30-32,	Figure	40c).			
Figure	 40	 Next	 generation	 sequencing	
analyses	 revealed	 different	
phylogenetic	 evolution	 patterns	 in	
metastatic	 EC.	WES	 followed	by	 targeted	massive	 parallel	 sequencing	 revealed	different	 clonal	 evolution	 patterns	 in	 the	metastatic	 EC	 analyzed.	 The	 most	heterogeneous	 cases	 (EEC-1	 and	 EEC-5)	showed	a	polyphyletic	evolution	(a),	while	in	 those	 cases	 with	 less	 ITH	 monophyly	was	found.	Two	subtypes	of	monophyletic	evolution	 patterns	were	 identified,	 one	 of	them	with	metastatic	regions	arising	 from	primary	 tumor	 regions	 and	 mostly	acquiring	 additional	 mutations	 in	 the	metastasis	 (EEC-2-4)	 (b),	 and	 the	 other	one	 with	 metastatic	 regions	 initially	evolved	 from	 an	 ancestor	 clone	 and	subsequent	 mutations	 acquired	 in	 the	primary	tumor	(EEC-6-7	and	SEC-1-3)	(c).								Interestingly,	 in	addition	 to	 the	common	mutations	 found	 in	each	 tumor,	 the	majority	of	the	 cases	 showed	 more	 specific	 variants	 in	 the	 primary	 tumor	 regions	 than	 in	 the	metastatic	lesions	(EEC-2,	-6,	and	-7	and	SEC-1-3).	In	all	these	cases,	except	EEC-7	patient,	the	metastatic	regions	were	detected	at	the	moment	of	diagnosis	and	were	located	at	the	ovary.	 These	 results	 could	 be	 pointing	 out	 that	 the	 metastatic	 disease	 appear	 from	 an	initial	clone	of	the	tumor	with	the	specific	molecular	features	to	spread	to	the	ovary,	while	the	same	tumor	clone	in	the	uterus	would	continue	acquiring	mutations	across	the	time,	modifying	the	initial	tumor	profile	(Figure	40c).	Remarkably,	all	the	serous	cases	shared	
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DISCUSSION	 		 	this	 specific	 pattern	 and	 similar	 phylogenetic	 threes	 (Figure	 32),	 though	 additional	tumors	should	be	analyzed	in	order	to	determine	if	this	pattern	could	be	related	to	tumor	histology	 or	 to	 metastasis	 tropism.	 Similar	 results	 have	 been	 previously	 observed	 in	synchronous	 endometrioid	 endometrial	 and	 ovarian	 carcinomas209,	258.	 In	 these	 studies,	evidences	 of	 clonality	 were	 found	 between	 both	 tumors,	 indicating	 dissemination	 from	one	 to	 other	 site.	 In	 those	 cases	 analyzed	 by	 WES,	 endometrial	 tumors	 showed	 more	mutations	than	ovarian	carcinomas	in	the	majority	of	patients209.	By	contrast,	recurrence	regions	were	 analyzed	 in	 the	 EEC-7	 patient	 (Figure	 31).	 In	 this	 case,	 although	 primary	tumor	 and	metastatic	 regions	 shared	 a	 low	 percentage	 of	 the	 variants,	 both	 developed	exclusive	 changes	 in	 each	 group	 of	 samples.	 Interestingly,	 the	 number	 of	 specific	mutations	 was	 higher	 in	 the	 primary	 tumor	 group	 of	 samples	 (T1-T3)	 than	 in	 the	recurrences	 (M-M5).	 These	 results	 could	 suggest	 that	 independently	 of	 the	 particular	mutational	 pattern	 found	 in	 the	 primary	 tumor	 and	 the	 relapse	 samples,	 the	 early	progression	of	a	clone	would	have	given	rise	to	the	recurrent	disease.	On	 the	 other	 hand,	 EEC-3	 and	 EEC-4	 patients	 showed	more	 variants	 in	 their	metastatic	lesions,	lymph	nodes	and	epiplon	respectively,	than	in	the	primary	tumor	regions	(Figure	
28).	 In	both	 cases,	metastases	were	detected	 as	 a	 recurrent	disease	 after	3	 years	of	 the	primary	 tumor	 treatment.	 These	 results	 may	 indicate	 that	 the	 recurrent	 metastatic	samples	 acquire	 additional	 mutations	 during	 or	 after	 tumor	 treatment,	 which	 enabled	their	growth	even	after	years	of	disease	remission	(Figure	40b).	In	these	cases,	metastasis	would	 be	 slowly	 acquiring	 a	 more	 complex	 genetic	 phenotype	 that	 could	 led	 to	 an	aggressive	 behavior	 during	 their	 development.	 These	 findings	 have	 been	 previously	observed	 in	 ovarian115,	 117,	 pancreatic24	 and	 renal25	 carcinomas	 as	 well	 as	 in	 secondary	acute	myeloid	leukemia42.	As	a	whole,	our	study	emphasizes	 the	 importance	of	analyzing	 the	maximum	number	of	samples	to	better	understand	tumor	evolution,	especially	when	the	genetic	heterogeneity	found	between	the	multiple	samples	of	the	primary	tumor	is	considered.	Nevertheless,	it	is	fairly	 difficult	 to	 calculate	 the	 number	 of	 tumor	 regions	 needed	 to	 ensure	 proper	assessment	of	ITH,	since	it	is	not	possible	to	anticipate	the	ITH	degree	that	each	tumor	will	have.	Another	important	point	on	this	subject	is	the	sequencing	methodology	used	in	the	ITH	 study.	 In	 our	 project,	 part	 of	 the	 WES	 variants	 were	 re-analyzed	 by	 targeted	sequencing.	This	technique	is	restricted	to	specific	regions,	which	may	limit	overall	tumor	characterization,	but	allowed	the	study	of	additional	FFPE	tumor	and	metastatic	samples.	Moreover,	 this	 sequencing	 approach	 reaches	 coverage	 values	more	 than	 20-fold	 higher	than	WES,	which	was	important	in	the	sequencing	of	cases	with	unstable	DNAs	as	those	of	MSI	 tumors.	 In	 these	 MSI	 tumor	 cases	 (EEC5-7),	 the	 percentage	 of	 shared	 mutations	
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DISCUSSION	 		 	significantly	 increases	when	compared	WES	and	targeted	sequencing	(Figure	 25),	being	more	variants	detected	during	the	validation	re-analysis.	Similar	results	were	found	in	the	study	 of	 localized	 lung	 cancers,	 also	 characterized	 by	 a	 high	 somatic	 mutation	prevalence16,	29,	30.	Thus,	targeted	sequencing	could	generate	more	reliable	data	but	limited	to	the	sequenced	regions.			In	conclusion,	different	degrees	of	ITH	as	well	as	distinct	patterns	of	tumor	evolution	were	found	 in	 each	 EC	 patient,	 apparently	 independently	 of	 their	 histological	 or	 molecular	classification.	 However,	 the	 relationship	 between	 ITH	 and	 prognosis	 or	 treatment	response	is	yet	to	be	determined.	Although	recent	studies	have	suggested	that	ITH	could	be	an	independent	prognostic	factor	of	disease	progression	and	survival	in	other	types	of	tumors43,	52,	the	mechanisms	involved	in	this	process	remain	still	unknown.	During	the	last	years,	 the	 fact	 that	 some	 ECs	 remain	 resistant	 to	 treatment	 was	 hypothetically	 related	with	the	presence	of	ITH	in	the	primary	tumor156.	However,	our	data	did	not	suggest	any	correlation	 between	 the	 heterogeneity	 found	 in	 the	 primary	 tumor	 and	 the	 presence	 of	recurrent	disease.			As	 a	 third	 aim,	we	 evaluated	 the	potential	 use	 of	 WES	 in	 the	 diagnosis	 and	 genetic	
characterization	of	ambiguous	pathological	entities.	Some	ECs,	recently	considered	as	morphological	 ambiguous128,	129,	 remain	 controversial	 in	 their	histological	diagnosis,	 and	in	consequence	in	their	clinical	treatment	and	outcome.	As	this	type	of	carcinomas	is	not	considered	 a	 clinical	 entity	 nowadays,	 advancing	 in	 its	 characterization	 supposes	 a	 goal	not	only	 from	a	molecular	point	of	view	but	also	 for	 its	clinical	management.	Thus,	until	biologically	and	clinically	validated	diagnostic	 criteria	are	developed	 for	 these	cases,	 the	genomic	 characterization	 of	 these	 tumors	 could	 offer	 additional	 knowledge	 about	 its	nature.		To	 this	 end,	 we	 performed	 WES	 in	 multiple	 samples	 from	 an	 ambiguous	 metastatic	endometrial	carcinoma	(AEC)	and	 its	patient	derived	xenografts	(PDXs).	The	histological	classification	 of	 this	 case,	 based	 on	 the	 pathologist	 observations	 and	 the	immunohistochemical	profile	of	the	tumor,	showed	a	diagnostically	challenging	case	that	was	 finally	 classified	 as	 an	 ambiguous	 tumor	 (Figure	 33).	 Moreover,	 after	 the	bioinformatics	 analysis	 of	 WES	 results,	 the	 endometrium	 was	 confirmed	 as	 the	 tissue	origin	 of	 this	 tumor	 (Figure	 34).	 The	 WES	 analysis	 performed	 in	 two	 primary	 tumor	regions	and	a	metastatic	lesion	revealed	the	presence	of	ITH,	being	considerably	higher	at	the	 SCNAs	 than	 at	 the	 genetic	 variants	 level	 (10%	 of	 shared	 genes	 affected	 by	 SCNAs	versus	80%	of	 shared	genes	with	genetic	mutations).	Additionally,	 the	calculation	of	 the	
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DISCUSSION	 		 	cancer	 cell	 fraction	 (CCF)	 for	 each	 variant	 of	 the	 three	 samples	 revealed	 80%	 of	 clonal	mutations,	indicating	that	the	majority	of	cells	of	each	sample	carried	most	of	the	variants	identified	 in	 this	 region	 (Figure	 35).	 The	 similarity	 between	 the	 two	 primary	 tumor	regions	(T1	and	T2)	was	higher	than	between	them	and	metastatic	lesion	(M),	supporting	its	 potential	 monophyletic	 evolution.	 However,	 targeted	 sequencing	 of	 three	 additional	tumor	samples	revealed	a	higher	degree	of	ITH	than	that	observed	by	WES,	with	only	17%	of	the	analyzed	variants	common	among	these	samples.	Therefore,	 the	phylogenetic	tree	showed	a	polyphyletic	branched	pattern	of	evolution,	being	 the	T4-T5-T3	tumor	regions	initial	clones	in	the	tumor	progression,	while	the	metastatic	 lesion	was	closely	related	to	T1	 and	 T2	 regions	 (Figure	 36).	 These	 controversial	 findings	 are	 again	 evidencing	 the	necessity	of	including	the	maximum	number	of	regions	as	well	as	using	of	high	coverages	during	the	sequencing	study,	in	order	to	reliably	understand	the	ITH	of	a	tumor.	Surprisingly,	none	of	the	most	frequently	mutated	genes	in	EC50,	196	were	detected	in	this	tumor.	In	fact,	only	one	of	the	identified	variants	was	considered	to	have	a	real	pathogenic	impact	 in	 its	 corresponding	 protein.	 This	 variant,	 detected	 in	 all	 the	 analyzed	 samples,	affected	one	splice	acceptor	site	of	the	Ataxia	Telangiectasia	Mutated	(ATM)	gene,	although	its	impact	on	protein	function	was	not	tested.	On	the	other	hand,	the	SCNAs	study	revealed	a	gain	of	material	affecting	the	CCND1	gene,	which	codifies	for	the	cyclin	D1	protein,	thus	suggesting	a	potential	cell	cycle	malfunction	in	this	tumor.		To	obtain	a	broader	view	of	 the	molecular	pathways	altered	 in	 this	AEC,	 the	mutational	signature	of	all	 the	samples	was	analyzed.	 It	 is	known	that	diverse	mutational	processes	produce	different	combinations	of	mutation	types,	called	‘signatures’	and	numbered	from	1	to	21	depending	on	their	variation	patterns16.	In	the	three	samples	analyzed	by	WES	in	this	 ambiguous	 carcinoma,	 enrichment	 in	 the	 mutational	 signature	 13	 was	 found.	 This	signature	 is	 produced	 by	 mutations	 generated	 by	 the	 APOBEC	 family	 of	 cytidine	deaminases,	which	convert	cytidine	to	uracil259.	 It	 is	worth	noting	that	this	signature	has	not	been	found	in	ECs	until	now,	but	it	has	been	observed	in	bladder	and	breast	cancers16.	Interestingly,	 it	 has	been	 recently	described	 the	 implication	of	DNA	replication	 stress	 in	the	 mutagenesis	 process	 mediated	 by	 the	 APOBEC3	 enzymes,	 with	 the	 involvement	 of	
ATM	and	CCND1	genes	among	others260.	Altogether,	these	alterations	could	be	implicated	in	the	initial	events	of	this	tumor,	maybe	driving	the	mutational	process	and	leading	to	this	specific	 mutational	 signature.	 The	 results	 obtained	 for	 this	 tumor	 contrast	 with	 those	obtained	 in	 the	 rest	of	metastatic	ECs	analyzed	by	WES,	 showing	all	 of	 them	mutational	patterns	 typical	 of	 EC16.	 While	 the	 majority	 of	 CN-low	 tumors	 (EEC1-4)	 showed	 the	mutational	signature	associated	to	the	age	of	 the	patients	(signature	1);	as	expected	MSI	cases	 (EEC5-7)	 were	 characterized	 by	 the	 mutational	 pattern	 related	 to	 DNA	 MMR	
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DISCUSSION	 		 	deficiency	 (signature	 6).	 These	 results	 could	 be	 revealing	 that	 different	 mechanism	underlying	 genetic	 instability	 give	 rise	 to	 several	 mutational	 signatures,	 being	 the	 AEC	outside	the	general	mechanism	involved	in	ECs.		To	 investigate	 further	 about	 the	 biology	 of	 this	 ambiguous	 tumor,	 patient	 derived	xenograft	(PDX)	models	were	generated	from	different	regions	of	the	primary	tumor	and	metastatic	 locations.	 Nowadays,	 PDX	 models	 are	 popular	 preclinical	 models	 in	translational	 oncology	 research	 due	 to	 their	 histological	 and	 genetic	 similarity	 to	 the	original	 tumors,	 as	 has	 been	 reported	 for	 EC261,	 and	 their	 potential	 use	 to	 predict	therapeutic	response	to	treatments262.		In	 our	 study,	 a	 total	 of	 five	 PDX	 mice	 were	 obtained,	 representing	 regions	 from	 the	superficial	and	deep	primary	tumor	as	well	as	areas	from	metastatic	disease	(right	and	left	lymphatic	nodes	and	cervix	implants).	Different	genetic	characterization	approaches	were	performed	 in	 the	 multiple	 PDX	 samples	 with	 the	 aim	 of	 investigating	 its	 reliability	representing	 the	 genomic	 landscape	 of	 this	 tumor	 patient.	 Firstly,	 a	 targeted	 massive	parallel	sequencing	study	revealed	that	 the	majority	of	mutations	previously	detected	 in	the	patient	(79/86,	81%)	were	also	found	in	all	the	analyzed	PDXs,	including	that	found	in	the	ATM	gene.	However,	most	of	the	variants	that	were	heterogeneously	identified	in	the	patient	did	not	appear	 in	the	PDX	samples.	 In	this	sense,	our	results	could	be	suggesting	that	these	PDX	models	did	not	completely	represent	the	ITH	found	in	the	multiple	tumor	regions	 of	 the	 patient.	 To	 validate	 this	 hypothesis	WES	 analysis	 was	 also	 performed	 in	these	 samples,	 obtaining	 similar	 results	 than	 those	observed	 in	 the	 targeted	 sequencing	analysis.	 However,	WES	 revealed	 that	 PDX	 tumors	 showed	 a	 high	 number	 of	 additional	mutations	 not	 previously	 identified	 in	 the	 tumor	 patient.	 From	 the	 total	 of	 the	 PDX	variants,	 around	 a	 half	 were	 those	 previously	 observed	 in	 the	 patient	while	 the	 rest	 of	them	were	new	in	the	PDX	samples	(Figure	37).	Altogether,	these	results	suggested	that	the	 genetic	 profile	 identified	 in	 our	 PDX	 models	 significantly	 differs	 from	 the	 original	found	 in	 this	patient,	 and	 this	 is	 in	 striking	 contrast	 to	 similar	 studies	with	other	 tumor	types,	where	PDX	models	mostly	retained	the	molecular	heterogeneity	of	their	originating	samples263,	264.	 This	 could	 indicate	 that,	 due	 to	 the	 original	 tumor	of	 this	 patient	 did	not	show	 a	 high	 degree	 of	 heterogeneity,	 the	 minor	 subclones	 not	 represented	 in	 the	 PDX	samples	could	not	have	the	capability	of	growth	in	the	PDX	models.	Besides,	the	additional	mutations	 found	 in	 these	PDX	models	may	 reflect	 a	 quick	 evolution	 of	 the	 tumor	 in	 the	host,	and	could	be	related	to	selection	pressure	that	occur	during	engraftment	into	diverse	species	(from	human	to	mouse)265,	266.		Despite	 the	 ITH	 differences	 between	 PDX	 and	 the	 patient	 tumor,	 we	 next	 tested	 the	potential	utility	of	 these	preclinical	models	 for	 therapy	selection,	as	has	been	previously	
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DISCUSSION	 		 	described	 in	 other	 tumor	 types262.	 We	 performed	 an	 in	 silico	 study	 based	 on	 the	comparison	of	the	mutational	profile	found	in	the	AEC	and	the	available	information	about	the	drugs	related	to	 this	genetic	status.	Although	this	 is	a	preliminary	study,	bortezomib	and	 paclitaxel	 were	 identified	 as	 potentially	 effective	 treatment	 in	 this	 patient	 (Figure	
38a).	 In	 this	 regard,	 the	 pathogenic	 mutation	 found	 in	 the	 ATM	 gene	 seems	 to	 be	indicating	a	malfunction	of	the	cell	cycle	and	the	DNA	repair	machinery	that	would	favor	the	 response	of	 this	 tumor	 to	 these	 selected	 therapies227,	267,	268.	 It	 is	 important	 to	notice	that,	 although	 previous	 evidences	 related	 these	 genes	 with	 the	 correspondent	treatment227,	269,	270,	functional	analysis	to	verify	the	effect	of	each	genetic	variant	would	be	needed.	Regarding	the	selected	treatments,	bortezomib	was	the	first	proteasome-inhibitor	to	 be	 approved	 in	 the	 clinics,	 and	 while	 it	 is	 mainly	 used	 in	 the	 treatment	 of	 multiple	myeloma	and	mantel	cell	lymphoma271,	272,	multiple	evidences	indicate	its	potential	utility	in	EC273-277.	Paclitaxel	is	a	well-known	taxane	that	acts	as	an	antimicrotubule	agent,	widely	used	in	the	treatment	of	multiple	type	of	solid	tumors,	including	EC278.		In	order	to	test	the	results	obtained	in	the	in	silico	study,	PDX	models	generated	from	the	AEC	 tumor	were	 treated	with	 the	proposed	 therapies.	Our	preliminary	data	pointed	out	that	 the	 combination	 of	 paclitaxel	with	 bortezomib	 showed	 a	 benefit	 in	 terms	 of	 tumor	reduction	 compared	 to	 standard	 treatment	 protocol,	 although	 the	 differences	 were	 not	statistically	 significant	 due	 to	 the	 low	 number	 of	 mice	 analyzed	 (Figure	 38b).	 These	results	suggest	the	potential	applicability	of	the	predicted	treatment	in	this	patient	and	the	utility	of	this	in	silico	study,	though	it	is	worth	mentioning	that	they	have	not	been	directly	validated	in	the	patient.			In	summary,	the	combination	of	genomic	profiling	in	tumors	and	PDX	preclinical	models	would	 be	 potentially	 useful	 in	 the	 clinical	 practice	 to	 identify	 the	 most	 beneficial	treatments	 for	 the	 patient,	 although	 they	 require	 testing	 large	 number	 of	 animals	 and	treatment	options,	 as	well	 as	 a	higher	number	of	EC	patients	of	diverse	histological	 and	molecular	subtypes.			In	 addition	 to	 the	 clinical	 outcome	 and	 treatment	 response,	 another	 important	 problem	derived	 from	 the	 ITH	 is	 the	 use	 of	 appropriate	 biomarkers	 for	 patient	 stratification51.	During	 the	 last	 years,	 several	 clinical	 trials	 have	 moved	 from	 histological	 to	 molecular	classification	 based	 on	 the	 somatic	 alterations	 of	 the	 tumors279-281.	 In	 this	 sense,	 in	numerous	 clinical	 trials	 the	 patients	 with	 EC	 have	 been	 stratified	 according	 to	 their	genetic	 tumor	features,	such	as	PTEN,	PIK3CA	or	FGFR3	mutational	status,	among	others	(https://clinicaltrials.gov)156.	 Moreover,	 a	 next	 generation	 of	 clinical	 trials	 (i.e.,	 NCI-
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DISCUSSION	 		 	MATCH,	 I-SPY282,	FOCUS	or	MATRIX)	 include	multiple	 subgroups	of	 tumor	 types	 treated	with	 a	 specific	 targeted	 therapy.	 The	 use	 of	 proper	 samples	 to	 stratify	 the	 patients	enrolled	in	these	trials	is	essential	and	a	current	challenge	in	the	molecular	oncology.	For	example,	 archival	 material	 should	 not	 be	 used	 when	 recurrent	 disease	 is	 studied,	underlining	 the	 need	 to	 re-biopse	 these	 cases.	 To	 this	 end,	 the	 Tracking	Non-small	 Cell	Lung	 Cancer	 Evolution	 Through	 Therapy	 (TRACERx)	 study	 has	 been	 designed	with	 this	aim,	 and	 includes	 multiple	 region	 samples	 as	 well	 as	 circulating	 DNA	 (ctDNA)	 and	circulating	 tumor	 cells	 (CTCs)283.	 However,	 these	 kinds	 of	 approaches	 are	 nowadays	unaffordable	for	the	clinical	application,	and	therefore,	two	different	solutions	have	been	proposed:	 a)	 combining	 DNA	 from	 different	 tumor	 samples	 before	 performing	 genetic	analysis,	but	this	would	lead	to	a	decrease	in	the	frequency	of	subclonal	mutations;	b)	the	use	of	liquid	biopsies,	which	could	be	the	best	option	to	capture	ITH	nowadays53-55.		In	 this	 regard,	 another	 important	 objective	 of	 this	 thesis	 was	 focused	 on	 the	
implementation	 of	 alternative	 biopsies	 in	 genetic	 characterization	 of	 EC	 to	
overcome	ITH.		Uterine	 aspirates	 (UAs)	 are	 low	 invasive	 and	 highly	 sensitive	 pre-operative	 biopsies149,	previously	 proposed	 as	 a	 molecular	 diagnostic	 tool	 on	 the	 basis	 of	 differential	 gene	expression	profiles153,	154.	Thus,	 in	 the	current	 study	we	evaluated	 the	potential	utility	of	UAs	 to	 uncover	 the	 overall	 tumor	 mutational	 profile	 by	 targeted	 massive	 parallel	sequencing	using	a	predesigned	panel	 that	 includes	the	most	 frequently	altered	genes	 in	EC	(PTEN,	KRAS,	FGFR2,	CTNNB1,	PIK3CA,	FBXW7	and	TP53).	Consequently,	 it	 is	a	useful	tool	to	characterize	the	mutational	profile	of	endometrial	tumors	into	the	clinical	practice	since	 it	 considerably	 reduces	 the	 time	of	 sample	processing,	data	analysis	as	well	as	 the	cost	 of	 the	 procedure,	 compared	 to	WES.	 Nevertheless,	 it	 is	 important	 to	 note	 that	 the	panel	used	for	this	analysis	is	focused	on	point	genetic	mutations,	less	commonly	found	in	SEC	and	CS,	which	are	better	characterized	by	big	genomic	changes124.		Our	study	revealed	that	this	approach	allowed	the	identification	of	genetic	variants	in	UAs	not	only	in	samples	derived	from	tumor	cases	but	also	in	those	from	atypical	hyperplasia,	while	only	4%	of	 the	control	patients	without	a	malignant	disease	at	 the	moment	of	 the	study	showed	mutations	(Figure	15).	Importantly,	variants	detected	in	the	UAs	accurately	represent	the	molecular	profile	of	their	corresponding	tumors	(Figure	16),	even	in	those	UAs	 considered	 non-diagnosable	 by	 the	 pathologist.	 It	 has	 been	 described	 that	 around	13%	 of	 the	 UAs	 are	 not	 valid	 to	 distinguish	 the	 presence	 or	 absence	 of	 disease	 (non-diagnosable),	either	due	to	a	small	proportion	of	representative	tumor	cells	or	to	the	poor	quality	of	the	sample146-148.	This	percentage	of	cases	is	concordant	with	the	fail	rate	found	
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DISCUSSION	 		 	in	 our	 series	 (8/62,	 13%).	 Therefore,	 the	 fact	 that	 genetic	 sequencing	 of	 UAs	 produced	valuable	 information	 even	 in	 non-diagnosable	 cases,	 confirms	 its	 potential	 utility	 in	 the	pathological	diagnosis	in	order	to	reduce	its	fail	rate.	Moreover,	 the	usefulness	of	UAs	to	recapitulate	 ITH	 in	EC	was	also	evaluated.	 Initially,	a	multiregion	analysis	was	performed	 in	EEC,	SEC	and	CS	samples,	 revealing	 that	 ITH	was	broadly	 present	 in	 EEC	 (71%)	 even	when	 targeted	 sequencing	 is	 performed,	 but	 not	 so	common	in	SEC	or	CS	(20%)	(Figure	18	and	19).	These	results	showed	that	UAs	detect	a	more	 representative	 mutational	 landscape	 than	 a	 unique	 surgical	 tumor	 specimen,	reproducing	 in	 a	 single	 sample	 the	 ITH	 found	 in	 the	multiple	 tumor	 regions.	 To	 better	characterize	 this	 observation,	 a	 quality	 score	 defined	 as	mutation	 discovery	 rate	 (MDR)	was	 calculated	 as	 the	 percentage	 of	mutations	 detected	 in	 each	 individual	 sample	with	respect	 to	 all	 mutations	 found	 in	 a	 given	 patient.	 Interestingly,	 MDR	 value	 was	significantly	higher	 in	UAs	than	 in	 the	tumor	regions	 from	EECs,	 indicating	that	 they	are	better	biopsies	to	characterize	the	genetic	profile	of	the	tumor.		Regarding	these	important	findings,	we	also	analyzed	the	UAs	from	two	of	the	metastatic	EC	 included	 in	 the	WES	study	(EEC2-	and	 -3).	 In	 this	case,	genetic	variants	 identified	by	WES	were	reanalyzed	by	targeted	sequencing,	being	72%	(EEC-2)	and	87%	(EEC-3)	of	the	analyzed	variants	also	detected	 in	 the	UA.	Remarkably,	 in	 the	UA	study	 from	EEC-3	case	we	observed	mutations	not	identified	in	the	primary	tumor	regions	but	mainly	detected	in	the	metastatic	samples,	which	arised	 from	recurrent	disease	diagnosed	three	years	after	primary	 tumor	diagnosis.	 In	 this	 regard,	 the	 study	of	 the	aspirate	 could	be	 representing	even	 those	mutations	present	 in	 tumor	 subclones	 that	would	progress	and	evolve	years	later.	As	this	biopsy	was	obtained	during	the	diagnosis	of	the	primary	tumor,	these	results	would	be	 indicating	 the	presence	of	 this	mutational	pattern	before	 treatment,	as	well	as	the	capability	of	UAs	to	represent	the	majority	of	the	subclones	that	make	up	the	tumor.		These	 results	 highlight	 the	 powerful	 utility	 of	 this	 type	 of	 alternative	 biopsy	 in	combination	with	 its	molecular	 characterization	 and	 confirmed	 that	 the	use	of	 a	 unique	tumor	 sample	 in	 diagnosis	 could	 underestimate	 the	 mutational	 landscape	 in	heterogeneous	 tumors.	 The	 fact	 that	 ITH	 is	 well	 represented	 in	 aspirates	 is	 probably	related	to	the	nature	of	such	samples,	consisting	of	cells	from	many	different	parts	of	the	uterine	cavity,	thus	providing	a	more	representative	picture	of	the	entire	tumor	specimen	than	 a	 single	 sample	 from	 a	 specific	 tumor	 region	 (Figure	 41).	 Similar	 results	 were	observed	in	ovarian	carcinomas,	where	ITH	was	represented	in	the	liquid	ascites114,	284.	In	this	 case,	 ascites	 could	be	 representing	 the	entire	 cavity	 in	a	 similar	way	 that	UAs	do	 in	uterine	cancer,	capturing	all	the	genetic	alterations	and	representing	the	ITH	found	in	the	
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DISCUSSION	 		 	different	tissue	tumor	samples.	This	underlines	the	importance	of	further	investigating	the	application	 of	 other	 organic	 fluids	 and	 its	 diagnostic	 implementation,	 for	 example,	peritoneal	 lavages	 in	 gastrointestinal	 tumors	 or	 fine	 needle	 aspiration	 cytology	 for	pulmonary	malignancies.	 However,	 the	 use	 of	 non-invasive	 biopsies53-55	 easily	 obtained	from	a	routine	blood	 tests,	as	ctDNA	or	CTCs	are	recommended	not	only	 to	unravel	 ITH	but	also	to	facilitate	patient	follow	up	in	the	near	future53,	55,	285.	 In	this	regard,	the	use	of	CTCs	 as	 a	 prognosis	 marker	 in	 EC	 has	 been	 previously	 described286,	 and	 its	 genetic	characterization	could	be	helpful	during	tumor	development.		
Figure	 41	 Uterine	 aspirates	 represent	
ITH	 found	 in	 the	 tumor	 multiregion	
analysis.	 Genetic	 analysis	 revealed	 that	uterine	 aspirates	 capture	 intratumor	heterogeneity	 found	 in	 the	 different	regions	of	the	patient	tumor	(represented	with	different	colored	cells),	probably	due	to	 the	 fact	 that	 uterine	 aspirates	 are	samples	that	contain	cell	from	all	different	parts	of	the	uterine	cavity.						Finally	 and	 to	 summarize,	 throughout	 this	 thesis	multiple	 approaches	 as	well	 as	 tumor	types	were	analyzed	in	order	to	decipher	the	implication	of	ITH	in	gynecological	cancers.	The	results	showed	in	this	work	have	shed	light	on	to	the	clonal	evolution	and	the	role	of	ITH	 in	 gynecological	 cancers,	 as	 well	 as	 the	 potential	 use	 of	 pre-operative	 diagnostic	biopsies	 in	 this	 specific	 clinical	 context.	 Nevertheless,	 an	 in-depth	 study	 considering	 a	larger	number	of	EC	patients	should	be	undertaken,	thus,	there	is	a	long	way	to	go	in	the	clinical	application	of	these	findings.	
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6 CONCLUSIONS		1.	 Massive	 (whole-exome	 and	 targeted)	 sequencing	 analyses	 allow	 the	 characterization	 of	different	 spatial	 and/or	 temporal	 intratumor	 heterogeneity	 degrees	 in	 multiple	 subtypes	 of	gynecological	 cancer,	 including	 a	TP53-null	 high	 grade	 serous	 ovarian	 carcinoma	 and	 several	metastatic	and	non-metastatic	endometrial	carcinomas.		2.	 Functional	 analysis	 based	 on	 the	 mutational	 profile	 of	 a	 patient	 may	 reveal	 signaling	pathways	involved	in	tumorigenesis	and	might	be	use	as	a	complementary	tool	to	reach	a	global	tumor	understanding.		3.	 The	 analysis	 of	 the	 maximum	 number	 of	 regions	 per	 tumor	 as	 well	 as	 high	 sequencing	coverage	 values	 achieve	 a	 better	 intratumor	 heterogeneity	 and	 clonal	 evolution	characterization.		4.	Different	phylogenetic	evolution	and	clonality	patterns	were	found	in	metastatic	endometrial	carcinomas,	apparently	not	related	to	the	classical	histological	or	molecular	classification.			5.	 The	 absence	of	 additional	mutations	 in	metastatic	 regions	 compared	 to	 the	primary	 tumor	could	be	suggesting	their	irrelevant	role	during	endometrial	tumor	progression.		6.	 Genomic	 and	 genetic	 characterization	 of	 ambiguous	 endometrial	 carcinomas	 could	 unravel	their	molecular	features	and	probably	help	in	their	clinical	management.		7.	 Patient	 derived	 xenograft	 (PDX)	 genetic	 profile	 retains	 the	majority	 of	 common	mutations	present	in	the	whole	human	tumor.	Nevertheless,	additional	variants	found	in	the	mice	could	be	indicating	a	new	tumor	evolution	within	the	host.		8.	 Genetic	 analysis	 in	 uterine	 aspirates	 recapitulates	 the	 mutational	 profile	 of	 endometrial	carcinomas,	even	in	non-diagnosable	cases,	and	captures	intratumor	heterogeneity	detected	in	the	multiple	endometrial	tumor	regions.			
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CONCLUSIONES		1.	 Los	 análisis	 de	 secuenciación	 masiva	 (tanto	 exomas	 como	 dirigida)	 permiten	 la	caracterización	de	 la	heterogeneidad	 intratumoral	espacial	y	 temporal	en	cáncer	ginecológico,	incluyendo	en	un	tumor	seroso	de	ovario	de	alto	grado	con	mutación	nula	en	TP53	así	como	en	varios	tipos	de	carcinomas	de	endometrio.		2.	 Los	 análisis	 funcionales	 basados	 en	 el	 perfil	 mutacional	 de	 un	 paciente	 pueden	 generar	información	sobre	de	las	vías	de	señalización	implicadas	en	su	tumorogénesis,	y	tienen	utilidad	como	una	herramienta	complementaria	para	entender	la	biología	del		tumor.		3.	El	estudio	mutacional	de	un	elevado	número	de	regiones	del	tumor	así	como	el	uso	de	altos	valores	de	cobertura	en	la	secuenciación	masiva	permiten	caracterizar	de	una	forma	fiable	tanto	la	evolución	clonal	como	la	heterogeneidad	intratumoral	presente.		4.	De	acuerdo	al	análisis	de	secuenciación	masiva	se	han	podido	identificar	diferentes	patrones	de	evolución	filogenética	y	composición	clonal	en	 los	carcinomas	de	endometrio	metastásicos,	sin	encontrar	una	relación	aparente	con	la	clasificación	histológica	y	molecular	clásica	en	estos	tumores.		5.	 La	 ausencia	 de	 mutaciones	 adicionales	 en	 las	 regiones	 metastásicas	 de	 carcinomas	 de	endometrio	 en	 comparación	 con	 el	 tumor	 primario	 sugiere	 que	 dichas	 alteraciones	 no	 	 están	implicadas	en	la	progresión	tumoral.		6.	 El	 uso	 de	 aproximaciones	 basadas	 en	 el	 análisis	 genómico	 de	 carcinomas	 ambiguos	 de	endometrio	puede	ayudar	a	mejorar	su	manejo	clínico	a	través	de	su	caracterización	molecular.		7.	El	perfil	genético	de	los	modelos	animales	PDX	(patient	derived	xenograft)	refleja	la	mayoría	de	 las	 mutaciones	 presentes	 en	 el	 tumor	 de	 origen.	 Sin	 embargo,	 la	 presencia	 de	 variantes	genéticas	adicionales	en	los	PDX	podrían	sugerir	una	nueva	evolución	tumoral	en	el	huésped.		8.	 El	 análisis	 genético	 de	 los	 aspirados	 uterinos	 representa	 el	 perfil	 mutacional	 de	 los	carcinomas	de	endometrio	de	los	que	proceden,	incluso	en	casos	de	difícil	diagnóstico,	y	captura	la	heterogeneidad	intratumoral	detectada	en	las	múltiples	muestras	del	tumor.	
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Abstract
Background: High grade serous ovarian cancer is characterised by high initial response to chemotherapy but
poor outcome in the long term due to acquired resistance. One of the main genetic features of this disease
is TP53 mutation. The majority of TP53 mutated tumors harbor missense mutations in this gene, correlated
with p53 accumulation. TP53 null tumors constitute a specific subgroup characterised by nonsense, frameshift
or splice-site mutations associated to complete absence of p53 expression. Different studies show that this
kind of tumors may have a worse prognosis than other TP53 mutated HGSC.
Methods: In this study, we sought to characterise the intra-tumor heterogeneity of a TP53 null HGSC
consisting of six primary tumor samples, two intra-pelvic and four extra-pelvic recurrences using exome
sequencing and comparative genome hybridisation.
Results: Significant heterogeneity was found among the different tumor samples, both at the mutational and
copy number levels. Exome sequencing identified 102 variants, of which only 42 were common to all three
samples; whereas 7 of the 18 copy number changes found by CGH analysis were presented in all samples.
Sanger validation of 20 variants found by exome sequencing in additional regions of the primary tumor and
the recurrence allowed us to establish a sequence of the tumor clonal evolution, identifying those populations that
most likely gave rise to recurrences and genes potentially involved in this process, like GPNMB and TFDP1.
Using functional annotation and network analysis, we identified those biological functions most significantly
altered in this tumor. Remarkably, unexpected functions such as microtubule-based movement and lipid
metabolism emerged as important for tumor development and progression, suggesting its potential interest
as therapeutic targets.
Conclusions: Altogether, our results shed light on the clonal evolution of the distinct tumor regions identifying the
most aggressive subpopulations and at least some of the genes that may be implicated in its progression
and recurrence, and highlights the importance of considering intra-tumor heterogeneity when carrying out
genetic and genomic studies, especially when these are aimed to diagnostic procedures or to uncover
possible therapeutic strategies.
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Supplementary	Table	1	FIGO	and	TNM	classification	of	tumors	of	the	ovary,	fallopian	tube	and	primary	
peritoneal	carcinoma		
FIGO	Stages	 TNM*	Categories	 Description	
I	 T1	 Tumor	limited	to	the	ovaries	IA	 T1a	N0	M0	 Tumor	limited	to	one	ovary	(capsule	intact,)	or	fallopian	tube	surface,	no	malignant	cells	in	ascites	or	peritoneal	washings	IB	 T1b	N0	M0	 Tumor	limited	to	one	or	both	ovaries	(capsule	intact)	or	fallopian	tubes;	no	tumor	on	ovarian	or	fallopian	tube	surface;	no	malignant	cells	in	ascites	or	peritoneal	washings	IC	 T1c	 Tumor	limited	to	one	or	both	ovaries	or	fallopian	tubes	with	any	of	the	following:	IC1	 T1c1	N0	M0	 Surgical	spill	IC2	 T1c2	N0	M0	 Capsule	ruptured	before	surgery	or	tumor	on	ovarian	or	fallopian	tube	surface	IC3	 T1c	3N0	M0	 Malignant	cells	in	ascites	or	peritoneal	washings	
II	 T2	 Tumor	involves	one	or	both	ovaries	or	fallopian	tubes	with	pelvic	extension	below	pelvic	brim	or	primary	peritoneal	cancer	IIA	 T2a	N0	M0	 Extension	and/or	implants	on	uterus	and/or	fallopian	tubes	and/or	ovaries.	IIB	 T2b	N0	M0	 Extension	to	other	pelvic	intraperitoneal	location	
III	 T3	and/or	N1	 Tumor	involves	one	or	both	ovaries	or	fallopian	tubes	or	primary	peritoneal	carcinoma,	with	cytologically	or	histologically	confirmed	spread	to	the	peritoneum	outside	the	pelvis	and/or	metastasis	to	the	retroperitoneal	lymph	nodes	IIIA1	 T1/2	N1	M0	 Retroperitoneal	lymph	node	metastasis	only	IIIA1i	 	 Lymph	node	metastasis	up	to	10	mm	in	greatest	dimension	IIIA1ii	 	 Lymph	node	metastasis	more	than	10	mm	in	greatest	dimension	IIIA2	 T3a	N0/N1	M0	 Microscopic	extrapelvic	(above	the	pelvic	brim)	peritoneal	involvement	with	or	without	retroperitoneal	lymph	node	IIIB	 T3b	N0/N1	M0	 Macroscopic	peritoneal	metastasis	beyond	the	pelvis	up	to	2	cm	in	greatest	dimension	with	or	withouth	retroperitoneal	lymph	node	metastasis	IIIC	 T3c	N0/N1	M0	 Macroscopic	peritoneal	metastasis	beyond	the	pelvis	more	than	2	cm	in	greatest	dimension,	with	or	without	retroperitoneal	lymph	node	metastasis	(excludes	extension	of	tumor	to	capsule	of	liver	and	spleen	without	parenchymal	involvement	of	either	organ)	
IV	 Any	T	Any	N	M1	 Tumor	involves	one	or	both	ovaries	with	distant	metastasis	excluding	peritoneal	metastasis	IVA	 	 Pleural	effusion	with	positive	cytology	IVB	 	 Parenchymal	metastasis	and	metastasis	to	extra-abdominal	organs	(including	inguinal	lymph	nodes	and	lymph	nodes	outside	the	abdominal	cavity)	*	T:	primary	tumor,	N:	regional	lymph	nodes**,	M:	distant	metastasis	(0:	absence,	1:	presence)	**	The	regional	lymph	nodes	are	the	hypogastric	(obturator),	common	iliac,	external	iliac,	lateral	sacral,	para-aortic,	and	inguinal	nodes.			 	
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Supplementary	Table	2	FIGO	and	TNM	classification	of	the	uterine	endometrium	tumors		
FIGO	Stages	 TNM*	Categories	 Description		 Tis	 Carcinoma	in	situ	(preinvasive	carcinoma)	
Ia	 T1	 Tumor	confined	to	the	corpus	uteria	IAa	 T1a	N0	M0	 Tumor	limited	to	endometrium	or	invading	less	than	half	of	myometrium	IB	 T1b	N0	M0	 Tumor	invades	one	half	or	more	of	myometrium	
II	 T2	N0	M0	 Tumor	invades	cervical	stroma,	but	does	not	extend	beyond	the	uterus	
III	 T3	and/or	N1	 Local	and/or	regional	spread	as	specified	below	IIIA	 T3a	N0	M0	 Tumor	invades	the	serosa	of	the	corpus	uteri	or	adnexae	(direct	extension	or	metastasis)	IIIB	 T3b	N0	M0	 Vaginal	or	parametrial	involvement	(direct	extension	or	metastasis)	IIIC	 T1,	T2,	T3	N1,	N2	M0	 Metastasis	to	pelvic	or	para-aortic	lymph	nodesb	IIIC1	 T1,	T2,	T3	N1	M0	 Metastasis	to	pelvic	lymph	nodes	IIIC2	 T1,	T2,	T3	N2	M0	 Metastasis	to	para-aortic	lymph	nodes	with	or	without	metastasis	to	pelvic	lymph	nodes	
IVA	 T4	Any	N	M0	 Tumor	invades	bladder/bowel	mucosac	
IVB	 Any	T	Any	N	M1	 Distant	metastasis	(excludes	metastasis	to	vagina,	pelvic	serosa	or	adnexae)	a	 Endocervical	 glandular	 involvement	 only	 should	 now	 be	 considered	 as	 stage	 I.	 b	 Positive	 cytology	 has	 to	 be	reported	 separately	 withouth	 changing	 the	 stage.	 C	 The	 presence	 of	 bullous	 oedema	 is	 not	 sufficient	 evidence	 to	classify	as	T4.	This	lesion	should	be	confirmed	by	biopsy.	*	 T:	 primary	 tumor,	 N:	 regional	 lymph	 nodes**,	M:	 distant	metastasis;	 (0:	 absence,	 1/2:	 presence).	 Differentation	between	N1	 (pelvic	 lymph	nodes)	 and	N2	 (para-aortic	 lymph	nodes)	was	 applied	due	 to	 significant	 differences	 in	survival	were	found	287,	288.				 	
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Supplementary	Table	3	Frequently	mutated	genes	in	endometrial	carcinoma			
Rank	 Gene	 Gene	name	 Discovery	in	Cancer	1	 PTEN	 phosphatase	and	tensin	homolog	 Known	in	EC	2	 PIK3CA	 phosphoinositide-3-kinase,	catalytic,	alpha	polypeptide	 Known	in	EC	3	 PIK3R1	 phosphoinositide-3-kinase,	regulatory	subunit	1	(alpha)	 Known	in	EC	4	 CTNNB1	 catenin		beta	1	 Known	in	EC	5	 TP53	 tumor	protein	p53	 Known	in	EC	6	 KRAS	 v-Ki-ras2	Kirsten	rat	sarcoma	viral	oncogene	homolog	 Known	in	EC	7	 FBXW7	 F-box	and	WD	repeat	domain	containing	7	 Known	in	EC	8	 SPOP	 speckle-type	POZ	protein	 Known	in	EC	9	 CTCF	 CCCTC-binding	factor		 Known	in	EC	10	 ARID1A	 AT	rich	interactive	domain	1A		 Known	in	EC	11	 PPP2R1A	 protein	phosphatase	2	(formerly	2A),	regulatory	subunit	A	,	alpha	isoform	 Known	in	EC	12	 CCND1	 cyclin	D1	 Known	in	EC	13	 FGFR2	 fibroblast	growth	factor	receptor	2		 Known	in	EC	14	 ARHGAP35	 glucocorticoid	receptor	DNA	binding	factor	1	 Known	in	EC	15	 CHD4	 chromodomain	helicase	DNA	binding	protein	4	 Known	in	EC	16	 ZFHX3	 zinc	finger	homeobox	3	 Known	in	EC	17	 SOX17	 SRY	(sex	determining	region	Y)-box	17	 Known	in	EC	18	 ERBB3	 v-erb-b2	erythroblastic	leukemia	viral	oncogene	homolog	3		 Known	in	EC	19	 ARID5B	 AT	rich	interactive	domain	5B		 Known	in	EC	20	 NRAS	 neuroblastoma	RAS	viral	(v-ras)	oncogene	homolog	 Known	in	EC	21	 NFE2L2	 nuclear	factor	(erythroid-derived	2)-like	2	 New	in	EC,	but	reported	in	other	cancers	22	 MAX	 MYC	associated	factor	X	 Novel	SMG	23	 SOS1	 son	of	sevenless	homolog	1	(Drosophila)	 Known	in	EC	24	 SGK1	 serum/glucocorticoid	regulated	kinase	1	 Known	in	EC	25	 ERBB2	 v	v-erb-b2	erythroblastic	leukemia	viral	oncogene	homologue	2	 New	in	EC,	but	reported	in	other	cancers	26	 BCOR	 BCL6	co-repressor	 Known	in	EC	27	 ESR1	 estrogen	receptor	1	 Novel	SMG	28	 RRAS2	 related	RAS	viral	(r-ras)	oncogene	homolog	2	 Novel	SMG	29	 SIN3A	 SIN3	homolog	A,	transcription	regulator	(yeast)	 Novel	SMG	30	 MYCN	 v-myc	myelocytomatosis	viral	related	oncogene,	neuroblastoma	derived	 Known	in	EC	31	 AFMID	 arylformamidase	 Novel	SMG	32	 MECOM	 MDS1	and	EVI1	complex	locus	 Novel	SMG	33	 FOXA2	 forkhead	box	A2	 Novel	SMG	34	 ALPK2	 alpha-kinase	2	 New	in	EC,	but	reported	in	other	cancers	35	 AKT1	 v-akt	murine	thymoma	viral	oncogene	homolog	1	 Known	in	EC	36	 METTL14	 methyltransferase	like	14	 Novel	SMG	37	 SERHL2	 serine	hydrolase-like	2	 Novel	SMG	38	 WDR45	 WD	repeat	domain	45	 Novel	SMG	39	 U2AF1	 U2	small	nuclear	RNA	auxiliary	factor	1	 New	in	EC,	but	reported	in	other	cancers	40	 TAB3	 TGF-beta	activated	kinase	1/MAP3K7	binding	protein	3	 Novel	SMG	41	 ADNP	 activity-dependent	neuroprotector	homeobox	 Known	in	EC	42	 MARK3	 MAP/microtubule	affinity-regulating	kinase	3	 Novel	SMG	43	 EDC4	 enhancer	of	mRNA	decapping	4	 Novel	SMG	44	 DICER1	 dicer	1,	ribonuclease	type	III	 Novel	SMG	45	 RBM39	 RNA	binding	motif	protein	39	 Novel	SMG	46	 POLE	 polymerase	(DNA	directed),	epsilon	 Known	in	EC	47	 RNF43	 ring	finger	protein	43	 Novel	SMG	48	 JAK1	 Janus	kinase	1	(a	protein	tyrosine	kinase)	 Novel	SMG	49	 NRIP1	 nuclear	receptor	interacting	protein	1	 Novel	SMG	Adapted	from	Gibson	et	al.,	201650.			 	
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Supplementary	Table	4	Primary	antibodies	used	in	immunohistochemistry	analysis		
Protein	 Antibody	 Trading	House	 Dilution	 Staining	pattern	
WT1	
Monoclonal	Mouse	AntHuman	Wilms’	Tumor	1	(WT1)	Protein	Clon	6F-H2i-	 Dako	(Glostrup,	Denmark)	 Ready-to-use	 Nuclear	
PTEN	 Monoclonal	Mouse	Anti-Human	PTEN	Clone	6H2.1	 Dako	(Glostrup,	Denmark)	 1:100	 Nuclear	and	cytoplasmic	
p53	 Monoclonal	Mouse	Anti-Human	p53	Protein	Clone	DO-7	 Dako	(Glostrup,	Denmark)	 Ready-to-use	 Nuclear	
Ki-67	 Monoclonal	Mouse	Anti-Human	Ki-67	Antigen	Clone	MIB-1	 Dako	(Glostrup,	Denmark)	 Ready-to-use	 Nuclear	
MLH1	
Monoclonal	Mouse	Anti-Human	MLH1	Clone	ES05	 Dako	(Glostrup,	Denmark)	 Ready-to-use	 Nuclear	
MSH2	
Monoclonal	Mouse	Anti-Human	MSH2	Clone	E11	 Dako	(Glostrup,	Denmark)	 Ready-to-use	 Nuclear	
MSH6	
Monoclonal	Mouse	Anti-Human	MSH6	Clone	EP49	 Dako	(Glostrup,	Denmark)	 Ready-to-use	 Nuclear	
PMS2	
Policlonal	Rabbit	Anti-Human	PMS2	Clone	EP51	 Dako	(Glostrup,	Denmark)	 Ready-to-use	 Nuclear	
PR		
Monoclonal	Mouse	Anti-Human	R.P.	Antigen	Clone	PgR636	 Dako	(Glostrup,	Denmark)	 Ready-to-use	 Nuclear	
ER		
Monoclonal	Mouse	Anti-Human	R.E.	Antigen	Clone	1D5	 Dako	(Glostrup,	Denmark)	 Ready-to-use	 Nuclear	
HMGA2	 Polyclonal	Rabbit	Anti-Human	HMGA2	 LifeSpan	BioSciences	(Seatle,	WA)	 1/100	 Nuclear	
IMP2	
Monoclonal	Rabbit	Anti-	IGF2BP2	Clone	EPR6741	(B)	 Abcam	(Cambridge,	MA)	 1/100	 Cytoplasmic	
IMP3	
Monoclonal	Mouse	Anti-Human	IMP3	Clone	69.1	 Dako	(Glostrup,	Denmark)	 1/100	 Cytoplasmic	
Cyclin	E1	
Polyclonal	Rabbit	Anti-Human	Cyclin	E1	 Sigma-Aldrich	(St.Louis,	MO)	 1/100	 Nuclear	
p16	 CINtec	Histology	Kit	 Dako	(Glostrup,	Denmark)	 Ready-to-use	 Nuclear	
FolR1	
Polyclonal	Rabbit	Anti-Human	Folate	Binding	Protein		 Abcam	(Cambridge,	MA)	 1/100	 Membranous	
CK7	
Monoclonal	Mouse	Anti-Human	CK7	Antigen	Clone	OV-TL	 Dako	(Glostrup,	Denmark)	 Ready-to-use	 Cytoplasmic	
Beta-
catenin	
Monoclonal	Mouse	Anti-Human	beta-cat	Antigen	Clone	b-catenin-1	 Dako	(Glostrup,	Denmark)	 Ready-to-use	 Cytoplasmic	and	membranous	/	Nuclear	(mutated)	
	
	
Supplementary	Table	5	Ampliseq	custom	panel	designs	Supplementary	Table	5	is	included	in	the	extra	CD	information.		 	
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Supplementary	Table	6	PCR	conditions	for	Sanger	analysis	of	variants	detected	by	NGS	in	the	ovarian	cancer	
project	(A),	the	uterine	aspirate	project	(B)	and	the	analysis	of	microsatellite	instability	(C)		
A) Ovarian	cancer	project	
Gene	 Forward	primer	(5'	to	3')	 Reverse	primer	(5'	to	3')	 Length	 Annealing	temperature	
CNOT1	 TGCGTTGTTTTTGTCTTGCT	 AGCCAGACCTAGTGCCATGT	 225	 58	
CSMD3	 TGAATGAGCCCTTTTGTTTTT	 GGCAGTTTTACCCAACCACT	 180	 58	
CTC1	 TCAAAGGAAACACTGGCACA	 CCCTTGCTCTTGGTCTTTCTT	 162	 58	
ECE1	 ACACGAATTCCCTCTCATGC	 CCTGTTTCACCCATCAGGTC	 234	 58	
FAP	 TTCTCCAGCTCCCTTCAGTC	 CGTGTTAAATGCTTTCACAGTAACA	 250	 58	
FRMPD1	 CAGAAGGCAAAAGTGACAGC	 CCTGCAAAACCCAAAGATGT	 127	 58	
GPNMB	 TCAGAAGCAAAGGCCTGAGT	 CAACTTCCCCAAACCACAAT	 235	 58	
GTF2I	 GTGTGATCCAGAGCTGCAAA	 AGGTGTGGGAGTTAAACAGCA	 214	 58	
HEPHL1	 GGCCTGTGTTTTGCCTTTAG	 CTGGTTTTGTCATGGGCACT	 161	 58	
KIF21A	 ATCACAGCATTCAGTTTACAACC	 TCTGCCCTTGTTCATATATCCAT	 176	 58	
KIF21B	 TCACAACAGCCTTTCTGCAC	 ACTGATTTGCTGGCTGGTCT	 168	 58	
KMT2A	 GAGGAAGACCTCCCACCTTC	 TTTGTACCCCCTTCCTTCCT	 231	 58	
LAMA2	 CCAGTGCATAGGCATGTACC	 GCACTTGGTCTCCCATTGAT	 176	 58	
OR56B1	 CATTCACAGCTGGCAACACT	 GCCAGACCCATGTCTACCAT	 165	 58	
PCYT2	 CAGAAGAAGGAAGCCAAGGA	 CAAGGAGGCAGAGTCCTCAC	 223	 58	
PLXNA1	 CGTACTGGAGCCACTCAGC	 CGATGAGCACCGTGTAGTTG	 212	 58	
ROBO2	 TACAAAGATGGGGAGCGAGT	 CCAAGATAGTTCCTCGCAACA	 209	 58	
SMG7	 TTTAGCAATGAAACCGAGCA	 GCTTTGCTACATCGATGAAATG	 153	 58	
TFDP1	 AGATGTCCAGGCCAACTCCT	 CTTCTTGCTGGTGTTGACGA	 241	 58	
TP53	 CCACAGGTCTCCCCAAGG	 TGGCAAGTGGCTCCTGAC	 183	 55	
TRERF1	 TCCACATCCTTGATGGGTTT	 ACAGAGGCAAAAGGCTCAGA	 138	 58	
UBE2D4	 CACCAGGAGAATTCCTTCCA	 ACTTACAGTCATCACCGACAGG	 162	 58	
UBR3	 TTGGACAGAATATCGGGCTTA	 TGGACATACGTCATGGCTTG	 202	 58	
ZFAT	 CAGCAGGTGTCTCAGGTCAA	 GCTGCCTTTCCTTACCACAG	 248	 58	
ZNF664	 ACACCTCCAGCCTCTGCAT	 AGGCCTTTCCGCACTCAT	 246	 58	
	
B) Uterine	aspirate	project	
Gene	 Forward	primer	(5'	to	3')	 Reverse	primer	(5'	to	3')	 Length	 Annealing	temperature	
ABL1	 ATCACCACGCTCCATTATCC	 CAGTCCCAGCCTACCTTCAA	 209	 55	
APC	 TCCAGGTTCTTCCAGATGCT	 TTTCCTGAACTGGAGGCATT	 156	 57	
BRAF	 TCATAATGCTTGCTCTGATAGGA	 GGCCAAAATTTAATCAGTGGA	 224	 52	
CDKN2A	 CAGCTCCTCAGCCAGGTC	 CCTGGCTCTGACCATTCTGTT	 245	 57	
CTNNB1	 ATGGAACCAGACAGAAAAGC	 GGTACTTGTTCTTGAGTGAAG	 200	 55	
FGFR2	 GCTGCCCATGAGTTAGAGGA	 TATTTGGGCGAATGCAGTTT	 201	 57	
GNAS	 TGGCTTTGGTGAGATCCATT	 GGACTGGGGTGAATGTCAAG	 176	 55	
KRAS	 GTGTGACATGTTCTAATATAGTCA	 GAATGGTCCTGCACCAGTAA	 214	 56	
PIK3CA	 CCGTGAGGCTACATTAATAACC	 AAGCTTTATGGTTATTTGCATTTT	 288	 55	
PIK3CA	 ATTCTCAACTGCCAATGGA	 AGTGCAAGAAAAAGGTTATCTAAAA	 244	 55	
PIK3CA	 TGAATTTTCCTTTTGGGGAAG	 GAGAGAAGGTTTGACTGCCATAA	 292	 57	
PIK3CA	 TTGAAAATGTATTTGCTTTTTCTGT	 AACAGAGAATCTCCATTTTAGCA	 249	 57	
PTEN	 TTGACCAATGGCTAAGTGAAGA	 TCTCAGATCCAGGAAGAGGAA	 217	 57	
PTEN	 TTTTTCAATTTGGCTTCTCTTTTT	 TGTTCCAATACATGGAAGGATG	 220	 55	
PTEN	 AAAGGCATTTCCTGTGAAATAA	 TTGGATATTTCTCCCAATGAAAG	 249	 55	
PTEN	 ACCAGGACCAGAGGAAACCT	 AGTCAACAACCCCCACAAAA	 224	 55	
SMAD4	 TGGGAAGAGATCACCCTGTC	 GGCCCGGTGTAAGTGAATTT	 200	 55	
TP53	 CCGTGTTCCAGTTGCTTTATC	 AGCCCTGTCGTCTCTCCA	 288	 58	
TP53	 CCACAGGTCTCCCCAAGG	 TGGCAAGTGGCTCCTGAC	 183	 55	
TP53	 CCTATCCTGAGTAGTGGTAA	 TCCTCCACCGCTTCTTGT	 192	 55		
C) Microsatellite	instability	analysis	
Gene	 Forward	primer	(5'	to	3')	 Reverse	primer	(5'	to	3')	 Length	 Annealing	temperature	
BAT25	 TCGCCTCCAAGAATGTAAGT	 TCTGGATTTTAACTATGGCTC	 100-150	 55	
BAT26	 TGACTACTTTTGACTTCAGCC	 AACCATTCAACATTTTTAACC	 100-150	 55	
D2S123	 AAACAGGATGCCTGCCTTTA	 GGACTTTCCACCTATGGGAC	 150-300	 55	
D5S346	 ACTCACTCTAGTGATAAATCGGG	 AGCAGATAAGACAAGTATTACTAG	 100-150	 55	
D17S250	 GGAAGAATCAAATAGACAAT	 GCTGGCCATATATATATTTAAACC	 100-200	 55	
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Supplementary	Table	7	Genetic	variants	idenfied	by	WES	in	TP53	null	HGSOC	samples	Supplementary	Table	7	is	included	in	the	extra	CD	information.		
Supplementary	Table	8	Functional	annotation	of	the	genetic	variants	identified	by	WES		
Category	 Term	 p-Value	 Genes	BIOCARTA	 Cyclins	and	Cell	Cycle	Regulation	 0.008	 CDK7,	CDC25A,	TFDP1	BIOCARTA	 Cell	Cycle:	G1/S	Check	Point	 0.010	 TP53,	CDC25A,	TFDP1	COG	ONTOLOGY	 Cell	division	and	chromosome	partitioning	 0.194	 MYH3,	CIT,	PLEC	GOTERM_BP_ALL	 GO:0007155:	Cell	adhesion	 0.003	 LAMA2,	PCDHA7,	MYBPC2,	DSG2,	FAT3,	TRO,	ZAN,	ROBO2,	MSLNL,	GPNMB,	SIRPA	GOTERM_BP_ALL	 GO:0022610:	Biological	adhesion	 0.003	 LAMA2,	PCDHA7,	MYBPC2,	DSG2,	FAT3,	TRO,	ZAN,	ROBO2,	MSLNL,	GPNMB,	SIRPA	GOTERM_BP_ALL	 GO:0007156:	Homophilic	cell	adhesion	 0.004	 PCDHA7,	DSG2,	FAT3,	TRO,	ROBO2	GOTERM_BP_ALL	 GO:0016337:	Cell-cell	adhesion	 0.013	 PCDHA7,	DSG2,	FAT3,	TRO,	ZAN,	ROBO2	GOTERM_BP_ALL	 GO:0000059:	Protein	import	into	nucleus,	docking	 0.083	 IPO8,	KPNB1	GOTERM_BP_ALL	 GO:0007018:	Microtubule-based	movement	 0.113	 KIF21A,	KIF21B,	DNAH5	GOTERM_BP_ALL	 GO:0006629:	Lipid	metabolic	process	 0.120	 ACADVL,	ST6GALNAC6,	TAZ,	INSIG1,	ETFDH,	SULT2B1,	PCYT2,	TRERF1	GOTERM_BP_ALL	 GO:0006635:	Fatty	acid	beta-oxidation	 0.134	 ACADVL,	ETFDH	GOTERM_BP_ALL	 GO:0009062:	Fatty	acid	catabolic	process	 0.168	 ACADVL,	ETFDH	GOTERM_BP_ALL	 GO:0019395:	Fatty	acid	oxidation	 0.181	 ACADVL,	ETFDH	GOTERM_BP_ALL	 GO:0034440:	Lipid	oxidation	 0.181	 ACADVL,	ETFDH	GOTERM_BP_ALL	 GO:0008283:	Cell	proliferation	 0.182	 INSIG1,	TP53,	CDK7,	CDC25A,	TFDP1	GOTERM_BP_ALL	 GO:0006351:	Transcription,	DNA-dependent	 0.187	 GTF2I,	TP53,	CDK7,	TTF2	GOTERM_BP_ALL	 GO:0006355:	Regulation	of	transcription,	DNA-
dependent	 0.187	 ZNF519,	ZNF568,	TP53,	ZNF813,	ZNF792,	CDK7,	TRERF1,	NR2C1,	BARX1,	TRAK2,	ZNF71,	NOBOX,	TFDP1	GOTERM_MF_FAT	 GO:0003774:	Motor	activity	 0.008	 MYH15,	MYH3,	KIF21A,	KIF21B,	DNAH5	GOTERM_MF_FAT	 GO:0003777:	Microtubule	motor	activity	 0.068	 KIF21A,	KIF21B,	DNAH5	GOTERM_MF_FAT	 GO:0004386:	Helicase	activity	 0.182	 DDX24,	TTF2,	SETX	KEGG	PATHWAY	 hsa04110:	Cell	cycle	 0.020	 TP53,	CDK7,	CDC25A,	TFDP1	REACTOME	PATHWAY	 REACT_578:	Apoptosis	 0.109	 DSG2,	KPNB1,	PLEC			
Supplementary	Table	9	Targeted	massive	parallel	sequencing	results	obtained	in	the	uterine	aspirates	
project	A)	Paired	samples	of	uterine	aspirates	(aspirate)	and	surgical	specimens	(hysterectomy)	 from	atypical	hyperplasia	(AH),	 endometrioid	 endometrial	 carcinomas	 (EEC),	 serous	 endometrial	 caricnomas	 (SEC)	 and	 carcinosarcoma	patients	(CS).	B)	Additional	tumor	regions	analyzed	in	heterogeneity	study.		Supplementary	Table	9	is	included	in	the	extra	CD	information.	 	
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Supplementary	Table	10	Quality	metrics	of	Ion	PGM	sequencing	in	the	uterine	aspirates	project 
	
A)	
					
	
	
B)		 	 	 	 	 	 								C)	
		
	
				A)	Quality	metrics	mean	of	Ion	PGM	sequencing	for	all	the	analyzed	samples.	Mapped	reads	refer	to	the	number	of	reads	that	were	aligned	to	the	full	reference	genome.	Bases	are	the	post	filtering	base	output.	The	parameter	>=20Q	Bases	 value	 represents	 the	 number	 of	 called	 bases	 with	 a	 predicted	 quality	 greater	 than	 or	 equal	 to	 20Q,	 the	predicted	quality	values	being	reported	on	the	Phred	scale,	defined	as	-10log10	(error	probability).	Therefore,	20Q	corresponds	to	a	predicted	error	rate	of	one	percent.	On	Target	value	is	the	percentage	of	mapped	reads	that	were	aligned	over	a	target	region,	while	the	Mean	Depth	is	the	average	base	coverage	depth	over	all	the	bases	targeted	in	the	 reference	genome.	Uniformity	 is	 the	percentage	of	 target	bases	covered	by	at	 least	0.2X	 the	average	base	 read	depth.	B)	Quality	sequencing	comparison	between	FFPE,	frozen	aspirates	and	FFPE	tumors,	using	the	proportion	of	>=20Q	Bases	and	the	total	bases	for	each	sample	as	a	standard	quality	criteria.	C)	Quality	metrics	compared	between	paired	samples	of	uterine	aspirates	and	primary	tumors	with	a	paired	T-test.			 	
	 Mean	
Mapped	Reads	 236535.2	
Bases	 27070288.7	
>=20QBases	 25257514.2	
>20QBases/Bases*100	 93.3	
On	Target	(%)	 95.5	
Mean	Depth	 1013.8	
Uniformity	(%)	 97.6	
	 Mean>=20QBases/Bases*100	FFPE	Aspirate	 93.50	
Frozen	Aspirate	 93.03	
FFPE	Tumor	 93.27	
	 pValue	Mapped	Reads	 0.100	
Bases	 0.109	
>=20QBases	 0.108	
>=20QBases/Bases*100	 0.712	
On	Target	(%)	 0.887	
Mean	Depth	 0.133	
Uniformity	(%)	 0.259	
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Supplementary	Table	11	Summary	of	the	histological	grade	an	mutational	profile	identified	in	endometrial	
cancers	and	their	paired	uterine	aspirates		
Patient	 Grade	
Common	variants	
(Aspirate	and	
Hysterectomy)a	
Hysterectomy	variants	
(not	detected	in	
Aspirate)b	
Aspirate	variants	
(not	detected	in	
Hysterectomy)	
%	Hysterectomy	
variants	detected	in	
Aspirate(a/(a+b))	
EEC-1	 3	 PTEN	(2),	TP53	(2),	APC	 -	 -	 100	
EEC-2	 3	 PTEN,	CTNNB1,	CDKN2A	 -	 -	 100	
EEC-3	 3	 PTEN,	PIK3CA	(2),	ABL1	 -	 -	 100	
EEC-4	 1	 PTEN,	KRAS	 -	 PIK3CA	(3)	 100	
EEC-5	 1	 PTEN,	APC	 -	 -	 100	
EEC-6	 3	 FGFR2,	PIK3CA,	KIT	 -	 PIK3CA	 100	
EEC-7	 3	 FGFR2,	PTEN	(2),	TP53	 PTEN,	TP53,	SMARCB1,	CTNNB1,	CKN2A	 -	 44	
EEC-8	 3	 PIK3CA,	CTNNB1	 -	 -	 100	
EEC-9	 3	 FGFR2,	PTEN,	PIK3CA,	CTNNB1	 -	 -	 100	
EEC-10	 3	 PIK3CA	 -	 -	 100	
EEC-11	 1	 FGFR2,	FBXW7	 -	 -	 100	
EEC-12	 2	 PTEN	(3),	KRAS,	RB1,	ERBB2,	TP53,	PIK3CA,	
CTNNB1,	FBXW7	
-	 -	 100	
EEC-13	 3	 NRAS,	PTEN	(2),	ATM,	HNF1A,	PIK3CA,	SMO,	ABL1,	
CDKN2A	
KRAS,	GNA11	(2)	 PTEN,	ATM,	TP53	(2),	SMAD4,	GNAS,	
CTNNB1	
75	
EEC-14	 3	 PTEN	(2),	ERBB2	 -	 -	 100	
EEC-15	 1	 PTEN	 RET,	STK11,	PIK3CA	 VHL	 25	
EEC-16	 3	 PTEN(3),	TP53	 -	 -	 100	
EEC-17	 3	 KRAS,	AKT1	 -	 -	 100	
EEC-18	 1	 PTEN,	PIK3CA	 -	 -	 100	
EEC-19	 3	 -	 FGFR2,	PTEN	(3),	KRAS	 -	 0	
EEC-20	 3	 KRAS	 -	 -	 100	
EEC-21	 1	 -	 -	 TP53,	PIK3CA	 -	
EEC-22	 3	 PTEN	(2)	 -	 -	 100	
EEC-23	 3	 FGFR2	 -	 -	 100	
EEC-24	 3	 PTEN,	PIK3CA	 -	 CTNNB1,	CDKN2A	 100	
EEC-25	 3	 TP53	 -	 -	 100	
EEC-26	 3	 KRAS,	TP53	 -	 -	 100	
EEC-27	 3	 FGFR2,	MLH1	 PTEN	 -	 67	
EEC-28	 2	 PTEN	(2),	CTNNB1	 -	 -	 100	
EEC-29	 2	 PTEN	 -	 -	 100	
EEC-30	 3	 PTEN,	TP53,	PIK3CA	 -	 -	 100	
EEC-31	 2	 PTEN	 -	 -	 100	
EEC-32	 2	 PTEN,	CTNNB1	 -	 -	 100	
EEC-33	 1	 FGFR2,	AKT1,	CTNNB1	 -	 -	 100	
EEC-34	 2	 FGFR2,	PTEN	 -	 -	 100	
EEC-35	 3	 PTEN	(3),	KRAS,	PIK3CA	 ATM,	RB1,	TP53,	MET	 RB1,	KIT	 56	
EEC-36	 3	 PTEN,	BRAF	 -	 -	 100	
EEC-37	 3	 PTEN,	PIK3CA	(2)	 -	 -	 100	
EEC-38	 3	 CTNNB1	 TP53,	VHL	 -	 33	
EEC-39	 2	 -	 -	 -	 -	
EEC-40	 1	 FBXW7,	PTEN	 -	 -	 100	
EEC-41	 3	 PTEN,	FGFR2	 FGFR2	 -	 67	
EEC-42	 1	 PTEN	 PIK3CA	 -	 50	
EEC-43	 2	 PIK3CA,	PTEN	 -	 TP53	 100	
EEC-44	 1	 PTEN,	CTNNB1	 -	 KRAS	 100	
SEC-1	 3	 TP53	 -	 -	 100	
SEC-2	 3	 TP53	 -	 -	 100	
SEC-3	 3	 KRAS	 -	 -	 100	
SEC-4	 3	 -	 ABL1	 TP53	 0	
SEC-5	 3	 TP53,	PIK3CA,	BRAF,	ATM	 -	 -	 100	
SEC-6	 3	 -	 TP53	 -	 0	
SEC-7	 3	 PIK3CA	 -	 -	 100	
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SEC-8	 3	 -	 TP53	(2),	FBXW7	 -	 0	
SEC-9	 3	 TP53	 -	 -	 100	
CS-1	 3	 PTEN,	TP53,	PIK3CA	 FBXW7	 KRAS	 75	
CS-2	 3	 TP53	 -	 -	 100	
CS-3	 3	 TP53	 -	 -	 100	
CS-4	 3	 TP53	 -	 -	 100	
CS-5	 3	 TP53	 -	 -	 100	
CS-6	 3	 PTEN,	KRAS,	PIK3CA	 -	 -	 100	
CS-7	 3	 KRAS,	TP53	 IDH2,	TP53	(3),	EGFR	 -	 29	
CS-8	 3	 TP53	 -	 -	 100	
CS-9	 3	 FGFR2,	PTEN	 -	 -	 100	-	:	mutations	were	not	found		
Supplementary	Table	12	Summary	of	the	mutational	profile	identified	in	atypical	hyperplasia	paired	samples	
of	hysterectomy	specimens	and	uterine	aspirates		
Patient	
Common	variants	
(Aspirate	and	
Hysterectomy)	
Hysterectomy	variants	
(not	detected	in	
Aspirate)	
Aspirate	variants	
(not	detected	in	
Hysterectomy)	
AH-1	 PTEN	 -	 PTEN	
AH-2	 -	 -	 CTNNB1,	PIK3CA,	
CDKN2A	
AH-3	 -	 -	 CTNNB1,	PIK3CA	
AH-4	 -	 -	 -	
AH-5	 -	 -	 -	
AH-6	 -	 -	 -	
AH-7	 PIK3CA	 -	 -	
AH-8	 -	 -	 -	
AH-9	 -	 -	 -	
AH-10	 -	 -	 PIK3CA,	PTEN,	KRAS	-	:	mutations	were	not	found			 	
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Supplementary	Table	13	Sanger	sequencing	study	to	determine	POLE	mutational	status	in	the	metastic	
endometrial	cancer	WES	project		
	 Hotspot	P286R	 HotspotV411L	
Forward	primer	(5'	to	3')	 CCCATCCCAGGAGCTTACTT	 ATGTCCTCCGGGTCTAGCTC	
Reverse	primer	(5'	to	3')	 GTGTTCAGGGAGGCCTAATG	 TTGCATCTGTCTGTGTGGTG	
Length	 211	 203	
Annealing	temperature	(°C)	 58	 58	
Start	position	 	g.133,253,300	c.802-62	 g.133,250,390	c.1227-97	
End	position	 	g.133,253,096	c.909+36		 	g.133,250,189	c.1331	
Aminoacids	covered	 268-303	 410-437			
Supplementary	Table	14	Somatic	variants	identified	in	the	metastatic	endometrial	cancer	WES	project	Supplementary	Table	14	is	included	in	the	extra	CD	information.			
Supplementary	Table	15	Somatic	copy	number	alterations	identified	in	the	metastatic	endometrial	cancer	
WES	project	Supplementary	Table	15	is	included	in	the	extra	CD	information.			 	
	171	
	 ANNEX	II:	Supplementary	Materials	 	
	 	
Supplementary	Table	16	Mutational	signatures	identified	in	the	metastatic	endometrial	cancer	WES	project		
Sample	 Mutational	Signature	 	 Sample	 Mutational	Signature	
EEC-1_T1	 Signature	1	 	 SEC-1_T1	 Signature	1	
EEC-1_T2	 Signature	1	 	 SEC-1_T2	 Signature	1	
EEC-1_M	 Signature	1	 	 SEC-1_T3	 Signature	1	
EEC-2_T1	 Signature	1	 	 SEC-1_T4	 Signature	1	
EEC-2_T2	 Signature	1	 	 SEC-1_M	 Signature	1	
EEC-2_M	 Signature	1	 	 SEC-2_T1	 Signature	6*	
EEC-3_T1	 Signature	1	 	 SEC-2_T2	 Signature	6*	
EEC-3_T2	 Signature	1	 	 SEC-2_T3	 Signature	6*	
EEC-3_M	 Signature	1	 	 SEC-2_M	 Signature	6*	
EEC-4_T1	 Signature	1	 	 SEC-3_T1	 Signature	1	
EEC-4_T2	 Signature	1	 	 SEC-3_T2	 Signature	1	
EEC-4_M	 Signature	6*	 	 SEC-3_M1	 Signature	6*	
EEC-5_T1	 Signature	6	 	 SEC-3_M2	 Signature	6*	
EEC-5_T2	 Signature	6	 	 AEC_M	 Signature	13	
EEC-5_M	 Signature	6	 	 AEC_T2	 Signature	13	
EEC-6_T1	 Signature	6	 	 AEC_T1	 Signature	13	
EEC-6_T2	 Signature	6	 	 	
EEC-6_M	 Signature	6	 	
EEC-7_T1	 Signature	20	 	
EEC-7_T2	 Signature	20	 	
EEC-7_M	 Signature	6	 		*	Signature	does	not	have	correct	associated	indels.	Patients	with	discordant	signatures	between	its	multiple	samples	are	marked	in	red.			 	
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Supplementary	Table	17	Quality	metrics	of	Ion	PGM	sequencing	in	the	validation	of	the	metastatic	
endometrial	cancer	WES	project		
A)										
B)						A)	Quality	metrics	mean	of	Ion	PGM	sequencing	for	all	the	samples	analyzed.	Mapped	reads	refer	to	the	number	of	reads	that	were	aligned	to	the	full	reference	genome.	Bases	are	the	post	filtering	base	output.	The	parameter	>=20Q	Bases	 value	 represents	 the	 number	 of	 called	 bases	 with	 a	 predicted	 quality	 greater	 than	 or	 equal	 to	 20Q,	 the	predicted	quality	values	being	reported	on	the	Phred	scale,	defined	as	-10log10	(error	probability).	Therefore,	20Q	corresponds	to	a	predicted	error	rate	of	one	percent.	On	Target	value	is	the	percentage	of	mapped	reads	that	were	aligned	over	a	target	region,	while	the	Mean	Depth	is	the	average	base	coverage	depth	over	all	the	bases	targeted	in	the	 reference	genome.	Uniformity	 is	 the	percentage	of	 target	bases	covered	by	at	 least	0.2X	 the	average	base	read	depth.	B)	Quality	sequencing	comparison	between	frozen	and	FFPE	tumors,	using	the	proportion	of	>=20Q	Bases	and	the	total	bases	for	each	sample	as	a	standard	quality	criteria.			
Supplementary	Table	18	Targeted	sequencing	results	obtained	in	the	validation	of	the	metastatic	
endometrial	cancer	WES	project	Supplementary	Table	18	is	included	in	the	extra	CD	
	
Supplementary	Table	19	Somatic	variants	identified	by	WES	in	the	PDX	tumors	derived	from	an	ambiguous	
endometrial	carcinoma	Supplementary	Table	19	is	included	in	the	extra	CD	
	 Mean	
Mapped	Reads	 224512.3	
Bases	 28474526.6	
>=20QBases	 26424517.3	
>20QBases/Bases*100	 93.5	
On	Target	(%)	 93.8	
Mean	Depth	 1242.6	
Uniformity	(%)	 97.7	
	 Mean>=20QBases/Bases*100	Frozen	Tumor	 93.2	
FFPE	Tumor	 93.8	
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Supplementary	 Figure	 1	
Cancer	 Cell	 Fraction	
heatmaps	obtained	from	WES	
data	 in	 metastatic	 CN-low	
endometrial	 carcinomas.	Heatmaps	 represent	 the	presence	 (blue)	 or	 absence	(grey)	 of	 the	 mutations	identified	by	WES	in	metastatic	endometrial	 carcinomas	molecularly	 classified	 as	 CN-low	 (EEC1-4).	 Different	 blue	tones	 indicate	 the	 cancer	 cell	fraction	 (CCF)	 value	 obtained	for	 each	 variant	 (see	 3.5.4.3).	Loss	 of	 heterozigosity	 (LOH)	 is	represented	 by	 a	 diagonal	white	line	in	the	corresponding	variant	box.	The	boxes	of	those	variants	identified	as	clonal	are	labeled	 with	 a	 yellow	 square.	EEC:	endometrioid	endometrial	carcinoma,	 T:	 primary	 tumor,	M:	metastasis.	 	 	
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Supplementary	 Figure	 2	 Cancer	 Cell	 Fraction	 heatmaps	 obtained	 from	WES	 data	 in	metastatic	 MSI	 and	 serous-like	 endometrial	 carcinomas.	Heatmaps	 represent	 the	presence	(blue)	or	absence	(grey)	of	the	mutations	identified	by	WES	in	metastatic	endometrial	carcinomas	molecularly	classified	as	MSI	(EEC5-7)	or	serous-like	(SEC1-3).	Different	blue	 tones	 indicate	 the	 cancer	 cell	 fraction	 (CCF)	 value	 obtained	 for	 each	 variant	 (see	 3.5.4.3).	 Loss	 of	 heterozigosity	 (LOH)	 is	 represented	 by	 a	 diagonal	 white	 line	 in	 the	corresponding	variant	box.	The	boxes	of	 those	variants	 identified	as	 clonal	are	 labeled	with	a	yellow	square.	EEC:	endometrioid	endometrial	 carcinoma,	SEC:	 serous	endometrial	carcinoma,	T:	primary	tumor,	M:	metastasis.	
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